












































































































Drawing  of  the  Isolated  Perfused  Human  Skin  Flap  model  and  its  infrared  photograph; 
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Skin  diseases  are  among  the  top 5 most  leading diseases  causing non‐fatal  health  burden 
worldwide and strategies to assure more effective treatments are urgently needed. Dermal 
therapy is very attractive due to the direct administration of the drug at the diseased skin site 

















The  enhancement  of  the  biological  activities  of  both  human  epidermal  growth  factor  and 
curcumin when incorporated in the liposomal system as compared to both active substances 
in solutions was found to be dependent on the liposomal surface charge.  
Positively  charged  deformable  liposomes  embedded  in  chitosan  hydrogel  enabled  stable 
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The Global Burden  report  (2010)  confirmed  that  the  skin diseases  represent an  important 
cause of  health  loss  and  their  impact  on patients'  life  and healthcare  costs  should not  be 
undervalued. Skin conditions are the 4th leading cause of non‐fatal disease burden (Hay et al., 
2014). Moreover, all age‐groups appear to be affected by skin diseases (Figure 1.1). Eczema is 












Some  of  the  skin  diseases,  such  as  chronic  wounds,  are  the  result  of  other  diseases' 
complications,  i.e.,  foot  ulcers  from  diabetes,  pressure  ulcers  resulting  from  spinal  cord 
injuries,  and  neurodegenerative  processes,  such  as  Pick's  disease  (Dreifke  et  al.,  2015). 
Therefore, the  increasing proportion of high risk‐populations, e.g. diabetic, obese, smokers 
and  elderly  people,  further  contributes  to  the  prevalence  of  skin  diseases.  Since  the  skin 
diseases under other medical categories were not included in the Global Burden of Disease 
2010  study,  i.e.,  melanoma  reported  under  cancer  and  cutaneous  leishmaniosis  under 
infectious  diseases  (Hay  et  al.,  2014),  the  true  burden  of  skin  diseases  is  substantially 
underestimated (Hollestein and Nijsten, 2014). Beyond these data, skin diseases have a high 
impact on patients' quality of life and their health status. Patients affected by skin diseases 











Since  1995,  more  than  100  dermatological  drugs  were  approved  by  the  Food  and  Drug 
Administration (FDA), indicating that the treatment of skin diseases is gaining more and more 
attention. Interestingly, more than 50% of these products are either in the form of tablets or 
solutions  for  intramuscular  or  intravenous  injections.  Therefore,  part  of  dermatological 
therapies  are  administered  systemically  although  the  pharmacologic  target  resides  in  a 
specific  tissue  or  single  compartment  of  the  body  (i.e.  the  skin).  Acne  is  one  of  the most 
common  skin  disease with  high  impact  on  adolescents.  It  is  characterized  by  high  sebum 








limited  because  it  often  causes  skin  irritation,  with  erythema,  burning  sensation  and 
photosensitivity (Goyal et al., 2016). Systemic antibiotics and antiandrogens are used either 
to  treat  severe  acne  manifestations  or  in  case  the  previous  approach  was  not  effective. 
However,  considering  the  high  prevalence  of  microbial  resistance  to  antibiotics  when 
systemically administered, the effectiveness of antibiotics has become less (de Leeuw et al., 
2009). The final remedy is oral isotretinoin that is very effective although moderate to serious 
side  effects  limit  its  use  (de  Leeuw  et  al.,  2009).  Treatment  of  psoriasis  has  also  a  great 
relevance  worldwide.  Although  research  has  moved  forward  to  better  understand  the 
pathogenesis  and  develop  strategies  to  control  the  disease,  the  need  for  safe,  cost‐  and 
disease‐effective  cures  remains  (Vanić,  2015).  Topical  treatment  with  anti‐inflammatory 
agents and antibiotics is the first‐line therapy of acute exacerbations of atopic dermatitis and 
contact  dermatitis.  Topical  administration  of  prednicarbate  has  desired  anti‐inflammatory 








Methotrexate  administered  systemically  is  used  for  controlling  recalcitrant  psoriasis,  but 
several side effects, for instance hepatotoxic effects, may occur. The topical administration of 









deep  dissections  followed  by  soft  tissue  reconstruction  (Goyal  et  al.,  2016).  Most  of  the 
chemotherapeutics  used  in  the  treatment  are  administered  systemically  and  are  toxic  to 
healthy cells. Numerous potential drugs fail clinically because of insolubility, further increasing 
the need to  find new approaches  to overcome these  limitations  (DeLouise, 2012). Chronic 
wounds and burns are those wounds that usually fail to complete the normal wound healing 








in post‐burn  recovery  is  cutaneous  scarring  causing  reduced quality of  life  and may affect 




fibroblast  growth  thus  resulting  effective  in  reducing  hypertrophic  scarring.  Promising  are 








to  reduce  the  amount  of  drug  that  will  reach  the  skin  targeted  site,  thus  decreasing  its 
therapeutic effect. On the other hand, high levels of metabolite(s) produced by drug's first 





impetigo,  cellulitis  (Gupta  et  al.,  2012).  Therefore,  considering  the  high  prevalence  of 






but  minimizing  manifestation  of  side  effects  (Cima  et  al.,  2014).  The  formation  of  drug 
reservoir in the targeted skin layer following topical application is likely to release the drug 
over an extended period of time. This drug depot might assure constant drug concentration 



























































The  topical  drug  administration  for  localized  skin  therapy  is  still  a  challenge,  especially  in 
controlling  the exact amount of drug  that  reaches  the different  skin  layers  to assure  skin‐
targeted  drug  delivery  (Pardeike  et  al.,  2009).  Ideally,  the  drug  after  its  release  from  the 
vehicle should penetrate the SC and permeate through the skin layers in order to reach the 
targeted  skin  site.  A  drug  depot  in  the  skin  site  might  maintain  therapeutic  drug 
concentrations for a long period of time and avoid systemic absorption (Vogt et al., 2016). The 
main limiting step is represented by drug penetration through the SC. The skin penetration 
potential  of  the  drug  is  dependent  on  its  physicochemical  properties,  such  as  molecular 
weight,  solubility, melting point,  ionization and partition  coefficient. Drugs with molecular 
weight lower than 500 Da, having low melting point and a log P of 2‐3 can penetrate the SC. 
Due  to  the  limited  number  of  drugs  that  fulfil  these  criteria,  the  effectiveness  of 
dermatological products is related to the type of vehicle (Roberts et al., 2017). The vehicle in 





The  current  dermatological  products  for  localized  skin  therapy  are  based  on  conventional 
vehicle  systems  including  liquids  (solutions),  semisolid  (ointments  and  cream),  and  solid 
systems (patches) (Planz et al., 2016). They are sufficiently effective to act as vehicle for the 
incorporated  therapeutic  agent.  Once  applied  onto  the  skin,  they  can  provide  sustained 
release  of  the  therapeutic  agent,  thus  assuring  prolonged  local  effect  and  minimizing  its 
systemic absorption and side effects (Frederiksen et al., 2015). Additionally, many excipients 
in  the  traditional  topical  dosage  forms  have  intrinsic  beneficial  properties  that  can  act 
synergistically  for  improving  and  accelerating  the  therapeutic  outcome  of  localized  skin 




skin  mediated  by  water‐absorbing  hydrogel  and  ointment  affects  the  SC  hydration  thus 



























Extensive  research  is  focusing on advanced dermal delivery  systems,  such as nanocarriers, 
especially  for  improving  drug  penetration  through  the  SC  and  enabling  controlled  drug 
delivery  (Mota  et  al.,  2017).  The  effectiveness  of  advanced  delivery  systems  depends  on 
several  factors, which  are  related  to  their  intrinsic  properties  but  also on  the  interactions 
between them, the skin and the drug (Jain et al., 2017). For these reasons, one of the key steps 





The employment of  skin penetration models as a  tool  in predicting  the  fate of drugs  from 
dermatological  products  once  applied  onto  the  skin  contributes  to  a  more  feasible 
development and optimization of effective localized skin therapies (Flaten et al., 2015). One 
of  the  advantages  of  localized  skin  therapy  is  the  avoidance  of  drug  systemic  absorption. 



















the  screening of  formulations during  their  early development  (Ilić  et al.,  2017).  For  a  long 
period of time, the use of in vivo animals has been the main alternative to the in vivo studies. 
In the last decades, the regulations finalized to restrict the use of animals have been generated 











correlation of  lipophilic  substances has been  found between newborn pig and human skin 
(Cilurzo et al., 2007). However, pig SC owns lipids organized in hexagonal lattice in contrast to 
the  orthorhombic  organization  of  human  SC,  thus  indicating  dissimilarities  in  the  SC  lipid 
organization (Silva Garcia Praça et al., 2018). In general, the penetration through animal skin 
is higher compared to the human due to differences in the cell type, lipid composition and 
organization,  water  content,  morphology  and  hair  density  (Schaefer  et  al.,  2008).  This 



































































human  skin  tissue  (Van Gele et  al.,  2011). When used ex  vivo,  the  viability of  human  skin 
cannot be guaranteed. Moreover, the excised human skin is often frozen for practical reason. 
Repeated  freeze‐thaw  cycles  can  alter  the  morphology  of  the  SC  lipids  thus  resulting  in 
different penetration profiles compared to the ones obtained with fresh human skin (Barbero 
and Frasch, 2016). The skin active metabolism plays also a role in the drug penetration through 


























(Lane, 2013).  It  is worth  to mention  that  some skin diseases,  such as chronic wounds, are 







drug  is  expected  to  be  delivered  through/into  the  upper  skin  layers  and  not  to  reach  the 
systemic absorption. However, skin penetration models might also serve as tool to prove that 
no  systemic  absorption  of  drug  occurred,  reducing  the  possibility  of  side  effects  (Schäfer‐
Korting et al., 2007). This condition is partially affected by the presence of subcutaneous fatty 















Figure  1.3:  Hierarchy  of  the  most  frequently  used  skin  models  according  to  their 












balance,  surface  washings,  tape  stripping,  can  be  easily  transferable  to  the  skin  perfused 





ear model, which  showed  to possess high permeability and was  later used only as  tool  to 
predict  penetration  through premature neonate  skin  (Schaefer  et  al.,  2008).  Research has 
then moved  towards  other  animal  body  parts,  i.e.  perfused  cow  udder (Kietzmann  et  al., 
1993), pig forelimb (Wagner et al., 2003), and the isolated perfused pig skin flap (obtained 
from pig abdomen) (Riviere et al., 1986). Skin penetration studies performed especially using 




















a  targeted drug delivery  resulting  in efficient  localized  skin  therapy  (Banerjee, 2013). As a 
consequence, the side effects to non‐targeted tissue(s) will be minimized (Mota et al., 2017). 
The drug therapeutic effect would also be enhanced if the carrier can provide drug protection 






Vierl,  2010). When  oils  and  amphipaths  (including  lipids) meet  polar  solvents  (e.g. water) 
spontaneous creation of several structures occurs. Micelles, cubic phases, micro‐ and nano‐
emulsions,  vesicles,  dendrimers  are  some  of  their  example.  These  structures  have  good 
potentials to overcome conventional topical treatments' limitations. Some of them can also 
act as the carriers, whereas others act as skin penetration enhancers thus influencing the drug 
transport  across  the  skin  (Cevc  and  Vierl,  2010).  Among  them,  spherical  micelles  and 
microemulsions are characterized by short‐life and ease to rearrange/fluctuate. Emulsions, on 
the  other  hand,  can  change  in  water  and  salt  concentration  after  exposure  to  open  skin 
surface (Cevc and Vierl, 2010). Nano‐sized carriers represent one of the most emerging and 
advanced drug delivery systems, offering novel directions in the treatment of skin diseases 





organization,  namely  vesicular  lipid‐based  nanosystems  (liposomes)  and  particulate  lipid‐
based nanosystems (SLNs, NLCs). Vesicular nanosystems are soft particles composed of a lipid 
bilayer  surrounding  an  aqueous  compartment,  whereas  particulate  nanosystems  are 










Liposomes,  SLNs  and  NLCs  are  currently  very  promising  as  nanocarriers  for  dermal  drug 
delivery (Kristl et al., 2010; DeLouise, 2012). Their lipid‐based composition makes them similar 
to the SC lipid composition thus enhancing the entry of the incorporated drug through the SC. 






(DeLouise,  2012).  Sustained  drug  release  can,  in  addition,  reduce  the  drug  doses,  further 
reducing the risks of side effects while maintaining its therapeutic levels. Due to their peculiar 
structure,  phospholipid‐based  vesicles  and  particles  can  also  increase  the  stability  and 
protection  of  the  incorporated  drug.  By  this  approach,  the  active  form  of  drugs  can  be 
protected via potential inhibition from enzymatic metabolism or degradation at certain pH, 




nanocarriers  well  tolerable,  biocompatible  and  biodegradable,  which  are  fundamental 
conditions to assure safety and patient compliance (Fireman et al., 2011). Their properties are 
a  function  of  their  size,  surface  characteristics  and  solubilisation  capacity.  Therefore,  by 
changes  in  their  physicochemical  characteristics  it  is  possible  to  obtain  nanocarriers  with 





One  of  the  first  nanocarriers  largely  investigated  as  skin  drug  delivery  systems  were  the 





them  to  promote  penetration  of  drugs  through  the  main  barrier  of  the  skin,  which  can 
consequently  facilitate  their  action  as  drug  carriers  through/into  the  skin,  thus  assuring 
targeted  drug  delivery  (Banerjee,  2013).  First  reports  on  their  potential  to  transport  and 
deliver  drugs  in  the  epidermis  and  dermis  were  published  in  the  early  1980s. Mezei  and 
Gulasekharam  (1980)  suggested  that  intact  liposomes  could pass  through  the SC,  allowing 
deposition  of  triamcinolone  acetonide  in  the  dermis  while  decreasing  its  percutaneous 
absorption  when  compared  to  a  standard  ointment.  This  theory  was,  a  few  years  after, 
criticised  by  other  groups  stating  that  the  liposomal  size  would  represent  an  obstacle  to 
liposome diffusion through the densely packed SC in order to reach the deeper skin layers in 
intact state (Ganesan et al., 1984; Ho et al., 1985). Therefore, the effect of liposome size on 



















layers  (Figure  1.2).  On  the  contrary,  liposomes  of  around  300  nm  can  exhibit  the  highest 
reservoir  in  both  epidermis  and  dermis  layers,  thus  showing  the  potential  to  be  used  for 







The  size  is  not  the  only  factor  that  affects  skin  drug  delivery  mediated  by  nanocarriers. 
Therefore, aiming at developing optimal nanocarriers for treatment of a wider variety of skin 












(Roberts  et  al.,  2017).  This  mainly  occurs  because  the  surfactant  disturbs  the  bilayer 












bearing  positive  or  negative  surface  charge,  namely  cationic  (CDLs)  and  anionic  (ADLs) 
deformable liposomes. The liposomal surface charge has shown to affect skin penetration of 
DLs  (Roberts  et  al.,  2017).  The  skin  penetration mechanism  for  charged  DLs  is  related  to 
electrostatic  interactions occurring between the nanocarrier and the negatively charged SC 
cells. Specifically, these interactions are more likely to be triggered when liposomes bear a 
positive  surface  charge  resulting  in  skin  penetration  enhancement  (Jain  et  al.,  2017).  For 
example, skin deposition of temoporfin was enhanced by CDLs to a higher extent compared 
to both ADLs and neutral deformable  liposomes  (NDLs)  (Dragicevic‐Curic et al., 2010). The 
ability of CDLs (SECosomes) to enhance delivery into the viable epidermis has also been shown 
towards macromolecules,  such  as  siRNA  (Geusens  et  al.,  2010).  On  the  other  hand,  ADLs 


















that  affects  the  extent  of  drug  deposition  into  the  skin  layers  is  represented  by  the 
nanocarriers'  lipid  organization.  Each  of  these  factors  influencing  the  skin  penetration 
potential  of  nanocarriers  cannot  be  considered  as  “single  responsible”,  but  they  are  all 









Müller‐Goymann,  2015).  Due  to  these  skin  penetration  potentials,  SLNs  have  been 
investigated as nanocarrier‐based topical formulations for  localized skin therapy, especially 
for treatment of acne, psoriasis, skin mycosis and inflammations (Puglia and Bonina, 2012). In 
addition,  the  particulate  SLNs'  lipid  organization  influences  other  characteristics,  such  as 
stability and safety. As an example, SLNs lack the bilayer structure of the liposomes, thus being 
more stable in both hydrophilic and lipophilic environment. This will allow safe transport and 








All  the  factors  discussed  earlier  that  need  to  be  explored  to  overcome  dermal  delivery's 
limitations  cannot  be  effectively  translated  in  the  development  of  effective  topical 
formulations for localized skin therapy, unless the most important characteristics of the skin 
that  account  for  ingress  and  diffusion  of  drugs  into/through  the  skin  are  considered. 





















robust  and  more  impermeable  to  water,  as  well  as  to  both  hydrophilic  and  lipophilic 











pathways  of  penetration  across  the  SC,  which  occurs  by  passive  diffusion  driven  by  the 
concentration  gradient  of  penetrant  molecules  (Figure  1.6)  (Bolzinger  et  al.,  2012).  The 
intercellular pathway comprises the diffusion of molecules across the continuous path formed 
by  the  SC  lipids.  Lipophilic  molecules  will  prefer  this  route.  An  alternative  route  is  the 
transcellular route through the corneocytes, which involves partitioning in and out of the lipid 




















vs.  diseased”  skin  barrier.  Bouwstra  and  Ponec  (2006)  provided  a  detailed  review  on  the 
differences  in  the  lipid  composition  and  organization  between  healthy/normal  skin  and 
diseased/damaged skin. In atopic dermatitis, a reduction in acylceramide content occurs thus 
altering the lamellar organization and consequently reducing the SC barrier properties. In dry 
skin,  the  same outcome  is observed, but  in  this  case,  the  reduced  skin barrier  is due  to a 
deficiency in essential fatty acids and an increase of lipids responsible for forming a more fluid 
phase. In ichthyosis skin, a prominent increase in cholesterol sulphate results in a reduction 






















metabolic  barrier  against  drugs  and  nanoparticles.  Enzymatic  activity,  for  instance,  on 








good  potential  to  confer  the  appropriate  rheological  properties  necessary  for  effective 
liposomes' application onto the skin (Pitorre et al., 2017). Hydrogels are hydrophilic polymer 
networks capable of absorbing large amounts of water (Gao et al., 2014; Gyles et al., 2017). 








biocompatible  and  possess  good  bioadhesiveness,  which  is  one  of  the  most  important 
features related to trans(dermal) semisolid and solid dosage forms to assure adequate drug 
retention  time  on  the  skin  administration  site  (Ribeiro  et  al.,  2009;  Cilurzo  et  al.,  2012). 
Therefore,  local  therapeutic  drug  levels  can  be  assured  favouring  the  pharmacological 
response  (Hurler  and  Škalko‐Basnet,  2012).  The  combination  of  two  delivery  systems  by 
incorporation of  liposomes in hydrogels  is a very promising strategy for  improved localized 
skin  therapy.  Liposomes  can  be  maintained  at  the  skin  site  due  to  avoidance  of  rapid 






to  come  in  contact with  the  skin.  Therefore,  the  drug  release  from  liposomes‐in‐hydrogel 
systems  will  be  affected  by  the  physicochemical  properties  of  the  drug  but  also  by  the 
interaction  between  drug,  liposome  and  hydrogel  (Grijalvo  et  al.,  2016).  Liposomal 
physicochemical properties and hydrogel texture properties need to be considered during the 
optimization  of  effective  liposomes‐in‐hydrogel  systems  for  skin‐targeted  drug  delivery. 
Considering the aqueous environment provided by the hydrogels, factors influencing the drug 
release  from the combined delivery systems are  the  lipophilicity of  the drug and  its water 












isopropylacrylamide)  hydrogel  are  responsible  for  liposome  stability  and  release  of 
hydrophilic model compounds (Liu et al., 2012). An  increase  in  liposome size was found to 
enhance sustained release of a hydrophilic compound, carboxyfluorescein,  in  liposomes‐in‐
hydrogel  system  (Ruel‐Gariepy  et  al.,  2002).  Natural  polymer‐based  hydrogels,  such  as 
chitosan hydrogels, possess positive chains due to the presence of amino groups. Therefore, 
incorporation  of  surface  charged  liposomes  can  trigger  electrostatic  interactions  with  the 
charged  polymer's  chains  of  the  hydrogel.  When  incorporated  in  the  chitosan  hydrogel, 
cationic  liposomes  have  shown  to  enable  a more  sustained  release  of model  compounds 





its  consequent  release  (Grijalvo  et  al.,  2016).  Last  but  not  least,  the hydrogel  texture  and 
bioadhesive properties might be affected when liposomes are incorporated in hydrogels. The 














The  optimization  of  effective  nanocarriers  for  skin‐targeted  drug  delivery  requires 
nanocarriers‐associated model substances as a proof‐of‐concept that the selected nanocarrier 
can  assure  controlled  delivery  to  the  specific  targeted  skin  layer(s).  In  this  thesis,  model 
substances  are  referred  to  as  model  compounds  and  drugs/active  substances.  Model 
compounds can be used for their specific properties, e.g. fluorescent nature, to follow their 
skin  penetration  through  the  skin  layers  once  topically  applied  onto  the  skin  surface  in 
nanocarrier‐based  formulations.  On  the  other  hand,  drugs/active  substances with  specific 
biological  properties  beneficial  for  treatment  of  skin  diseases  can  be  incorporated  in 
nanocarriers  as  model  substances.  During  the  screening  of  nanocarriers  with  different 






skin penetration potential and  to which specific  skin  layer(s)  they deliver  the  incorporated 
active  substance  can  assist  in  the  right  choice  of  the  nanocarriers  for  skin‐targeted  drug 
delivery, according to the skin condition and disease.  
Among  the  techniques  used  to  investigate  the  distribution  of  a  drug  mediated  by  the 
nanocarrier through the skin layers after topical administration onto the skin, confocal laser 
scanning microscopy  (CLSM) has  the advantage  to avoid  the cryofixing process of  the  skin 
sample  (van  Kuijk‐Meuwissen  et  al.,  1998).  This  will  avoid  possible  changes  in  skin  lipid 
organization or eventual redistribution of the marker that might occur during cryofixing the 
sample  (van  Kuijk‐Meuwissen  et  al.,  1998).  Fluorescent  compounds  are  incorporated  in 
nanocarriers and their distribution in the skin layers can be followed by a confocal microscope. 
















Incorporation  of  calcein  in  DLs  helped  to  clarify  the  controlled  drug  release  in  the  skin 
mediated by DLs (Bahia et al., 2010). Gillet et al (2011) employed both calcein and rhodamine 
to compare the skin penetration potential of CLs and DLs using pig skin, concluding that both 

















Vanić  et  al.,  2015).  Despite  their  high  potential  as  skin  therapeutic  agents,  biologicals 
represent  a  formulation  challenge  since  they  are  chemically  unstable  and  prone  to 
aggregation, deamidation, isomerization, hydrolysis, oxidation and denaturation. Moreover, 
their high molecular weight and hydrophilicity limit their penetration through the SC, resulting 
in  limited drug concentrations at  the  targeted site and a need  for parenteral  formulations 
(Mitragotri et al., 2014).   











cell  proliferation  and  promoting  re‐epithelialisation  (Xue  et  al.,  2018).  However,  the 
endogenous hEGF is degraded by proteases  in the wound bed further delaying the chronic 
wound healing (Saghazadeh et al., 2018). Localized therapy with hEGF might represent a good 
approach  to  assure  a  faster  and  effective  wound  healing  (Garcia‐Orue,  et  al.,  2017).  As 
mentioned  previously,  poor  in  vivo  stability  and  enzymatic  degradation  limit  local 
administration of hEGF. Additionally, its relatively high molecular weight (6 kDa) affects its SC 











Additionally,  persistent  bacterial  infections  are  also  a  cause  of  prolonged  inflammations. 
Therefore,  topical administration of multitargeting active  ingredients may  result  in a more 
effective localized skin therapies, improving a patient compliance by reducing the number of 
administrations.  










anti‐oxidant,  anti‐inflammatory  and  anti‐bacterial,  have  made  curcumin  an  attractive 
compound for treatment of skin inflammation and infections (Krausz et al., 2015; Mehanny et 
al.,  2016). The action of  curcumin as anti‐inflammatory agent  is due  to downregulation of 
different  proinflammatory  cytokines,  such  as  tumour  necrosis  factor,  interleukins  and 
chemokines.  Curcumin  also  inactivates  the  nuclear  transcription  factor  kappa  B,  further 
reducing the degree of inflammation. Additionally, curcumin has shown to act at molecular 
levels  in different phases of the wound healing process,  further  increasing  its potential  for 
chronic wound therapy. Curcumin is promising for managing scar formation and treatment of 
post burn hypertrophic  scarring  (Amini‐Nik et al.,  2018). More  recently,  the  revealed anti‐
bacterial effect of curcumin makes it a good alternative to the overuse of antibiotics, often 
object  of  microbial  resistance  (Krausz  et  al.,  2015).  Curcumin,  as  multitargeting  active 
ingredient, might  therefore  be  a  good  candidate  for  local  treatment  of  skin  diseases  that 
require interventions at different levels. However, its hydrophobic nature (log P = 3.29, Araiza‐
Calahorra  et  al.,  2018)  makes  its  incorporation  in  conventional  topical  dosage  forms 
challenging  (Basnet  et  al.,  2012).  Moreover,  it  is  chemically  unstable,  especially  at  the 
physiological  pH,  and  photosensitive.  When  applied  locally  on  skin,  side  effects,  such  as 
erythema, peeling and hot phenomenon, might occur  (Zhao et al., 2013).  Incorporation of 
curcumin in nanocarriers, such as CLs, SLNs, propylene glycol (PG) liposomes, has shown to 







































of  wounds  thus  further  contributing  to  improve  wound  healing.  Chitosan  might  also 
synergistically  act  with  the  beneficial  effects  of  the  incorporated  active  ingredient  thus 
increasing the efficacy of wound dressings. Additionally, the combination of nanocarriers and 
chitosan  hydrogel  as  advanced  delivery  systems  has  shown  to  be  promising  for  improved 
chronic wound healing (Hurler et al., 2013a). Tigecycline nanoparticles‐in‐chitosan hydrogels 
exhibited strong anti‐bacterial activity against S. aureus  in both  in vitro and  in vivo studies, 
additionally assuring in vitro wound closure within 48 hrs (Nimal et al., 2016). Niosomes‐in‐
chitosan  hydrogel  showed  to  enhance  the  anti‐bacterial  properties  of  the  incorporated 








The  general  aim  of  this  thesis was  the  development  and  optimization  of  nanocarriers  for 
tailored  skin  delivery.  The  possibility  to  develop  nanocarriers  that  can  carry/transport  the 
incorporated  drug/substance  into  the  specific  targeted  skin  layers,  according  to  the  skin 
condition  and disease  state,  can  contribute  to  the development  of  effective  localized  skin 
therapy.  
The specific aims were the following: 




 Assessment of  the  influence of  the  surfactants used  to prepare  nanocarrier on  the 
physicochemical properties of the selected nanocarrier. 














to‐in  vivo  skin  penetration model  to  be  used  as  a  tool  in  optimization  of  dermal  delivery 
systems for skin therapy.  
The  IPHSF was validated  in  terms of  its ability  to discriminate  the  skin penetration of  two 






























We  showed  that  the  model  could  be  used  in  skin  penetration  studies  assuring  constant 
experimental conditions and reproducible results. Moreover, the model appeared to be able 
to show the different penetration potential of the two markers. The role of skin perfusion on 
the  skin  penetration  of  the model  compounds  was  also  revealed.  This model  could  be  a 










solvent  injection  method.  Two  fluorescent  markers,  calcein  (hydrophilic)  or  rhodamine 






three  nanocarriers.  No  penetration  of  both  nanocarrier‐associated markers  was  observed 
through  the  full  IPHSF confirming  the  suitability of all  tested nanocarriers  for dermal drug 
delivery. The delivery of both markers into/through the skin layers was dependent on the type 
of  nanocarriers,  as  observed  by  CLSM  technique.  CLs  formed  a  depot  on  the  skin  surface 
retaining both markers to a higher extent in the superficial skin layers. DLs and SLNs enabled 




The  skin  penetration  studies  on  IPHSF  model  highlighted  the  differences  in  the  skin 















Franz  diffusion  cells  system  were  used  to  evaluate  the  in  vitro  release  and  ex  vivo  skin 
penetration of hEGF, respectively.  
Finally,  the mitogenic  activity of  hEGF  in  all DLs was explored by  in  vitro  cell  proliferation 





significant  differences  were  observed  in  the  in  vitro  hEGF  release  from  the  different  DLs 
through polyamide membrane, although ADLs exhibited the most sustained release of hEGF. 
All  DLs  assured  dermal  delivery  of  hEGF  because  no  penetration  of  hEGF  through  the  full 
thickness human skin was detected. Comparing the liposomal surface charge, ADLs exhibited 
the highest retention onto the human skin surface thus providing a hEGF depot. Moreover, 
ADLs  exhibited  the  best  enhancement  of  hEGF mitogenic  activity,  even  compared  to  the 
positive control (hEGF in solution). This effect was highly evident in both HFF and in HaCaT 
treated for 48 and 24 hrs, respectively. 












penetration  studies  using  the  full  thickness  human  skin.  The  anti‐bacterial  activity  of 
curcumin‐DLs was  evaluated  in  vitro  against  two  clinical  strains  of Gram‐positive  bacteria, 
namely S. aureus and Streptococcus pyogenes. Curcumin‐DLs were also evaluated  for anti‐
inflammatory  activity  by  exploring  their  effect  on  nitric  oxide  (NO)  production  in 
lipopolysaccharide (LPS)‐induced macrophages. The biological activities of curcumin‐DLs were 
compared  to  free  curcumin  (curcumin  in  solution)  and  empty  NDLs,  CDLs  and  ADLs, 


































































areas with a higher perfusion,  so‐called hot spots, and areas  that are  less perfused. These 
areas are easily identified using an IR camera, which provides real‐time information on skin 
perfusion. The perfusion pattern is related to the vascular anatomy of the flap (de Weerd et 



























the aid of  a peristaltic pump  in order  to be  filtered and gassed with 95% O2/5% CO2.  The 
perfusate  additionally  passed  by  a  heating  circulator  set  at  38  °C  to  assure  an  inlet 
temperature  in  the  flap of  32  °C.  The  temperature of  the perfusate entering  the  flap was 
monitored by a thermocouple, whereas a drop counter was used to monitor the perfusate 
flow  rate  (PFR)  (6‐8  mL/min).  The  perfusion  inlet  pressure,  expressed  as  left  ventricular 
pressure  (LVP)  was  monitored  by  a  pressure  transducer,  whereas  the  skin  surface 




temperature of 32  °C). DIRT  images were  then taken every 1 hr  for a period of 6 hrs. The 
physiological  parameters of  IPHSF,  namely PFR  (mL/min),  LVP  (mmHg)  and perfusate  inlet 




























Figure 4.2: Schematic drawing of  the analytical method used  to quantify  the  fluorescent 
marker in IPHSF perfusate. 
 




in  10 mL  of  Triton  solution  (5% w/v).  The  supernatant  from  the  first  and  second  cycle  of 






min  at  +4  °C.  After  incubation,  the  sample  was  centrifuged  at  16000  g  for  10  min.  The 
supernatant (blood cells‐ and plasma proteins‐free) was separated from the pellets and the 



















P C 	⁄                                                             (Equation 1) 
The equation is a simplification of the Fick's first law, where Cd (µg/mL) is the concentration 






two  model  compounds  with  different  lipophilicities,  namely  calcein  (hydrophilic)  and 
rhodamine (lipophilic) (Figure 4.4). In Paper II we performed the skin penetration experiments 
on IPHSF model exploring the skin penetration enhancement of three different phospholipid‐
based  nanocarriers,  namely  CLs,  DLs  and  SLNs,  on  calcein  and  rhodamine  individually 
incorporated in the nanocarriers (Figure 4.4). In addition to the weight of the human skin flaps, 
the  flap  thickness was measured before  and after  the  skin penetration experiments.  Both 
parameters were used to exclude oedema formation. The IPHSF perfusate, withdrawn every 
1 hr, was treated as described above (Figure 4.2) to quantify the penetrated markers. The non‐

















analysed  to  explore  possible  effects  of  the  perfusion  on  the  skin  penetration  of  the  two 
markers. In Paper I‐II, a human skin flap slices taken before starting the perfusion were used 














elasticity  of  empty  NDLs,  CDLs  and  ADLs  was  determined  with  a  home‐made  device  as 
described  earlier  (Palac  et  al.,  2014).  Liposomal  dispersions  were  extruded  through  a 
membrane with  a  pore  size  of  100 nm using  a  constant  external  pressure of  2.5  bar.  The 
amount of  liposomal dispersion extruded in 5 min was determined (J). The mean diameter 















delivery  of  active  substances.  Their  ability  of  nanocarriers  to  deliver  the  incorporated 












ability  as  a  dermal  carrier  and  possible  enhanced  therapeutic  effect  of  two  substances 
individually  incorporated  in  the nanocarrier.  Effective  skin  formulations  should also assure 
adequate  retention  time  of  the  nanocarrier‐associated  drug/substance  at  the  skin  site. 
Chitosan hydrogel was  therefore used as  a  second  vehicle  for  active  substance‐containing 
nanocarriers and the effect of nanocarrier surface charge on both hydrogel properties and 


























flap  perfusion  has  been  monitored  by  several  techniques,  such  as  dermofluorimetry 
(Kreidstein et al., 1995; Black et al., 2001). Miland et al (2008) employed DIRT technique as a 
less  invasive  method.  The  authors  found  a  good  correlation  between  skin  surface 
temperature, measured  by  an  IR  camera,  and  human  skin  flap  perfusion.  DIRT  technique 






The optimization of  the experimental  setups  to perform skin penetration studies on  IPHSF 
involved: 


















when perfused with  cool  perfusate.  The  physiological  parameters  of  the  human  skin  flap, 























(°C),  were  recorded  at  the  same  time  intervals  of  DIRT  images  acquisition.  The  skin  flap 
perfusion was performed starting with cool perfusate (a) and alternating cycles of perfusion 


















solution  indicated  and  confirmed  a  constant  good  perfusion  of  the  treated  area.  IPHSF 
physiological  parameters  were  also maintained  constant  throughout  the  experiment.  The 
perfusion  inlet  pressure,  expressed  as  LVP,  differed  from  the  recorded  values  during  the 
preliminary  perfusion  experiment  (Figure  5.1).  The  higher  pressure  observed  in  the  skin 
























































below  the  SC  might  be  enhanced  because  of  the  presence  of  desmosomes  in  the  viable 







































when testing compounds with different  log P values on  the  isolated perfused pig skin  flap 
model. The higher the log P, the lower was the amount of compound detected in the perfusate 






IPHSF,  while  rhodamine  was  mainly  located  in  the  SC  and  superficial  skin  layers.  When 
performing the skin penetration experiments of rhodamine on the  IPHSF, we were able to 
visualize a non‐perfused area (Figure 5.4 a). This was analysed by CLSM to further explore the 





























skin compared  to other animal  species, especially  referring  to  skin  thickness and histology 






























the  depth within  the  skin  to which  the  drug/substance will  be  delivered  can  be  achieved 
(Schmieder  et  al.,  2015).  This  translates  in  a  good  potential  to  develop  nanocarrier‐based 
formulations with  skin‐targeted drug delivery according  to  the  skin conditions and disease 
state. In this study, we selected three phospholipid‐based nanocarriers, namely CLs, DLs and 
SLNs, commonly used as dermal delivery systems. The choice was based on the fact that they 
possess  different  lipid  organization.  CLs  and  DLs  have  the  phospholipids  arranged  into 
vesicular  structures  that  surround  an  aqueous  core,  whereas  SLNs  are  particulate 
nanosystems where the phospholipids are organized in a homogeneous solid matrix (Jain et 
al., 2017).  
Aiming  at  developing  nanosystems  for  dermal  drug  delivery,  we  decided  to  develop 
nanocarriers with a targeted particle size between 200 and 300 nm. The selected size range 
has shown to be optimal in assuring nanocarrier deposition into the skin providing adequate 
drug  reservoir  (du  Plessis  et  al.,  1994).  Considering  other  physicochemical  properties,  the 
surface of both CLs and SLNs was neutral due to the presence of the neutral PC. DLs were 
found negatively charged and this can be attributed to the presence of anionic surfactant, 




similar  to  the human studies. This also applies  for screening of nanocarriers with different 
physicochemical properties. The IPHSF model showed a good potential in providing closer‐to‐
in vivo predictions of skin diffusion kinetics. We therefore used the developed skin penetration 






well‐perfused  throughout  the  skin  penetration  experiments  (data  presented  in  Paper  II). 
These  findings  further confirmed the use of  the  IPHSF model  in constant and reproducible 
experimental conditions. The penetrated amount of both nanocarrier‐associated markers in 
the perfusate was below the detectable level, indicating no markers penetration through the 
full  IPHSF. This  confirmed  the  suitability of all nanocarriers  as dermal delivery  systems. As 
discussed earlier, this might be explained considering the nanocarrier size, which was targeted 
to be optimal for dermal delivery of drugs. Considering calcein penetration through the IPHSF 
when  applied  in  solution  (Paper  I),  the  lack  in  calcein  dermal  absorption when  applied  in 


















according  to  the  lipid  organization.  CLs  have  demonstrated  that  their  skin  penetration 
enhancing effect on drugs is limited to the SC and eventually to the more superficial skin layers 
(Dreier  et  al.,  2016).  DLs  have  shown  superior  ability,  compared  to  CLs,  in  enhancing 
drug/substance transport into the deeper skin layers due to their deformability provided by 
the presence of  surfactant  in  the  liposomal phospholipid bilayer  (Jain et al., 2017). On the 




5.3).  This  indicates  that  the  skin  penetration  rate  of  any  compound  is  the  result  of  its 




The  skin  penetration  studies  using  the  three  nanocarriers  allowed  us  to  prove  that  all 
nanocarriers were able to assure dermal delivery of both markers when tested on the IPHSF 
model.  The  evaluation  of  the  amount  of markers  retained  onto  the  IPHSF  surface was  an 
indication of the different skin penetration behaviour of the tested nanocarriers. However, no 















As earlier observed  for  the markers  in  solution  (Paper  I) and  independently of  the  type of 
nanocarrier, calcein was found more uniformly distributed through the IPHSF as compared to 
rhodamine, which was mainly  located  in  the upper  skin  layers  close  to  SC.  Therefore,  the 
different lipophilicities of the two markers affected their distribution through the IPHSF, even 
when applied associated with nanocarriers. Calcein penetration into the dermal layer might 









compared  to  SLNs.  Regarding  rhodamine,  DLs  enabled  higher  deposition  of  the  lipophilic 
marker into the SC than CLs and SLNs, whereas both DLs and SLNs delivered rhodamine into 
the deeper skin layers compared to CLs. CLSM analysis confirmed that the skin penetration 
depth  of  the  two markers was  dependent  on  the  type  of  nanocarrier.  The  enhanced  skin 
penetration mediated by both DLs and SLNs was more evident for calcein, which was localized 
into  the  deeper  skin  layers  compared  to  rhodamine.  This  can  be  related  to  the  different 






of  the  tested  nanocarriers.  DLs  exhibited  satisfactory  dermal  delivery  for  both  model 
compounds, with potential ability to enhance skin drug penetration and assure controlled and 









5.3 Effect  of  surfactants  on  the  physicochemical  properties  of 
nanocarriers (Paper III and IV) 
To  further explore  the effect of  liposomal surface charge on  the nanocarriers' potential as 
dermal delivery systems, different surfactants were selected and employed to prepare NDLs, 
CDLs  and ADLs,  respectively, with  adequate  liposome membrane elasticity.  Therefore,  the 






related  to  administration  of  surfactants  in  higher  concentrations,  especially  referring  to 
polysorbate 20 and stearylamine (Eskandani et al., 2013; Dhawan and Nagarsenker, 2017). 
Two  model  drug/active  substances,  namely  hEGF  and  curcumin,  were  selected  and 
individually  incorporated  in  the  DLs  bearing  different  surface  charge  to  evaluate  the 




oxidant,  anti‐inflammatory  and  anti‐bacterial  effects  of  curcumin  make  this  pleiotropic 





lipophilicity  and  chemical  instability  limit  its  incorporation  in hydrophilic wound dressings, 
















The  zeta  potential  of  all  DLs was  found  to  be  dependent  on  the  type  of  surfactant. NDLs 
exhibited  a  neutral  surface  due  to  the  presence  of  both  neutral  lipid,  PC,  and  non‐ionic 
surfactant, polysorbate 20. CDLs and ADLs bear strong positive and negative surface charges 
















much  smaller  than  their  actual  size  (Jain  et  al.,  2017).  The  liposomal  component  mainly 
responsible  for  the membrane  elasticity  is  the  surfactant, which  influences  the  interfacial 
tension of the liposomal membrane. Therefore, the degree of membrane elasticity may vary 



















presented  in  Paper  IV).  The  presence  of  curcumin  in  both  NDLs  and  ADLs  reduced  their 
membrane elasticity by more than five‐ and three‐fold, respectively. Despite this finding, the 
degree  of  membrane  elasticity  of  both  curcumin‐NDLs  and  curcumin‐ADLs  was  found 
acceptable  for elastic  liposomal membranes and  in agreement with  literature  (Palac et al., 
2014). On the contrary, curcumin in CDLs contributed to an increased membrane elasticity by 








To  assure  the  effectiveness  of  nanocarrier‐based  skin  formulations,  a  sufficient 
drug/substance load in the nanocarrier should be achieved. Adequate entrapment efficiency 
can assure that  the nanocarrier can achieve the drug/substance concentration at  the  level 








The  entrapment  efficiency  of  curcumin  was  found  to  be  affected  by  the  presence  of 
surfactants  in  the DLs phospholipid bilayer, as expected. The  lipophilic nature of  curcumin 
enables its accommodation in the phospholipid bilayer, therefore a competition might occur 








The  screening  of  the  physicochemical  properties  of  the  nanocarriers  was  considered 








5.4 Effect  of  the  liposomal  surface  charge  on  DL's  skin  penetration 
potential (Paper III and IV) 
To  evaluate  the  skin  penetration  of  both  hEGF  and  curcumin  from NDLs,  CDLs  and  ADLs, 
respectively, ex vivo full human skin in FDC was employed as a skin penetration model. At this 
stage, due to time and access limitations, we could not test the liposomal formulations on the 
IPHSF  model. Moreover,  the  non‐fluorescent  nature  of  hEGF  would  require  the  use  and 
validation of other methods such as fluorescence labelling, to visualize the drug distribution 
through the IPHSF. Therefore, both hEGF‐ and curcumin‐containing DLs were tested using ex 













































weight  compound  similar  to  hEGF,  mediated  by  ADLs,  has  been  recently  reported  by 
Pleguezuelos‐Villa et al. (2018).  
The most  sustained  skin  penetration  of  hEGF mediated  by  ADLs  differed  from  the  earlier 
findings  obtained with  calcein,  although  both  compounds  are  hydrophilic.  The differences 
might  be  explained  considering  the  different  molecular  weight,  which  affects  their  skin 





























skin  penetration  enhancing  effect on  curcumin,  as  previously  reported  for  other  lipophilic 
compounds  incorporated  in ADLs (Paolino et al., 2012). On the contrary, CDLs enabled the 
most  sustained  skin  penetration  of  curcumin.  Curcumin‐containing  cationic  deformable 












dressings  to  optimize  the  frequency  of  dressing  changes.  Wound  dressings  are  normally 
applied  on  open  wounds,  with  compromised  SC  barrier  properties.  This  might  result  in 






As  discussed  in  this  chapter,  the  liposomal  surface  charge  showed  to  play  a  role  in  the 





























































treatment,  both  hEGF‐NDLs  and  hEGF‐ADLs,  at  the  highest  lipid  concentration,  exhibited 
superior  mitogenic  effect  in  HaCaT  cells  as  compared  to  both  control  and  free  hEGF.  As 
observed  for  HFF,  ADLs  exhibited  the  best  enhancement  of  hEGF  mitogenic  activity  and 
increased  HaCaT  proliferation  by  36  and  41%  more  compared  to  control  and  free  hEGF, 
respectively.  Regarding  hEGF‐CDLs,  the  same  effect  was  observed  as  in  the  HFF  cells. 




















fact  that  this  molecule  has  numerous  beneficial  activities,  such  as  anti‐oxidant,  anti‐
inflammatory  and  anti‐microbial,  allowing  curcumin  action  at  different  pathology  levels 





anti‐oxidant  activity  has  been  fully  established  (Mohanty  and  Sahoo,  2017),  therefore we 






cause  morbidity  and  even  mortality  among  patients  (Siddiqui  and  Bernstein,  2010).  The 
treatment  with  oral  antibiotics  often  fails  due  to  the  increasing  incidence  of  bacterial 
resistance  to  antibiotics  (Zhou  et  al.,  2018).  The  administration  of  topical  curcumin 
formulations might  represent a promising approach  to  limit  the overuse of antibiotics and 
their related microbial resistance. We evaluated the possible in vitro anti‐bacterial activity of 


























Gram‐negative bacteria, P.  aeruginosa,  commonly  colonizing  the wounded area  and often 
able to form biofilms. All DLs did not show any enhanced anti‐bacterial activity of curcumin 
when compared to free curcumin (data not shown). Considering the interaction between DLs 
and  bacterial  cell membrane,  a  possible  explanation might  be  in  the  differences  between 
Gram‐positive  and  Gram‐negative  bacterial  membranes.  The  different  membrane 







Skin  inflammation,  especially  in  chronic  wounds,  is  characterized  by  an  excessive  NO 
production by LPS‐induced macrophages. Large quantities of NO might result in the cell death 
caused  by  a  formation  of  an  extremely  reactive  radical  (Deldar  et  al.,  2018).  Moreover, 
regarding the chronic wounds, NO can  induce  impaired collagen synthesis  further delaying 
wound healing (Park et al., 2013).  
Curcumin‐containing DLs were  evaluated  in  terms of  in  vitro  anti‐inflammatory  activity  by 
exploring  any  possible  NO  inhibition  in  LPS‐induced  macrophages  (Figure  5.13).  A  dose‐
dependent  effect  was  observed  for  all  curcumin‐containing  DLs.  Independently  of  the 
liposomal  surface  charge,  all  curcumin‐containing  DLs  (10  and  50  µg/mL  as  lipid 







of  CDLs with  the  negative membrane  of macrophages  compared  to  both NDLs  and  ADLs. 
Considering  the  ex  vivo  skin  penetration  profiles  (Figure  5.9),  the  most  sustained  skin 
penetration of curcumin by CDLs might assure constant therapeutic levels of curcumin at the 
targeted  cellular  level  thus  enhancing  curcumin's  interaction  with  macrophages  and 
consequently  increasing  its  anti‐inflammatory  activity.  Zhao  et  al.  (2013)  observed  this 









w/v) solution, CUR‐PG),  tested at  the same curcumin concentrations as  in DLs. Results are 



































into  a  second  vehicle  and  develop  potential  curcumin‐based wound  dressings.  As  second 
vehicle,  we  selected  chitosan  hydrogel  that  has  shown  to  possess  adequate  rheological 
properties  that  can  guarantee  efficacy  of  the  wound  dressings  for  treatment  of  chronic 
wounds/burns (Hamedi et al., 2018). Chitosan can offer a moist environment and protect the 
wounded area from bacterial infections, also because of its intrinsic anti‐bacterial as well as 
wound  helaing  effect  (Perinelli  et  al.,  2018;  Hurler  et  al.,  2013a).  The  latter  effect  might 
synergistically  act  with  curcumin  assisting  in  effective  localized  chronic  wound  therapy, 
especially preventing microbial colonization and biofilm development. The incorporation of 







































Compared  to  plain  chitosan  hydrogel,  the  incorporation  of  all  DLs  weakened  the  texture 
properties,  regardless  of  the  liposomal  surface  charge  and  the  presence  of  glycerol  as 
stabilizing  agent.  Similar  results  were  also  observed  when  incorporating  deformable 
propylene glycol liposomes in Carbopol hydrogel, although the effect of the liposomal surface 
charge was not investigated (Vanić et al., 2014). Hurler et al. (2013b) observed a reduction of 
chitosan  hydrogel'  texture  properties  after  incorporation  of  CLs  bearing  different  surface 
charge,  in agreement with our  findings. The negative effect observed  for all DLs was even 
more evident compared to the incorporation of free curcumin (curcumin in PG solution). PG 
has  been  shown  to  enhance  the  viscoelasticity of  hydrogels  by  triggering hydrogen bonds 
between  the polymer and water  (Islam et  al.,  2004).  This might  explain  the more positive 
effect  of  free  curcumin  compared  to  DLs.  Comparing  the  liposomal  surface  charge,  the 
charged  DLs  increased  the  hydrogel  hardness,  whereas  negatively  affected  both  the 
cohesiveness  and  adhesiveness.  Possible  interactions  between  the  charged  DLs  and  the 
positively  charged  chitosan  chains might  result  in  an  increased hydrogel  hardness. On  the 
other hand,  the electrostatic  interactions between charged DLs  and  chitosan  chains might 


















exhibit  strong  bioadhesion  (Boateng  and Catanzano,  2015).  For  these  reasons, we  further 
investigated  the  DLs‐in‐hydrogel  formulations  in  terms  of  hydrogel  bioadhesiveness.  We 
based our bioadhesiveness study on a method previously developed in our group by Hurler 
and Škalko‐Basnet (2012). Briefly, the DLs‐in‐hydrogel formulations were placed onto a die, 





not  affected  by  incorporation  of  DLs.  Regarding  the  detachment  force,  no  significant 
















the  force  necessary  to  detach  the  die  from  the  part  of  hydrogel  left  onto  the  skin 
(adhesiveness). We are aware that the obtained values might not be the absolute values of 
bioadhesiveness. We were mainly interested in using the constant experimental conditions 









retained  on  the  skin  surface  (b).  (c)  is  the  detachment  force  determined with  the  second 
experimental  setup  (the  skin  on  the  die  and  the  formulation  placed  at  the  bottom). 
aSignificantly greater than both CUR‐NDL‐in‐hydrogel and CUR‐ADL‐in‐hydrogel. 
 
Although  the  absolute  values  determined  in  the  second  experimental  set  up  were  found 




chitosan  bioadhesiveness  (plain  hydrogel)  was  not  significantly  weakened  by  DLs 
incorporation  into  the  hydrogel.  In  this  case,  NDLs  exhibited  slightly  lower  bioadhesion 
compared  to  plain  chitosan  hydrogel  and  curcumin‐in‐hydrogel, whereas  CDLs‐in‐hydrogel 
exhibited  the  highest  detachment  force.  To  explain  these  discrepancies  between  the  two 
experimental setups, it is also important to mention that the second experimental setup was 
performed  with  DLs‐in‐hydrogel  formulations  which  were  non‐freshly  prepared  (approx.3 
weeks old). Therefore, the lower detachment force observed for NDLs‐in‐hydrogel might be 
explained  by  lower  stability  of  NDLs,  whose  neutral  surface  might  cause  faster  liposome 
aggregation  compared  to  the  charged  DLs  thus  resulting  in  lower  bioadhesiveness.  In 
agreement with this hypothesis are the findings from the stability studies of DLs‐in‐hydrogel 
formulations,  whose  bioadhesiveness  was  determined  using  the  first  experimental  setup. 


















embedded  in  the  chitosan  matrix  to  a  greater  extent  thus  preserving  the  hydrogel 
bioadhesiveness. Therefore, although the original texture properties were weakened after the 









the skin  is  the result of more complex penetration dynamics. We additionally  included the 
liposomal surface charge as another parameter that can play a role in curcumin penetration 
from  DLs‐in‐hydrogel  through  skin.  The  evaluation  of  any  effect  of  the  liposomal  surface 
charge on the skin penetration of curcumin from DLs‐in‐hydrogel systems may assist in the 
development  of  liposomal  hydrogel  formulations  with  tailored  curcumin  skin  penetration 
profiles.  The possibility  to  obtain wound dressings with  controlled  skin penetration of  the 
incorporated  drug/substance  can  directly  improve  localized  skin  therapy  according  to  the 
targeted skin condition/disease. 
Curcumin  penetration  from  DLs‐in‐hydrogel  systems  through  the  ex  vivo  human  skin  is 
presented  in  Figure  5.17.  The  previous  findings  from  ex  vivo  skin  penetration  studies  on 














surface  charge.  The  DLs‐in‐hydrogel  formulations  enabled  dermal  delivery  of  curcumin 














and  was  in  agreement  with  our  findings.  On  the  other  hand,  low  mobility  of  liposomes 
embedded in hydrogel bearing opposite charge has been recently reported by El Kechai and 
collaborators  (2017),  who  observed  that  positive  liposomes  were  highly  immobilized  in  a 
negative  hyaluronic  acid  hydrogel.  Therefore,  the  electrostatic  interactions  between  our 
negative  ADLs  and  positive  chitosan  chains  can  cause  immobilization  of  ADLs  within  the 
hydrogel matrix thus limiting curcumin diffusion. This might explain the sustained curcumin 
penetration  from  ADLs‐in‐hydrogel.  NDLs‐in‐hydrogel  exhibited  the  highest  amount  of 








hydrogel  formulations through the ex vivo human skin. The evaluation of  the effect of  the 
liposomal surface charge on the skin penetration of curcumin assisted in the selection of the 
optimal DLs to be combined with chitosan hydrogel to obtain desired skin penetration profile 
of  curcumin.  These  findings,  together  with  the  longer‐term  bioadhesiveness  of  CDLs‐in‐
















The  selected  nanocarrier  could  be  optimized  to  entrap  active  substances  with  different 
physicochemical properties. Nanocarriers with tailored characteristics and satisfactory drug 
load  could  be  developed  by  manipulating  the  type  of  incorporated  surfactant.  Further 
nanocarrier  optimization  showed  that  the  liposomal  surface  charge  affected  the  skin 





active  substance  and  making  it  available  at  the  targeted  site  of  action.  Therefore,  the 
optimization of deformable liposomes,  in terms of liposomal surface charge, permitted the 
development of promising skin formulations for improved localized skin therapy. 
The  nanocarriers  bearing  different  surface  charge  incorporated  in  the  chitosan  hydrogel 
affected both the stability of hydrogel and its bioadhesiveness, as well as the skin penetration 







Further  validation  of  the  IPHSF  model  as  a  skin  penetration  model  mimicking 
damaged/diseased  skin  could provide a promising  tool  for  exploring drug penetration and 





Both  hEGF‐  and  curcumin‐containing  deformable  liposomes  could  be  tested  on  the 
damaged/diseased  skin  to  further  prove  the  effectiveness  of  the  developed  liposomal 
formulations  in  terms  of  sustained  penetration  of  the  nanocarrier‐associated  active 
substances.  
To  confirm  the  anti‐inflammatory  activities  of  curcumin‐containing  deformable  liposomes, 
their effect on proinflammatory cytokines could be explored. 
To evaluate the anti‐biofilm effect of curcumin‐containing deformable  liposomes,  the anti‐
bacterial  effect might  be  also  evaluated  against  other Gram‐negative  bacteria  and biofilm 
models. 
The liposomal hydrogel formulations with curcumin should be tested in terms of both anti‐
inflammatory  and  anti‐bacterial  activity  to  confirm  their  potential  in  treatment  in  chronic 
wounds. 
The  selected  formulations  with  the  most  promising  properties  in  terms  of  both  dermal 
delivery and enhancement of therapeutic properties of the associated active substance could 
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Available online 05 October 2016Development of effective (trans)dermal drug delivery systems requires reliable skinmodels to evaluate skin drug
penetration. The isolated perfused human skinflap remainsmetabolically active tissue for up to 6 h during in vitro
perfusion. We introduce the isolated perfused human skin flap as a close-to-in vivo skin penetration model. To
validate the model's ability to evaluate skin drug penetration the solutions of a hydrophilic (calcein) and a lipo-
philic (rhodamine) fluorescence marker were applied. The skin flaps were perfused with modified Krebs-
Henseleit buffer (pH 7.4). Infrared technology was used to monitor perfusion and to select a well-perfused
skin area for administration of the markers. Flap perfusion and physiological parameters were maintained con-
stant during the 6 h experiments and the amount of markers in the perfusate was determined. Calcein was de-
tected in the perfusate, whereas rhodamine was not detectable. Confocal images of skin cross-sections shoved
that calcein was uniformly distributed through the skin, whereas rhodamine accumulated in the stratum
corneum. For comparison, the penetration of bothmarkerswas evaluated on ex vivohuman skin, pig skin and cel-
lophanemembrane. The proposed perfused flapmodel enabled us to distinguish between the penetrations of the
two markers and could be a promising close-to-in vivo tool in skin penetration studies and optimization of for-
mulations destined for skin administration.





Isolated perfused human flap1. Introduction
(Trans)dermal delivery of drugs and cosmeceuticals has gained in-
creasing interest in pharmaceutical and cosmetic fields. The skin repre-
sents an attractive route of drug delivery for both local and systemic
effects. In this context, investigating the drug penetration into/through
the skin is of fundamental importance regarding both the desired drug's
therapeutic efficacy and its potential toxicity (DeLouise, 2012; Prow et
al., 2011). Skin, especially the stratum corneum (SC) layer, exhibits
very efficient barrier properties which limit drug penetration into/
through the skin and needs to be overcome for successful trans(dermal)
delivery (Bouwstra et al., 2003; Lane, 2013).ocal laser scanningmicroscopy;
n cells; HS, human skin; IR, infra
fied Krebs-Henseleit buffer; PS,
Drug Transport and Delivery
romsø The Arctic University of
, Louis.De.Weerd@unn.no (L. de
r@uit.no (A.M. Holsæter),Therefore, reliable skin models able to predict and evaluate the (de-
sired or undesired) penetration of molecules/nanosystems in vivo and
serve as a tool in optimization of topical formulations are required
(Flaten et al., 2015). In vivo studies, especially in humans, are the golden
standard tool in skin penetration studies. However, in the early stages of
drug development, in vivo studies are restricted due to ethical and eco-
nomical concerns (Parra et al., 2016). Moreover, new regulations limit
the use of animals for in vivo studies in the initial stages of product de-
velopment (Flaten et al., 2015). Therefore, in vitro and ex vivo tech-
niques are gaining more interest as tools to study skin penetration
(Patel et al., 2016).
The skin perfusion models comprise a surgically prepared portion of
skin (flap) including subcutaneous fatty tissue with assured continuous
vascular circulation. These models offer the benefits of living metaboli-
cally-active tissue and are considered the missing link between in vitro
and in vivo methods (Schaefer et al., 2008). These models overcome
some of the limitations of the in vitro studies using human or animal
skin, such as the use of only epidermis and the upper part of the dermis
and the lack of a dermal vascular system (de Lange et al., 1992; Patel et
al., 2016). Several animal specimens have been used for the skin perfu-
sion model, such as the isolated perfused pig skin flap (Riviere et al.,
1986), the isolated blood-perfused pig ear (de Lange et al., 1992), the
isolated perfused bovine udder (Kietzmann et al., 1993) and the pig
335S. Ternullo et al. / European Journal of Pharmaceutical Sciences 96 (2017) 334–341forelimb (Wagner et al., 2003). Pig skin is considered the most suitable
animal model to mimic human skin. Therefore, pig skin flap has been
widely studied as skin perfusionmodel and skin penetration of different
substances has been investigated using the isolated perfused pig skin
flap model (Carver et al., 1989, 1990; Williams et al., 1990; Wester et
al., 1998; Inman et al., 2003).
However, use of animal skin retains the limitations of correlations
between animal and human skin. Kreidstein et al. (1991) designed the
isolated perfused human skin flapmodel using transverse paraumbilical
skin flap. This tissue is normally discarded in abdominal
dermolipectomy (Kreidstein et al., 1991). Several techniques have con-
firmed the perfusion of the flap (Black et al., 2001; Kreidstein et al.,
1995; Lipa et al., 1999; Miland et al., 2008). Miland et al. (2008) con-
firmed the suitability of the dynamic infrared thermography (DIRT) to
monitor skin flap perfusion and to differentiate between well and less
perfused areas.
To the best of our knowledge, the isolated perfused human skin flap
(IPHSF) has not been used to study (trans)dermal penetration. Such a
model could be a valuable tool in skin penetration studies and in optimi-
zation of dosage forms/delivery systems for skin therapy.
This study evaluated the feasibility of the IPHSF as a skin penetration
model. To validate the IPHSF model, two fluorescent markers, a hydro-
philic (calcein) and a lipophilic (rhodamine), were used and their pen-
etration investigated over a 6 h period. Confocal laser scanner
microscopy (CLSM) technique was used to follow the fluorescent
markers penetration through the IPHSF. These data were compared
with the ex vivo (human and pig skin) and in vitro (cellophane mem-
brane) penetration studies in Franz diffusion cells (FDC).
2. Material and methods
2.1. Material
Calcein, rhodamine B, sodium chloride, potassium chloride, magne-
sium sulfate, sodiumbicarbonate, trichloroacetic acid ( ≥99.0%), ethanol
(96%, v/v) and Triton™ X-100 were from Sigma-Aldrich Chemie
(Steinheim, Germany); human serum albumin (30 mg/mL) from
Octapharma AG (Lachen, Switzerland); propylene glycol (PG) from
NMD –NorwegianMedical Depot AS (Oslo, Norway) and glucose, calci-
um chloride and potassium dihydrogen phosphate from Merck KGaA
(Darmstadt, Germany). Sucrose was product of VWR International
bvba/sprl (Leuven, Belgium). Pig ears were purchased from Nurtura
AS (Bardufoss, Norway).
2.2. Human skin flap
Eight human skin flaps were used in this study and were obtained
from the abdomen of female patients (mean age 49.5 years, range 40–
66 years) who underwent abdominoplasty (Table 1). All patients gave
their written consent prior to the surgery and the experiments wereTable 1
Characteristics of human skin flaps.
Flap number Age (years) Weight (g) Thic
0a 51 –a –a
0b 42 1110 –a
1 47 443 1.90
2 41 526 1.63
3 54 603 1.26
4 40 1187 0.90
5 57 1570 1.68
6 66 525 0.93
7 42 – 0.23
8 42 – 0.17
a Weight and thickness of the flaps were not determined in the preliminary study used to v
b Thickness (cm) refers to the full skin obtained from the human skin flap. Weight was notperformed according to the Declaration of Helsinki Principles. Since
these skin panni are normally disposed of by incineration, no ethical ap-
proval for their use was required according to Norwegian Ethical Com-
mittee. The procurement and disposal of human skin flaps were in
accordance with the policy of the University Hospital of North Norway,
Tromsø.
2.3. Preliminary perfusion experiment
A modification of the perfusion design of the model described by
Miland et al. (2008) was used. The human skin flap, after its excision,
was wrapped in gauze soaked with physiological solution and placed
in a sealed plastic box to maintain it at room temperature until it was
transferred in the laboratory where the flap experiments were per-
formed. To perfuse the human skin flap, it was placed on a metal grid
and one vesselwas selected and cannulatedwith an arteriotomy cannu-
la (diameter 1 mm; DLP® Metronic Inc., Minneapolis, USA), which was
then connected to the perfusion apparatus (Fig. 1). The cannulationwas
performed at room temperature. The perfusate was modified Krebs-
Henseleit buffer (KHb) comprising (in mM): 110 NaCl, 3.8 KCl, 1.4
KH2PO4, 1.2 MgSO4, 31 NaHCO3, 2.5 CaCl2, 11 glucose and 10 sucrose.
Human serum albumin (30 mg/mL) was added to the perfusate. The
perfusate had a pH of 7.4 and an osmolarity of 290 mOsm mimicking
the physiological conditions.
The perfusion flow rate (6–8 mL/min) was monitored using a drop
counter and the pressure by inline pressure transducer (Transpac® IV;
Abbott Laboratories, North Chicago, IL, USA).
All perfusions were initiated within 90 min after the excision of skin
panni (Miland et al., 2008).
2.4. Validation of the IPHSF model
Preliminary calcein skin penetration experiments through the IPHSF
were performed to validate the experimental setups and the analytical
method of the quantification of penetrated marker in the perfusate.
Calcein solution (10 mM) in KHb was applied onto the perfused skin
flap (Fig. 1). The skin diffusion area (49 cm2) exhibiting best perfusion
(skin temperature of ca. 32 °C) was measured with an IR camera (FLIR
ThermaCAM S65 HS, FLIR Systems). An adhesive patch constituted the
donor chamber and calcein solution (7mL)was applied onto the select-
ed well-perfused skin area using a syringe. The experiment was carried
out for 6 hwhen no leakage of the solutionwas observed. Theweight of
the flapwas determined before and after the perfusion period. The pen-
etrated calcein was assessed spectrofluorometrically in the perfusate
collected after 6 h from a metal container placed under the flap. To as-
sure that no inherent fluorescent skin constituents were detected, the
perfusate was also collected when calcein solution was applied (time
0). Moreover, the non-penetrated calcein (retained on the flap surface)
was swept and quantified at the end of experiment.kness (cm) Type of experiment
Preliminary perfusion test
Preliminary skin penetration experiment (calcein)
Skin penetration experiment (calcein)
Skin penetration experiment (calcein)
Skin penetration experiment (calcein)
Skin penetration experiment (rhodamine)
Skin penetration experiment (rhodamine)
Skin penetration experiment (rhodamine)
b Ex vivo skin penetration experiment in FDC (calcein)
b Ex vivo skin penetration experiment in FDC (rhodamine)
alidate the experimental design of the perfusion technique and experimental set up.



















Fig. 1. Flap perfusion design. The perfusate was filtered and gassedwith 95% O2/5% CO2 using a rotating surface oxygenator. The perfusion flow rate (6–8mL/min) wasmonitored using a
drop counter and the perfusion pressure measured with an inline pressure transducer. A heating circulator was set at 38 °C and a thermocouple inserted in the cannula to monitor the
temperature of the perfusate entering the flap. The IR camera monitored the skin surface temperature throughout the perfusion period. The flow, pressure and temperature of the
perfusate were monitored on-line using PhysAcq software. The perfusate from IPHSF was collected using a metal container.
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The analyticalmethod used to detect and quantify calcein in the per-
fusate was based on Bahia et al. (2010) with modifications. The collect-
ed perfusatewas centrifuged to remove blood cells (1914 g, 20min). To
assure that no calcein precipitated with the blood cells the pellets were
firstly washed with KHb (10 mL) and secondly dissolved in Triton solu-
tion5% (w/v; 10mL). Trichloroacetic acid (58.82%,w/v)wasused topre-
cipitate plasma protein. Calcein concentrations in the supernatants,
pellets washed after blood cells precipitation and pellets dissolved in
Triton solution were determined spectrofluorometrically (excitation
and emission wavelengths at 485 and 520 nm, respectively) on a
Polarstar fluorimeter (Fluostar; BMG Technologies, Offenburg, Germa-
ny) using a multiplate reader (COSTAR 96). Three parallels were deter-
mined for each sample. Eq. (1) (derived from the Fick's first law) was
used to calculate the apparent permeability coefficient (Papp) where J
is the observed flux rate (μg/cm2/s) and Cd is the concentration of
calcein solution in the patch (μg/mL). The flux was calculated from the
linear part of the curve, representing the steady-state condition.
Papp cm=sð Þ ¼ J=Cd ð1Þ
2.5. Skin penetration experiments on IPHSF model
Calcein (10 mM) in KHb and rhodamine (10 mM) in KHb/PG (0.5%,
v/v) were applied onto the skin flaps perfused with KHb (Fig. 1). The
weight and thickness of each flap were determined before and at the
end of the experiment. The perfusate was collected at time 0 and
every hour for a period of 6 h and sink conditions were maintained.
The penetrated and non-penetrated markers were quantified as de-
scribed in the methods for validation of the IPHSF model.2.6. Confocal laser scanning microscopy (CLSM)
CLSM analysis was performed on a Leica TCS SP5 microscope (Leica
Microsystems CMS GmbH, Mannheim, Germany) equipped with an
Argon laser. The samples were prepared using the imprint method
(Brommeland et al., 2003). A cross-sectioned slide of the flap was cut
by a scalpel and attached onto a microscope slide. The cells remaining
on the slide were fixed in formalin (SPRAYFIX®, Histolab Products AB,
Gothenburg, Sweden). The flap areas used in CLSM are shown in Fig.
2a. Calcein and rhodamine were excited using 488 and 568 nm laser
lines, respectively. Fluorescence was detected using the following spec-
tral range: 500–550 nm for calcein, 570–610 nm for rhodamine. When
required, images were acquired in Z-sections of 1 to 100 μm thickness
and were superimposed.2.7. Ex vivo and in vitro skin penetration experiments
Ex vivo and in vitro skin penetration experimentswere carried out on
Franz diffusion cells (FDC; PermeGear, Bethlehem, USA) of 1.77 cm2 dif-
fusion area andwith 12mL receiver volume (Hurler et al., 2012). Ex vivo
skin penetration experiments were performed using human skin (HS)
and pig ear skin (PS). Human skin (HS) was obtained from human
skin flaps,whichwere not the same as the flaps used in skin penetration
experiments on IPHSF model (Table 1). Cellophane membrane (CM;
Max Bringmann KG, Wendelstein, Germany) was employed in in vitro
experiments. The same solutions of the fluorescent markers tested in
the IPHSF were added into the donor chamber (600 μL). The receiver
chamber was filled with KHb. Samples (500 μL) were collected at 1, 2,
4 and 6 h and replaced by fresh acceptor medium to maintain sink con-
ditions. All experiments were carried out at 32 °C. Calcein and rhoda-
mine concentrations were determined spectrofluorometrically. Eq. (1)
was used to calculate the Papp.
Fig. 2.Photographs andDIRT images of representativeflaps in skin penetration experiments. The a represents the photographs offlaps. The b are DIRT images recorded1min after the start
of the perfusion (skin temperature below 32 °C). The c, d and e are DIRT images recorded at time 0, 3 and 6 h after the application of the markers, respectively (skin temperature at ca.
32 °C).
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The Student's t-test was used for the comparison of two means. A
significance level of p b 0.05 was considered significant.3. Results
Anymodel destined for application in the development and optimi-
zation of skin formulations needs to be validated to confirm its robust-
ness and wider applicability.3.1. Validation of IPHSF model
Table 1 provides an overview of the characteristics of the flaps used
in experiments. The perfusion experimental set up of Miland et al.
(2008) was modified to identify the areas of the flap with skin temper-
ature of at least 32 °C corresponding to adequate perfusion (Fig. 1). This
enabled us to establish the area (49 cm2) of well-perfused skin surface
suitable to apply fluorescent markers. Once the area was selected, we
focused on optimizing the volume (mL) of themarker solution to be ap-
plied. Calcein solution (7 mL) was injected into an adhesive patch
(donor chamber) attached to the selected well-perfused skin area and
penetration studies performed to further validate the model and con-
firmed its applicability.
The IPHSF was further validated in respect to possible oedema for-
mation and the weight changes. Variation of b10% in the weight ob-
served during 6 h of perfusion was found acceptable (data not shown).
Calcein was detected in the perfusate. Moreover, in the perfusate
collected at time 0 no fluorescence was detected, indicating that no in-
herent fluorescent skin constituents were present in the perfusate and
could be detected spectrofluorometrically.Table 2
Characteristics and physiological parameters of IPHSF recorded during 6 h of experiment (mea
Flap Flow (mL/min) Perfusion inlet pressure (mm Hg) Inlet
1 5.96 ± 0.02 311.95 ± 46.37 35.6
2 6.06 ± 0.18 305.88 ± 50.29 35.4
3 6.59 ± 0.06 307.84 ± 63.70 35.9
4 7.00 ± 0.05 393.23 ± 36.60 36.9
5 5.61 ± 1.12 325.90 ± 12.75 36.0
6 6.46 ± 0.55 295.72 ± 11.82 36.3
a Variation (%) calculated from weight and thickness measured before and after perfusion o3.2. Assuring perfusion during the skin penetration studies
Physiological parameters were monitored throughout the experi-
ment. The flow, perfusion pressure and inlet temperature were kept
constant during 6 h (Table 2).
All areas where the markers were applied were well perfused
throughout the experiment and no leakage of markers from the donor
chambers were observed (Fig. 2a). DIRT images, taken 1 min after the
start of the perfusion, showed a hot spot indicating where the skin per-
fusion started (Fig. 2b). A distinct area of rewarming appeared corre-
sponding to the perfusion area of the cannulated vessel. DIRT images
were also taken before and after the application of markers (Fig. 2c)
and confirmed well-perfused skin in areas where themarkers were ap-
plied throughout the experiment (Fig. 2d, e).
3.3. Penetration of fluorescent markers in IPHSF model
DIRT images of flap areas where markers were applied showed that
the area was still perfused after 6 h. Interestingly, DIRT images of flap
areas next to where rhodamine was applied showed also the less well-
perfused area (skin surface temperature lower than 32 °C) (Fig. 2e). To
further investigate this area, a cross-section of the area was analyzed
by CLSM. CLSM images of themarker-free skin area showed no presence
of bothmarkers, as expected (Fig. 3a). CLSM images of calcein (green) in
the perfused-treated area indicated a uniformly distributed fluorescence
through the skin flap, while rhodamine (red) exhibited a bright fluores-
cence in the SC but decreasing fluorescence in the viable epidermis and
subcutaneous fat tissue (Fig. 3b). CLSM images of both markers in the
well-perfused-untreated area indicated a weaker fluorescence as com-
pared to the treated area (Fig. 3c). In the less well-perfused areas we
could only detect a weak fluorescence of rhodamine (Fig. 3d).
CLSM images confirmed the skin penetration profiles of the two
markers in the IPHSF model.n ± SD).
temperature (°C) Weight variation (%)a Thickness variation (%)a
9 ± 0.18 + 8.58 − 13.16
3 ± 0.19 + 5.70 − 1.23
3 ± 0.18 + 8.79 + 2.38
0 ± 0.06 + 6.40 + 4.44
4 ± 0.13 + 2.58 + 2.38
3 ± 0.14 + 7.81 + 6.45
f flaps.
Fig. 3. Representative CLSM images of cross-sections of IPHSF at the end of skin penetration experiments. CLSM images of calcein (green fluorescence) in IPHSF are shown in the left
column, while CLSM images of rhodamine (red fluorescence) are shown in the right column. The a represents the intact flap cut before the perfusion (control). The b is treated area; c
untreated area. The d is a non-perfused area observed by DIRT in flap where rhodamine was applied. Cross-sectioned slides of IPHSF were cut starting from the skin surface (S; left
side) to the subcutaneous fat (SF; right side). Scale bar represents 500 μm.
Fig. 4. Penetration profiles of calcein and rhodamine through IPHSF (a), HS (b), PS (c) and CM (d). The concentration of calcein in KHb and rhodamine in KHb/PG (0.5%, v/v) solutionswas
10 mM. The penetration of both markers was investigated for a period of 6 h. All experiments were conducted in triplicates and the results are presented as mean ± SD. *p b 0.05.
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vivo and in vitro studies
Penetration of twomarkers through IPHSFmodel is presented in Fig.
4a. No fluorescence was detected in the perfusate at time 0, assuring
that no inherent skin constituents were detected with our analytical
method employed to quantify the penetrated markers in the perfusate.
Calcein was detected in the perfusate, whereas rhodamine was not de-
tectable. Ex vivo skin penetration studies using human skin revealed
lower calcein penetration as compared to IPHSF (p b 0.05) (Fig. 4b).
The same penetration profiles of rhodamine were observed both in
the IPHSF and in ex vivo studies on human skin (Fig. 4a, b). More calcein
and rhodamine penetrated through the pig skin and cellophane mem-
brane compared to the ex vivo human skin and the IPHSF (Fig. 4c, d).
Calcein exhibited higher flux and Papp than rhodamine; whereas the
non-penetrated rhodamine was recovered to higher extent (Table 3).
4. Discussion
The organization of the lipid domains in the SC is considered the
main contributor to the barrier property of the skin (Bouwstra et al.,
2003; Schmieder et al., 2015). This barrier property of the skin can be
seen as a synergy between the cooperation and interactions between
SC macro- and micro-structure, bi- and three-dimensional supramolec-
ular organization of the lipid matrix and composition of the SC (Baroli,
2010). However, dermal circulation is responsible for the clearance of
the drug from the skin and should not beneglected (Lane, 2013). The in-
troduction of nanocarriers has opened a means to improve penetration
of drug into/through the skin. Nanoparticles are expected to enhance or
limit the ingress and diffusion of drugs into/through the skin depending
on their physicochemical properties, particularly size (Vanić et al.,
2015).
Consequently, there is an increasing need to understand the pene-
tration into/through the skin and the interaction between the carrier,
drug and the skin not only to optimize the therapeutic applications,
but also to minimize potential side effects (Bolzinger et al., 2012;
DeLouise, 2012). However, reliable skin models able to predict and in-
vestigate desired or undesired penetration through the skin remain
challenging. Human skin perfusion models offer the benefits of living
tissue with active microcirculation, mimicking the application in
human to a greater extent (Schaefer et al., 2008; Patel et al., 2016).
Moreover, they provide a mean to study the effects of dermal vascula-
ture on the systemic absorption. However, no human skin perfusion
model has been used to assess the penetration of drugs/markers into
the skin and as a tool in dermatological product development.
Kreidstein et al. (1991) have shown that the human skin flap is meta-
bolically and physiologically stable for at least 5 h of in vitro perfusion.
We used DIRT to measure skin perfusion. A number of studies have
shown a good correlation between skin temperature and skin perfusion.
As such DIRT can provide us indirectly with information on skin perfu-
sion and its dynamics (de Weerd et al., 2006, 2009).
The perfusion of IPHSFwas performed using the establishedmethod
by Miland et al. (2008) with modifications. To validate the model, pre-
liminary skin penetration studies were performed on perfused skinTable 3
In vitro and ex vivo penetration of calcein and rhodamine (mean ± SD).
Barrier type
Calcein
Flux (10−3 μg/cm2/s) Papp (10−7 cm/s) Non-penetrated amounta
IPHSF 0.27 ± 0.29 0.41 ± 0.40 69.74 ± 17.16
HS 0.06 ± 0.01 0.09 ± 0.02 86.60 ± 12.28
PS 20.47 ± 6.53 25.92 ± 8.27 43.15 ± 16.41
CM 67.67 ± 1.85 91.22 ± 2.49 28.49 ± 2.23
a The amount retained at skin surface.
b nd, flux and Papp were not determined because no penetrated rhodamine was detected.flaps in order to establish the experimental design of skin penetration
studies on IPHSF. In both preliminary and skin penetration studies, we
observed the same dynamics of perfusion. This confirmed that experi-
mental conditions remained constant throughout the experiments.
Moreover, little variation (b10%) in the weight and thickness of all
flaps during 6 h perfusion excluded oedema formation and assured a
good tissue perfusion as reported earlier (Black et al., 2001; de Lange
et al., 1992; Lipa et al., 1999). Similar to Miland et al. (2008) a perfusion
flow rate between 6 and 8 ml/min was maintained during the experi-
ments. The perfusion pressure was higher than 50mmHg, whichwe at-
tribute to the smaller cannula diameter and the different software used
to monitor the baseline perfusion in our experiments as compared to
Miland et al. (2008).
The IPHSF model was able to distinguish between the penetrations
of two markers (0.7% calcein and 0% rhodamine). Calcein penetrated
to a lower extent, as expected, since it is a hydrophilic marker with
low logP (−5.02) (Gillet et al., 2011) with limited skin penetration po-
tential (Bolzinger et al., 2012). Interestingly, calcein was detected in the
perfusate, whichwould suggest that the circulation enabled its penetra-
tion. Rhodamine has a higher logP (1.95) (Anissimov et al., 2012) and
due to its lipophilicity was prepared in solution containing PG (0.5%;
v/v) as a solubilizing agent. Therefore, we expected that PG would act
as a penetration enhancer (Lane, 2013). However, the concentration of
PG used in our study was relatively low compared to the PG concentra-
tion used in other studies suggesting its role as penetration enhancer
(Trottet et al., 2004;Watkinson et al., 2009). Similar penetration results
were reported by Wester et al. (1998) and their studies on the isolated
perfused pig skin flap model. Tested compounds with lower logP were
detected in higher percentage in the perfusate compared to compounds
with higher logP. Although we could not detect rhodamine in the per-
fusate, the amount of rhodamine retained at the administration site
on the flap was less than calcein. This suggests that rhodamine
remained within SC rather than penetrating deeper into epidermis, as
expected (Bolzinger et al., 2012). The extracellular space in SC and stra-
tum granulosum exhibits hydrophobic properties due to its lipid-rich
composition, whereas the layers below the stratum granulosum repre-
sent hydrophilic environment due to desmosome-rich composition
(Iwai et al., 2012; Schmieder et al., 2015). The IPHSF results were sup-
ported by the CLSM images of the cross-section of skin flaps. While
calcein was found uniformly distributed throughout the flap, rhoda-
mine exhibited a bright fluorescence in the SC but weaker fluorescence
in the viable epidermis and subcutaneous fat tissue. Gillet et al. (2011)
reported similar accumulation of rhodamine in the SC and negligent
amount within the epidermis. The same penetration profile of rhoda-
mine observed in the IPHSF model was seen in full human skin in FDC.
Water present on the surface of skin might cause swelling of the polar
head-group regions in the lipid bilayers, and hence disruption of the
lipid domains, which could explain the higher fluxes of hydrophilicmol-
ecules such as calcein (Bolzinger et al., 2012). However, the percentage
of penetrated calcein through full human skin in FDC was significantly
lower (p b 0.05) than through the IPHSF model indicating that the per-
fusion might play an important role in the penetration of compounds
through the skin, as recently suggested by Patel et al. (2016). For the hy-
drophilicmarker calceinwe observed a positive effect of perfusion on itsRhodamine
(%) Flux (10−3 μg/cm2/s) Papp (10−7 cm/s) Non-penetrated amounta (%)
ndb nd 45.11 ± 8.45
nd nd 39.28 ± 9.16
0.15 ± 0.22 0.19 ± 0.27 4.12 ± 2.49
10.87 ± 0.40 22.11 ± 0.82 2.40 ± 0.38
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etration profile was not influenced by the perfusion to a greater extent.
These results support considerations that ex vivo skin studies do not
resemble the in vivo situations to a satisfactory extent. This is a clear ad-
vantage of the skin perfusionmodels, since thesemodels investigate the
drug penetration considering also the dermal perfusion (Schaefer et al.,
2008). Wagner et al. (2002) also reported that hydrophobic flufenamic
acid penetrated less through the human skin in FDC system than in in
vivo studies. We confirmed that the perfusion played a role in the pen-
etration of bothmarkers by analyzing cross-section of perfused skin flap
areas where the markers were not applied (as visible by DIRT images).
CLSM images of these untreated perfused areas showed the presence
of both markers in the skin and subcutaneous tissue of untreated
areas confirming that perfusion affected the penetration. Such findings
stress the importance of perfusion in a skin penetration model.
The results obtained with the IPHSF model were compared with the
results obtained on the established skin models. Both penetration stud-
ies through the pig skin and cellophane membrane showed a higher
penetration of the markers compared to their penetration through the
IPHSFmodel and human skin in FDC system, strongly indicating the im-
portance of having a model that contains human skin. Interestingly,
calcein penetrated through pig skin more than rhodamine. Observed
Papp of calcein across pig skin was similar as in an established in vitro
model mimicking human SC lipid composition (Engesland et al.,
2013). Rhodamine penetration through the pig skin, IPHSF model and
human skin on FDC system was similar and as expected since it is
known that pig skin mimics human skin better for the lipophilic pene-
trants (Dick and Scott, 1992). Penetration of both markers through cel-
lophane membrane was significantly higher than in other models used
in this study (p b 0.05); calcein penetrated more than rhodamine in
agreement with Ansari et al. (2006) who tested the penetration of
three drugs with different lipophilicity through human skin, cellophane
and natural membranes. They found that penetration of water soluble
diclofenac sodium through cellophane was higher than through all
other membranes, while penetration of lipophilic erythromycin
through cellophane was lower (Ansari et al., 2006).
Although different in vitro and ex vivo animal skin models help us to
simplify the drug penetration, the results obtained from those models
differ from the results obtainedwith IPHSFmodel suggesting the impor-
tance of this missing link in reaching the close-to-in vivo situation.
The limitation of this study is the relatively small number of experi-
ments; therefore, the results should be interpretedwithin the context of
this limitation.Moreover, the IPHSFmodel ismetabolically active for 6 h
and skin drug penetration studies on IPHSFmodel have to be performed
within this time limit. Specific equipment, such as infrared camera, is
needed to perform skin flap experiments as well as the help of selected
professionals to cannulate the skin flap. Therefore, we are aware that
the IPHSF model cannot be used as skin perfusion model in the early
stages of drug development. However, the model might be used, after
the fully validated methodologies have been employed, to study skin
drug penetration in conditions closer to the in vivo human ones since
the importance of perfusion and the use of human skin in skin penetra-
tion studies is clear.
The next step in full utilization of the proposed model is to evaluate
the penetration of nanoparticles and nanoparticle-associated drugs.
5. Conclusions
We demonstrated that the isolated perfused human skin flap model
can beused in the skin penetration studies since it provides constant ex-
perimental conditions and perfusion, assuring reproducible results.
Moreover, the model proves the benefits of working with living tissue
using a byproduct of surgery, and avoiding animal use. The model was
able to distinguish between the penetrations of two markers and is a
promising tool in optimization of formulations destined for skin
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Isolated perfused human flap
A B S T R A C T
Phospholipid-based nanocarriers are attractive drug carriers for improved local skin therapy. In the present
study, the recently developed isolated perfused human skin flap (IPHSF) model was used to directly compare the
skin penetration enhancing potential of the three commonly used nanocarriers, namely conventional liposomes
(CLs), deformable liposomes (DLs) and solid lipid nanoparticles (SLNs). Two fluorescent markers, calcein (hy-
drophilic) or rhodamine (lipophilic), were incorporated individually in the three nanosystems. The nanocarrier
size ranged between 200 and 300 nm; the surface charge and entrapment efficiency for both markers were
dependent on the lipid composition and the employed surfactant. Both carrier-associated markers could not
penetrate the full thickness human skin, confirming their suitability for dermal drug delivery. CLs exhibited
higher retention of both markers on the skin surface compared to DLs and SLNs, indicating a depo formation. DLs
and SLNs enabled the deeper penetration of the two markers into the skin layers. In vitro and ex vivo skin
penetration studies performed on the cellophane membrane and full thickness pig/human skin, respectively,
confirmed the findings. In conclusion, efficient dermal drug delivery can be achieved by optimization of a lipid
nanocarrier on the suitable skin-mimicking model to assure system’s accumulation in the targeted skin layer.
1. Introduction
According to the Global Burden of Disease Study 2010, the skin
diseases are the fourth leading cause of disease burden at global level.
The skin-related illnesses are cause of the disability affecting between
30 and 70% of individuals [1]. Despite progress achieved in the local
skin therapy, the treatment of skin diseases remains challenging [2].
Topical drug delivery for localized skin therapy bears some advantages
compared to the traditional administration routes, such as the avoid-
ance of systemic administration, the lower dose of drug required to
reach the desired level at the targeted site and the reduction of systemic
side effects [3]. In addition, an increase in the antimicrobial resistance
among the drugs used to treat skin infections systemically, is empha-
sising the need for an efficient localized antimicrobial skin therapy [4].
However, the penetration of drugs into the deeper skin layers, espe-
cially through the stratum corneum (SC), remains an important
challenge in the development of effective topical formulations destined
to exert localized effect in the skin [5]. For example, in the in-
flammatory skin diseases (e.g. dermatitis, psoriasis) and fungal skin
infections, leucocytes invade the skin leading to an increase in the
proliferation and differentiation of keratinocytes and consequent in-
crease in the skin thickness and further enhancement of the skin barrier
properties exerted mainly by the SC [6]. The formulations that fail to
achieve the optimal therapeutic drug levels within the deeper skin
layers, or to assure the depot at the skin surface, are considered sub-
optimal. Among the emerging approaches employed to improve the
dermal delivery of drugs, nanodermatology represents one of the most
promising [7,8]. Nanocarriers have shown to improve the solubility of
highly hydrophobic drugs, increase drug chemical and physical stabi-
lity, deliver higher concentration of drugs to the targeted site and
provide sustained and controlled release of the associated drugs [9].
Phospholipid-based nanosystems are of a particular interest and have
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been widely investigated for improving the topical skin therapy. Their
phospholipid nature contributes to low toxicity and high compatibility
with physiological skin lipids, especially in the SC [10]. These lipid-
based nanocarriers have shown to enhance the penetration through the
skin by overcoming the intact skin barrier and allowing dermal delivery
of associated drugs [11]. One of the first proposed vesicular nanosys-
tems were the conventional liposomes (CLs). Their structure permits the
incorporation of lipophilic, hydrophilic and amphiphilic compounds
[12]. The similarities between CLs and skin lipids allow their accu-
mulation on the SC surface and fusion with skin lipids. This induces
changes in the SC intercellular lipids, thus increasing the skin perme-
ability and drug penetration [10]. However, most of the literature
proves that CLs remain mainly confined to the SC thus building a re-
servoir to release slowly the associated drug. To improve drug pene-
tration deeper into the skin layers, deformable liposomes (DLs) were
proposed by Cevc and Blume [13]. These liposomes are composed of
lipids and an edge activator, which provides elasticity and deform-
ability to the liposomes. Consequently, DLs could potentially squeeze
through the SC thus increasing the transport of the drug deeper into the
skin layers [14].
Alternative to liposomes are particulate lipid-based nanosystems,
such as solid lipid nanoparticles (SLNs). SNLs are composed of one or
more solid lipids dispersed in an aqueous medium with an addition, if
necessary, of a surfactant as a stabiliser [15]. These nanocarriers lack
the bilayer structure of the liposomes, thus being more stable in both
hydrophilic and lipophilic environment [16]. SLNs allow controlled
release of the drug and penetration enhancement exerted by their oc-
clusive properties [17]. Furthermore, they exhibit good skin toler-
ability, and are considered to be safe and biocompatible [18].
The lipid composition of the lipid-based nanocarriers is strongly
influencing their physicochemical characteristics, such as particle size,
surface charge, bilayer elasticity and thermodynamic phase. By opti-
mizing the lipid composition, it is possible to influence/optimize vesicle
deposition onto/within the skin and modulate the depth to which the
drug will be delivered [19].
For the first time, we directly compared the skin penetration en-
hancement of three different lipid-based nanocarriers on the isolated
human skin flap (IPHSF) model, a recently developed human skin
perfusion model [20]. To follow the drug penetration from different
lipid-based nanocarriers, two fluorescent markers with different lipo-
philicities, calcein and rhodamine, were employed and their penetra-
tion from the CLs, DLs and SLNs followed. The IPHSF model offers the
advantage of working with the skin in the presence of dermal circula-
tion, thus mimicking the in vivo human conditions to a higher extent.
The confocal laser scanner microscopy (CLSM) technique was used to
follow the penetration profiles. Moreover, a comparison of the marker
penetration on IPHSF model with some of the established skin pene-
tration models such as cellophane membrane and full thickness pig/
human skin in the Franz diffusion cells system was performed.
2. Materials and methods
2.1. Materials
Lipoid S 100 (phosphatidylcholine from soybean,> 94% pure; PC)
was a gift from Lipoid GmbH (Ludwigshafen, Germany). Calcein, rho-
damine B, methanol CHROMASOLV®, magnesium sulfate heptahydrate,
potassium chloride, sodium bicarbonate, sodium chloride, tri-
chloroacetic acid (≥99.0%), Fiske-Subbarow reducer reagent, ammo-
nium molybdate, phosphorus standard solution, sodium deoxycholate
(SDCh) and Triton™ X-100 were purchased from Sigma-Aldrich Chemie
(Steinheim, Germany). Potassium dihydrogen phosphate, glucose, hy-
drogen peroxide (30%) and calcium chloride were obtained from Merck
KGaA (Darmstadt, Germany). Propylene glycol (PG) was purchased
from NMD – Norwegian Medical Depot AS (Oslo, Norway), Albunorm®
(human serum albumin, 200 mg/mL) from Octapharma AG (Lachen,
Switzerland) and sucrose from VWR International bvba/sprl (Leuven,
Belgium). Sulfuric acid was purchased from May and Baker LTD
(Dagenham, UK). Cellophane membrane was obtained from Max
Bringmann KG (Wendelstein, Germany) and pig ears from Nortura AS
(Bardufoss, Norway).
2.2. Preparation of liposomes
CLs and DLs with calcein or rhodamine were prepared by the film
hydration method [21].
PC (300 mg) for CLs or PC/SDCh (total 300 mg; 85/15% as weight
ratio) for DLs were dissolved in approximately 20 mL of methanol in a
round bottomed flask. When applicable, rhodamine (47.9 mg) was
dissolved together with the lipid in organic solvent resulting in 10 mM
rhodamine solution. The organic solvent was completely removed
under a vacuum (50 mbar) using a rotary vacuum evaporator (Büchi
Rotavapor R-124 with Büchi Vacuum Pump V-700, Büchi Labortechnik
AG, Flawil, Switzerland) for 1 h at 45 °C. The resulting lipid film was
then rehydrated in 10 mL of modified Krebs-Henseleit buffer (KHb) (pH
7.40; 280 mOsm; 110 mM NaCl, 3.8 mM KCl, 1.4 mM KH2PO4, 1.2 mM
MgSO4, 31 mM NaHCO3, 2.5 mM CaCl2, 11 mM glucose and 10 mM
sucrose) by hand shaking at room temperature (23–24 °C) for 20 min.
For calcein-containing liposomes, calcein (62.2 mg) was dissolved in
the KHb to form 10 mM calcein solution used to rehydrate the film. All
liposomal suspensions were stored overnight in the fridge (+4 °C) prior
to the characterisation.
2.3. Preparation of solid lipid nanoparticles
SLNs with calcein or rhodamine were prepared by the solvent in-
jection method [22] with some modifications. PC (1.20 g) was dissolved
in methanol. The obtained lipid solution (120 mg/mL; 2 mL) was then
rapidly injected via an injection needle (Sterican® 0.30 × 12 mm,
Braun Melsungen AG, Melsungen, Malaysia) into KHb solution (6 mL)
under the stirring (300 rpm). For SLNs containing calcein, the marker
was dissolved in the KHb solution used to prepare nanoparticles,
whereas for SLNs containing rhodamine, the lipophilic marker was
dissolved in the lipid solution. Both markers were applied in the same
concentrations as used for CLs and DLs preparation. The suspension was
stirred for 2 h at room temperature (23–24 °C) and kept overnight in the
fridge (+4 °C) prior to the characterisation.
2.4. Size reduction
The original size of CLs, DLs and SLNs containing either calcein or
rhodamine was reduced by the hand extrusion through the poly-
carbonate membrane (Nuclepore® Track-Etched Membranes, Whatman
House, Maidstone, UK). The pore size of the membranes and the
number of extrusion cycles were adjusted for each formulation to ob-
tain vesicles within the size range of 200–300 nm. CLs, DLs and SLNs
containing calcein were extruded stepwise through the 0.8, 0.4 and
0.2 µm pore size membranes, three times for each pore size. The same
was done for CLs containing rhodamine, while DLs containing rhoda-
mine were extruded two times through the 1.2 µm pore size membrane.
SLNs containing rhodamine were extruded stepwise through 0.8 and
0.4 µm pore size membranes (three times each) and two times through
0.2 µm pore size membranes. All extruded CLs, DLs and SLNs were then
kept in the fridge (+4 °C) for a minimum of 3 h prior to characterisa-
tion and usage.
2.5. Size measurements
The particle size distributions of all CL, DL and SLN suspensions
were determined by the dynamic light scattering [23] (NICOMP Sub-
micron Particle Sizer Model 370; NICOMP Particle Sizing system, Santa
Barbara, California, USA). The sample preparation was performed in a
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laminar flow bench. Firstly, the test tubes were flushed once with KHb
previously filtrated through 0.2 µm syringe filter (Bulk Acrodisc®
25 mm Syringe Filter, Pall Life Sciences, East Hills, New York, USA).
The samples were diluted with the KHb to obtain a particle intensity
between 250 and 350 kHz. The analyses were run in a vesicle mode for
CLs and DLs, and solid particle mode for SLNs, respectively. Each
measurement was done in triplicates (runtime of 10 min; 23–24 °C).
The size distributions of all nanocarriers, expressed as the mean dia-
meter and polydispersity index (PI), were determined using the in-
tensity-weighted distribution.
2.6. Zeta potential measurements
The zeta potential of liposomal and solid lipid nanoparticles sus-
pensions was determined on Malvern Zetasizer Nano – ZS (Malvern,
Oxford, UK) [24]. The instrument was calibrated with Malvern Zeta
potential transfer standard (−42 ± 4.2 mV). A folded capillary cell
(DTS1060) was used for the measurements. The cell was rinsed with
ethanol and then with filtered water (0.2 µm syringe filter) prior to the
sample. Each sample was diluted in a filtrated water (1:10 and 1:20 vol
ratio for calcein- and rhodamine-containing nanocarriers, respectively)
to achieve a suitable count rate. The diluted sample was injected into
the folded capillary cell, assuring that no air bubbles formed during the
injection. All measurements were performed at 25 °C with an equili-
bration time of 180 s. Three measurement runs were performed for each
sample, assuring an attenuator of 6–7.
2.7. Entrapment efficiency determination
The unentrapped calcein was separated from the extruded CLs, DLs
and SLNs by dialysis. Typically, 5 mL of suspension were placed in a
dialysis bag (Mw cut off 12,000–14,000 Da, Medicell International Ltd,
London, UK) and dialysed against 500 mL of KHb for 6 h at room
temperature. The dialysis bag was immersed in fresh KHb (500 mL) and
dialysis continued for additional 3 h. The volume of the receptor
medium was chosen to assure the sink conditions. After the dialysis,
CLs, DLs and SLNs were mixed with a Triton solution (5%, v/v) to
dissolve the lipids before quantification of calcein by measuring fluor-
escence on a Polarstar fluorimeter (Fluostar; BMG Technologies,
Offenburg, Germany) with excitation and emission wavelengths at 485
and 520 nm, respectively. Standard curves of calcein in KHb solution
and calcein in Triton solution (5%, v/v) were used to determine the
unentrapped and entrapped calcein, respectively. A concentration
range between 0.12 and 1.37 µg/mL was used for both the standard
curves (R2 of minimum 0.9990). A blank consisting of KHb or Triton
solution (5%, v/v) was subtracted from the fluorescence values.
Ultracentrifugation was performed to separate unentrapped rhoda-
mine from CLs and SLNs, while gentle centrifugation was used for DLs.
Extruded CLs and SLNs were centrifuged (Beckam model L8-70M ul-
tracentrifuge with an SW 60 Ti rotor, Beckam Instruments, Palo Alto,
California, USA) at 110,000g for 1 h at 10 °C. Extruded DLs were cen-
trifuged (Biofuge stratos centrifuge with a swinging bucket rotor
4 × 180 mL; Heraeus instruments GmbH, Hanau, Germany), at 3,000g
for 25 min at 10 °C. The supernatants were separated from the pellets,
which were resuspended in KHb. Lipids in both supernatants and pellets
were dissolved in methanol and the rhodamine content was determined
fluorometrically on a Polarstar fluorimeter (Fluostar; BMG
Technologies, Offenburg, Germany) with excitation and emission wa-
velengths at 544 and 590 nm, respectively. To avoid evaporation of
methanol during the fluorescence measurements, all samples were di-
luted in KHb to obtain a methanol concentration of 50% (v/v). The
standard curve of rhodamine in methanol/KHb solution (1:1, v/v) was
prepared using the concentrations ranging from 0.10 to 1.20 µg/mL (R2
of minimum 0.9980). A blank consisting of methanol/KHb solution was
subtracted from the fluorescence values.
The recovery of calcein and rhodamine was determined and found
to be between 100.3 and 107.7%, respectively.
2.8. Phospholipid content
The phospholipid content in CLs, DLs and SLNs was determined to
enable calculation of entrapment efficiency expressed as the marker/
lipid ratio. A modification of Bartlett method was used [25]. In brief, all
samples were diluted in distilled water (typically 1:200, v/v). An ali-
quot of diluted sample (1 mL) was mixed with sulfuric acid (5 M;
0.5 mL) and then incubated at 160 °C for a minimum of 3 h. After the
cooling, two drops of hydrogen peroxide 30% were added and the so-
lutions incubated at 160 °C for 1.5 h. After the cooling, ammonium
molybdate (0.22%, w/v; 4.6 mL) and Fiske-Subbarow reducer (0.2 mL)
were added, vortexed and incubated at 100 °C for 7 min. The samples
were then cooled down and analysed by UV–VIS spectrophotometry at
830 nm using a SpectraMax 190 Microplate Reader (Molecular Devices,
California, USA). The standard curve was prepared using a phosphorus
standard solution in a concentration range of 1–8 µg/mL (R2 of
minimum 0.9990).
2.9. Skin penetration experiments on IPHSF model
The skin penetration of calcein and rhodamine from CLs, DLs and
SLNs was evaluated on the recently established IPHSF model [20]. The
human skin flaps (the mean age of 49.3 years, range 26–72 years) were
obtained from the abdominoplasty operations of female patients, after
receiving their written consent prior to the surgery. The excess of skin
and subcutaneous fatty tissue as residue after the surgery are normally
disposed, therefore no ethical approval by the Norwegian Ethical
Committee was required. However, all experiments were performed in
accordance with the Declaration of Helsinki Principles. Each formula-
tion (CLs, DLs and SLNs containing either calcein or rhodamine) was
tested in triplicates on three independent human skin flaps, obtained
from different female donors. Human serum albumin (final concentra-
tion of 30 mg/mL) was included in the KHb to prepare the perfusate
solution. The human skin flaps were cannulated and perfused with the
perfusate within 90 min after their excision. The temperature of the
perfusate entering the flap (inlet temperature) was maintained at ap-
proximately 32 °C using a heating circulator set at 38 °C. The use of an
infrared (IR) camera (FLIR ONE, Thermal Imaging Camera for iOS; FLIR
Systems) allowed the selection of the best perfused skin diffusion area
(49 cm2) having a skin temperature of ca. 32 °C. The formulation (7 mL)
was applied onto the selected perfused skin diffusion area using an
adhesive patch as described by Ternullo and colleagues [20]. The ex-
periments were carried out for 6 h and sampling was performed by
collecting the perfusate every hour, assuring the sink conditions
throughout the experiment. The physiological parameters, namely the
perfusion inlet pressure, perfusion flow rate and inlet temperature,
were recorded throughout the experiments [20]. To exclude oedema
formation, the weight and thickness of each flap were measured before
and at the end of the experiment. A weight and thickness variations of
less than 10% was found acceptable. Blood cells were removed from the
collected perfusate by the centrifugation (1914g, 20 min), while plasma
proteins were precipitated using trichloroacetic acid (58.82%, w/v)
[20]. The obtained samples were then analysed fluorometrically, as
described above, to quantify the penetrated markers through the full
thickness IPHSF. Moreover, the amount of the markers retained onto
the skin flap surface was determined fluorometrically.
2.9.1. Confocal laser scanning microscopy on IPHSF model
To localise the two markers in the IPHSF model after the skin pe-
netration experiments, CLSM technique was employed [20] (Leica TCS
SP5 microscope equipped with an Argon laser; Leica Microsystems CMS
GmbH, Mannheim, Germany). Briefly, the imprint technique was used
to prepare the samples. At the end of the skin penetration experiments,
the treated perfused skin flap area was cut cross-sectionally and
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attached onto a microscope slide. Formalin (SPRAYFIX®, Histolab Pro-
ducts AB, Gothenburg, Sweden) was sprayed to fix the cells that re-
mained on the slide. Laser lines of 488 and 568 nm were used to excite
calcein and rhodamine, respectively. A spectral range of 500–550 nm
and 570–610 nm were used to detect the calcein and rhodamine
fluorescence, respectively.
2.10. In vitro skin penetration experiments
Franz diffusion cells (PermeGear, Bethlehem, USA) were used to
perform in vitro skin penetration experiments following the method
reported earlier [20]. Cells of 1.77 cm2 diffusion area with a receptor
volume of 12 mL were used. Cellophane membrane was pre-soaked in
KHb for 30 min prior to the experiment. KHb constituted the receptor
phase, which was maintained at 37 °C throughout the experiment to
assure the physiological skin temperature of 32 °C. CLs, DLs and SLNs
containing either calcein or rhodamine were added to the donor
chamber (sample volume of 600 µL). As controls, calcein in KHb and
rhodamine in KHb/PG (0.5%, v/v) were used. The content of the two
markers in the tested samples was determined fluorometrically prior to
the penetration study and the concentration of markers in the donor
chamber was equalised in all samples to assure the same concentration
gradient. Sampling from the receptor chamber was done every hour for
a period of 8 h. The withdrawn samples (500 µL) were replaced by an
equal volume of fresh KHb to assure the sink conditions. All experi-
ments were performed in triplicates. The markers penetrated through
the cellophane membrane and non-penetrated markers were quantified
fluorometrically as described in Section 2.7.
2.11. Ex vivo skin penetration experiments
Full thickness pig and human skin were used for ex vivo skin pe-
netration studies [20]. Frozen pig ear skin slices were thawed, rinsed
with water and cleared from the subcutaneous fat. Human skin was
obtained from the resected skin during abdominoplasty of female pa-
tients, after their written consent was received. No ethical approval for
the use of human skin was required by the Norwegian Ethical Com-
mittee, since the excess of skin panni is normally disposed after the
surgery. The experiments were conducted in accordance with the De-
claration of Helsinki Principles. The excised portion of human skin was
rinsed with water and, after a removal of the subcutaneous fat, stored at
−20 °C and thawed 30 min before the start of the experiment. Each
formulation and controls were tested in triplicates on human skin that
was obtained from the same patient. Pig and human skin thicknesses
were measured prior to the experiment and skin with thickness of ap-
proximately 1.50 mm was used. The skin was mounted into the same
Franz diffusion cells used for the in vitro experiments; the SC side was
facing the donor chamber. The tested formulations, receptor medium
and sampling time were the same as in the in vitro skin penetration
experiments (Section 2.10). The markers penetrated through the full
thickness pig/human skin and non-penetrated markers were quantified
as described in Section 2.7.
2.12. Statistical analyses
The student's t-test (paired) was used to determine a statistical sig-
nificance. A p value of less than 0.05 was considered statistically sig-
nificant.
3. Results and discussion
Improved drug delivery to deeper skin layers could enable improved
drug outcome in many topical therapies reducing the need for systemic
treatment. However, the complex barrier of the skin, particularly the
SC, which is the barrier responsible for rate-limiting step in skin drug
penetration, should be addressed when designing/developing the
dermal formulations [26]. Phospholipid-based nanocarriers have
shown ability to enhance drug penetration through the SC and allow
the sustained and controlled release of associated drugs [27–29]. The
changes in the composition of phospholipid-based nanocarriers affect
their interaction with the skin [14]. Therefore, a direct comparison of
the skin penetration enhancement by the different phospholipid-based
nanocarriers is helpful in the optimization of efficient nanopharma-
ceuticals destined for localized skin therapy. The right choice of the
nanocarrier would lead to the optimal therapeutic drug levels in the
specific skin layers, and could be tailored for the specific skin disease.
3.1. Characteristics of the phospholipid-based nanosystems
Table 1 presents the characteristics of phospholipid-based nano-
systems used in this study. The optimal size of nanocarriers for dermal
drug delivery was proposed to be 200–300 nm [30]. The size of lipo-
somes and solid lipid nanoparticles containing either calcein or rho-
damine was between 200 and 300 nm, as targeted. The extrusion as a
method for a vesicle/particle size reduction has shown to be a suitable
method to obtain the desired vesicle/particle size and rather homo-
genous systems. The PI was found to be lower than 0.3 for all vesicles/
particles (between 0.06 and 0.27) indicating relative homogeneity in
size. Among the nanocarriers containing calcein, a significant difference
(p < 0.05) in the size was observed for DLs, which were smaller
(201 nm) as compared to both CLs (265 nm) and SLNs (220 nm), re-
spectively. Our finding is in accordance with literature [31–33]. The
presence of SDCh in the phospholipid bilayers of DLs provides elasticity
and flexibility to the liposomes, and reduces their surface tension. Ra-
ther homogenous size (PI < 0.3) was also obtained for rhodamine-
containing nanocarriers. CLs and SLNs were of similar mean size (244
and 227 nm, respectively); a bimodal size distribution (Nicomp dis-
tribution) was observed for SLNs where a small percentage (6.5%) of
Table 1
Characteristics of phospholipid-based nanocarriers containing calcein or rhodamine (n = 3 ± SD).
Marker Nanocarrier Diameter (nm)a PIb Zeta potential (mV) Marker/lipid ratio (µg/mg)
calcein CL 265 ± 3 (100%) 0.16 ± 0.02 −1.2 ± 0.2 72.3 ± 7.6
DL 201 ± 1c (100%) 0.06 ± 0.00 −32.8 ± 0.5 79.6 ± 14.2
SLN 220 ± 12 (100%) 0.16 ± 0.03 −2.9 ± 1.2 82.3 ± 2.1
rhodamine CL 244 ± 16 (100%) 0.17 ± 0.06 −1.4 ± 0.1 92.9 ± 2.2
DLd 294 ± 34 (87.4%)
76 ± 18 (12.6%)
0.27 ± 0.03 −31.5 ± 0.5 63.3 ± 4.1
SLNd 227 ± 26 (93.5%)
24 ± 42 (6.5%)
0.18 ± 0.01 +1.6 ± 0.1 53.0 ± 3.4
a The diameter is expressed as peaks in size distributions (nm) and weight intensity of each peak (%), which is indicated in parentheses.
b Polydispersity index.
c p < 0.05.
d Bimodal size distribution.
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smaller particles (24 nm) was found. DLs containing rhodamine were
characterised by a bimodal size distribution (Table 1) as observed for
SLNs. The main peak within the size distribution of DLs was higher
(294 nm) compared to both CLs and SLNs; the PI (0.27) was also the
highest as compared to the other formulations. This size was obtained
after only two cycles of extrusion through the polycarbonate membrane
with 1.2 µm pore size membranes. Considering a potential pilot scale
manufacturing, this could be considered an advantage regarding the
manufacturing.
The surface charge of nanocarriers is also a factor that can play an
important role in the skin penetration of associated drugs [34]. Our
phospholipid-based nanosystems exhibited zeta potential in accordance
with the nature of the material used for their preparation. CLs and SLNs
containing either calcein or rhodamine had a zeta potential close to
neutral, due to the main presence of neutral PC. DLs containing either
calcein or rhodamine beard a strong negative surface charge, providing
them with additional stability [21]. Although the skin has a net nega-
tive charge, negatively charged liposomes have shown to enhance skin
drug penetration [34].
To assure improved skin deposition of nanocarrier-associated drugs,
it is crucial to assure high drug load. In this study, we have used two
different markers as model substances for hydrophilic and lipophilic
drugs, respectively. The entrapment efficiencies for nanocarriers con-
taining calcein, expressed as a marker/lipid ratio, were not significantly
different. Unexpectedly, DLs entrapped more calcein compared to CLs,
although DLs were smaller. The presence of SDCh may increase the
incorporation of this marker in DLs [35]. We expected a lower en-
trapment efficiency for SLNs, since they are known to possess low
loading capacity for hydrophilic compounds [36]. However, Suter and
collaborators [37] have recently demonstrated that SLNs might also
incorporate high load of hydrophilic compounds, such as peptides,
which is in agreement with our results. CLs containing rhodamine in-
corporated the highest amount of the marker compared to both DLs and
SLNs (Table 1). The presence of SDCh in DLs decreased the entrapment
efficiency, possibly due to a competition between rhodamine and SDCh
both accommodated in the phospholipid bilayer of liposomes [31]. It is
known that the lipids in SLN can re-crystallize into a highly ordered
crystalline structure. This process can cause drug expulsion, reducing
the entrapment efficiency [38]. Our results are in accordance with lit-
erature [39].
3.2. Penetration enhancing effect of the phospholipid-based nanocarriers in
the IPHSF model
Optimization of effective nanosystems for skin therapy requires
validated skin penetration models. The recently established drug pe-
netration (IPHSF) model was used for this purpose. The model offers the
possibility of working with the presence of dermal circulation in the
conditions similar to the in vivo, important parameter in the penetration
studies [40]. The use of an IR camera allowed visualisation of the
perfused skin flap area destined for the topical application of the tested
formulations on the IPHSF model and served as a validation module of
the model. IR images of the representative flaps taken during the ex-
periments are shown in Fig. S1. The skin area, where the formulations
were applied, was perfused throughout the whole penetration experi-
ment. The physiological parameters were monitored during the ex-
periment. The perfusion inlet pressure, flow and inlet temperature were
adjusted to maintain the perfusion of the human skin flaps (skin surface
temperature of ca. 32 °C). Physiological parameters recorded during the
skin penetration experiments in the IPHSF model are shown in Fig. S2.
Although the perfusion inlet pressures varied, the flap perfusion was
assured throughout the experiments and the variation of weight and
thickness of flaps was found to be less than 10% (data not included).
The lower perfusion inlet pressures did not affect the perfusion and the
higher pressures did not cause oedema formation, which was found
acceptable. The temperature remained constant throughout the ex-
periments.
No markers were found in the perfusate, indicating that our nano-
carriers were not able to deliver the two markers deeper into the dermis
layer allowing them to become absorbed in the systemic circulation.
Therefore, all the investigated nanocarriers can be used as drug delivery
systems for dermal, rather than transdermal drug therapy. This was
expected considering their size. However, the limited time (6 h) of the
experiment should be considered. Whether a longer time would permit
some of the nanocarriers to penetrate deep enough into the dermis to
enable marker absorption remain to be addressed in in vivo experi-
ments. Our results are in accordance with Chen and colleagues [19],
although their studies were performed using human skin in the Franz
diffusion cells. No permeation of the tested markers through the full
thickness human skin was observed in finite dose application for all
tested nanocarriers and only low percentages (0.001%) of the hydro-
philic marker were detected in the receptor fluid when the formulations
were applied in infinite dose [19]. The perfusion of the IPHSF could not
be assured over a longer time (more than 6 h), and we assumed that the
perfused skin should permit penetration through the full thickness skin
barrier at faster rate than the non-living skin. Assessment of the pene-
tration potential of three types of nanocarriers containing either calcein
or rhodamine was also evaluated by the amount of the marker retained
on the top of the skin at the end of skin penetration experiments. Fig. 1
presents the percentages of the non-penetrated markers, indicating the
markers retained on the top of skin surface of the IPHSF. The rank order
of the tested nanocarriers according to their capability to enhance the
penetration of the two markers through the SC was CLs < DLs≈ SLNs.
DLs are expected to be more effective than CLs in drug transport across
Fig. 1. Skin penetration of calcein and rhodamine from phospholipid-
based nanocarriers (CL, DL, SLN) through the IPHSF model. The pe-
netrated amount (marker in perfusate) was below detectable level in
all skin penetration experiments (6 h). The non-penetrated markers
were quantified after 6 h experiments. Results are presented as
mean ± SD (n = 3).
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the skin [41]. Regarding SLNs, our results are in accordance with lit-
erature [27]. Clares and colleagues [27] did not find a significant dif-
ference in the permeation of retinyl palmitate from CLs and SLNs (4.36
and 3.64 µg, respectively) through human skin. However, SLNs were
found to be more effective in enhancing the penetration into the upper
SC, similar to our findings.
To assure that our assumption on the penetration within the SC was
correct and visualise the differences between the investigated nano-
carriers, a CLSM study was performed. The obtained confocal images
(Figs. 2 and 3) supported our findings on the skin penetration profiles
through the IPHSF model. Compared to the control (untreated human
skin flap), fluorescence was detected in all skin samples, indicating a
presence of marker. The delivery of the two markers into/through the
skin layers was, however, dependent on the investigated nanocarriers.
Calcein distribution through the IPHSF was found more uniform
throughout the whole skin flaps treated with DLs (Fig. 2C) compared to
CLs (Fig. 2B). This confirmed the better ability of DLs to enhance the
skin penetration of the marker deeper through/into the skin layers.
Earlier CLSM studies comparing skin-penetration depth of the hydro-
philic marker fluorescein sodium from CLs and DLs showed stronger
fluorescence and deeper penetration in the skin samples treated with
DLs compared to CLs [42]. Although the authors performed the pene-
tration study using the pig skin, the same results as obtained in our
model were reported. Calcein from SLNs was found in the deeper skin
layers (Fig. 2D) as compared to CLs-associated calcein. This indicates
and confirms the ability of SLNs to enhance the penetration of calcein as
a hydrophilic model substance through the SC. For rhodamine, the
strongest fluorescence was found in SC and was not depend on the type
of vesicles, in agreement with literature [19]. The weakest fluorescence
was detected in the IPHSF treated with the rhodamine-containing CLs
(Fig. 3B), while the strongest was detected in the flaps treated with
SLNs (Fig. 3D). DLs and SLNs assured higher penetration of rhodamine
through/into the skin layers (Fig. 3C and D) compared to CLs. These
results might be explained in part by the negatively charged surface of
DLs; accumulation within the skin has shown to be more pronounced
for negatively charged liposomes [14]. The enhanced penetration of
lipophilic compounds from SLNs through the SC is also in agreement
with literature [43,44].
The depth of the skin penetration of the two markers was clearly
affected by the type of lipid-based nanocarriers the markers were as-
sociated with. The different composition of the nanocarriers plays a
crucial role in determining their mechanism of action. CLs made of PC
possess certain similarities with the SC lipids, which allow the fusion of
the vesicles with the SC lipids, causing changes in the structure of the
intercellular SC lipids. Therefore, CLs can act as penetration enhancers
by loosening the lipid structure of the SC and lowering the permeability
barrier of the skin. CLs can collapse onto the skin due to their fusion/
mixing with the SC lipids, leading to the formation of an additional
barrier and limiting the penetration of the incorporated drug to a higher
extent [11].
When SDCh is incorporated in liposomes to form DLs, the skin pe-
netration enhancing effect appears to be stronger. The presence of an
edge activator in the lipid bilayer determines flexibility of the DLs and
allows them to potentially squeeze into the corneocytes in the SC, thus
delivering the drug deeper into the skin layers. Therefore, DLs appear to
enhance drug penetration due to a synergistic effect between their de-
formability and their action as penetration enhancers. The deform-
ability of DLs is also composition dependent. El Zaafarany and colla-
borators [28] have shown that the optimal deformability of DLs is
reached when the ratio of phosphatidylcholine:edge activator is
85:15%, the same as used in our study. This further explains the cap-
ability of DLs in enhancing drug penetration into the skin compared to
CLs [28]. As discussed earlier, the surface charge of nanocarriers plays a
role in the skin penetration of drugs. Our DLs were negatively charged
and it has been shown that a negative vesicle surface charge increases
drug skin penetration [14].
Fig. 2. Representative CLSM images of calcein-in-nanocarriers in IPHSF after 6 h of skin
penetration experiments. The IPHSF was cross-sectionally cut, starting from the skin
surface (upper side) to the subcutaneous fatty tissue (lower side). (A) Control, untreated
IPHSF. (B), (C) and (D) IPHSF treated with calcein-containing CLs, DLs and SLNs, re-
spectively.
Fig. 3. Representative CLSM images of rhodamine-in-nanocarriers in IPHSF after 6 h of
skin penetration experiments. The IPHSF was cross-sectionally cut, starting from the skin
surface (upper side) to the subcutaneous fatty tissue (lower side). (A) Control, untreated
IPHSF. (B), (C) and (D) IPHSF treated with rhodamine-containing CLs, DLs and SLNs,
respectively.
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Regarding SLNs, two mechanisms of skin penetration enhancement
are proposed; SLNs can adhere and fuse with the SC lipid [43] or they
can form an occlusive film onto the skin surface preventing transepi-
dermal water loss [29,45]. The penetration enhancement of SLNs is
dependent on the physicochemical properties of the encapsulated drug
and the lipids. A stronger fluorescence observed for rhodamine as
compared to calcein indicates that SLNs assured higher penetration of
rhodamine through/into the skin layers (Fig. 3). This might be ex-
plained by the lipophilicity of the drugs, which affects the drug-particle
interactions, the distribution of the drug within the SLNs and conse-
quently the drug delivery by SLNs [46]. Küchler and collaborators
performed electron spin resonance spectroscopy studies on SLNs using
the spin probes with different lipophilicities. The authors showed that
lipophilic probes were attached to the particles lipid surface, while
hydrophilic probe was located in the layer of the surfactant. These
distributions in the SLNs affected the skin penetration: the lipophilic
probe penetrated faster and in a higher extent compared to the hy-
drophilic one [46], in agreement with our results. Similar studies have
been performed by Saeidpour and collaborators [47], regarding the
distribution of a lipophilic drug, dexamethasone, in SLNs. The authors
found that the drug is located in the outer shell of the SLNs when im-
mersed in aqueous solution but it can be easily released from the na-
noparticles, which is in accordance to our results on rhodamine-con-
taining SLNs (Fig.3D).
When describing the skin penetration process of drugs, the inter-
action between the nanocarrier and the skin is not the only factor that
has to be taken into account. The partitioning of the drug from the
nanocarrier to the skin also plays a role in the skin penetration [19].
Comparing the penetration of calcein and rhodamine in the IPHSF
model, calcein was found to be more uniformly distributed throughout
the skin layers (Fig. 2) compared to rhodamine (Fig. 3), which was
mainly accumulated in the SC. The percentage of non-penetrated cal-
cein, a hydrophilic marker with a low logP (−5.02), was higher com-
pared to rhodamine that has lipophilic properties and higher logP
(1.95). The same behaviour was observed for all investigated nano-
systems. The lipophilic rhodamine is mainly released from nanocarriers
in the lipophilic environment provided by the SC [48], while the hy-
drophilic calcein is able to reach deeper into the hydrophilic dermal
layer that is maintained perfused by KHb (hydrophilic medium) [20].
Therefore, dermal perfusion affected the skin penetration of the hy-
drophilic marker. Moreover, DLs and SLNs enhanced skin penetration
of calcein to a higher extent compared to CLs, whereas the difference
between DLs/SLNs and CLs was not observed for rhodamine (Fig. 1).
This might be explained by the difference in lipophilicity of the two
markers. For highly lipophilic compounds, such as rhodamine, the pe-
netration enhancement by the nanocarriers is less evident because they
possess the intrinsic capacity to move with relative ease through the SC.
In the case of hydrophilic substances such as calcein, the nanocarriers
have the opportunity to act as penetration enhancer due to the low
partition coefficient of hydrophilic compounds [19].
3.3. In vitro and ex vivo skin penetration
All nanocarriers exhibited a sustained permeation of calcein
through the cellophane membrane compared to the control (calcein in
KHb solution) (Fig. 4A). Among the investigated nanocarriers, the
highest calcein permeation was observed from CLs. DLs are known to
increase the penetration of incorporated drugs due to their elasticity
[31]. We did not observe this typical mechanism of action for DLs in our
in vitro studies. A possible explanation might be due to their net ne-
gative surface charge (−32 mV), which is similar to the charge of
cellophane membranes [49]. Since both surfaces have negative zeta
potentials, the energy barrier might prevent DLs deposition on the
cellophane membrane, interfering with calcein penetration through the
barrier. SLNs permitted the lowest calcein penetration through the
barrier, in agreement with reported studies on SLNs incorporating
hydrophilic compounds [38,50].
Rhodamine permeation profiles from all nanocarriers through the
cellophane membrane are presented in Fig. 4B. Both CLs and SLNs were
able to sustain the permeation of rhodamine, as expected for lipophilic
compounds [27,29]. However, SLNs sustained rhodamine release to a
higher extent compared to CLs. The presence of a solid lipid matrix in
SLNs, in contrast with the fluid core of liposomes, reduces the mobility
of the incorporated drugs. This might assure a more controlled release
of the drug from the SLNs compare to CLs [51]. The highly ordered
crystalline structure of the SLNs strongly accommodates the drug and
slows the drug release [38]. DLs containing rhodamine exhibited the
highest marker penetration through the barrier. Although a charge re-
pulsion between the DLs and cellophane membrane might be relevant
for the calcein penetration (Fig. 4A), for rhodamine the observed higher
higher release, compared to the other nanocarriers, might be con-
tributed to the lipophilicity of the marker. Rhodamine is accommodated
in the bilayer of DLs, while calcein is incorporated in the inner aqueous
core. Therefore, rhodamine is more likely to be released from DLs even
with a possible charge repulsion of DLs with the cellophane membrane.
Skin permeation of calcein from nanocarriers through the full
thickness pig skin is shown in Fig. 4C. The amount of penetrated calcein
through the full thickness pig skin from all nanocarriers was lower
compared to in vitro studies (cellophane membrane). A sustained re-
lease of calcein from all nanocarriers was obtained compared to the
control. DLs assured higher calcein penetration through the full thick-
ness pig skin compared to CLs and SLNs, as expected [42]. These results
also confirmed that the lower calcein permeation from DLs observed in
in vitro studies (Fig. 4A) might be due to charge repulsion between DLs
and cellophane membrane. Skin penetration of rhodamine from nano-
carriers through the full thickness pig skin (Fig. 4D) showed similar
trend as in in vitro studies as well as in literature [52]. However, no
significant difference was observed among the nanocarriers and the
penetration of rhodamine through the full thickness pig skin was lower
from all nanocarriers compared to in vitro studies. Both markers, re-
gardless of the nanocarrier type, were not found to permeate the full
thickness human skin in the Franz diffusion cells system (data not
shown). Therefore, the skin penetration through the full thickness
human skin in the Franz diffusion system appears to closely resemble
the penetration observed in our IPHSF model. This highlights the im-
portance of using the human skin in the skin penetration studies.
The amount of non-penetrated markers (retained on the top of the
different skin membrane models) was quantified at the end of in vitro
and ex vivo skin penetration experiments to compare the penetration
determined on the IPHSF model with the established skin models. Fig. 5
represents a summary of the two markers penetration through the in
vitro and ex vivo full thickness skin models. As discussed earlier, all
nanocarriers exhibited lower penetration of calcein compared to the
control both through the cellophane membrane and full thickness pig
skin; while no calcein was detected in the receptor medium when full
thickness human skin was tested in Franz diffusion cells system.
Moreover, all nanocarriers were able to retain higher amount of calcein
on the top of the skin in all tested skin models as compared to the
control (Fig. 5A). Retention of calcein on the top of the human skin in
the Franz diffusion cells system and IPHSF model were comparable,
except for SLNs. SLNs mediated a lower retention of associated calcein
on the IPHSF model compared to ex vivo human skin. This might be
explained by the fact that the perfusion of human skin flap is performed
with an aqueous medium (KHb), which can influence skin penetration
of hydrophilic compounds [20].
Retention of rhodamine on the top of all skin models is shown in
Fig. 5B. The non-penetrated amount of rhodamine was found to be
lower compared to calcein, in agreement with data obtained from the
IPHSF model. Our results indicate that rhodamine remained accumu-
lated within the SC, due to its lipophilic nature. Among the investigated
nanocarriers, CLs and SLNs assured higher retention of rhodamine on
all the skin models, while DLs were able to enhance rhodamine
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penetration through the full thickness skin barriers. DLs containing
rhodamine were earlier tested in the pig skin by Carrer and co-authors
[53]. The authors found that negatively charged DLs, as our DLs, were
able to increase a marker penetration through the pig skin to a greater
extent. CLs and SLNs did create a drug reservoir in the skin [53]. Jensen
and collaborators [29] tested the penetration properties of SLNs con-
taining corticosteroids, lipophilic drugs, in the pig skin and compared
SLNs with an ointment. The penetration of the drug through the intact
skin was reduced when the drug was formulated in SLNs and a higher
amount of drug remained in the upper layers of the skin [29], in
agreement with our findings. DLs exhibited the lowest retention of
rhodamine on the human skin in Franz diffusion cells compared to the
other nanocarriers. This suggests that DLs improved the penetration of
the marker through the human SC. Skin penetration studies and two-
photon microscopy analysis from Simonsson and collaborators [54]
support our findings. Although they tested rhodamine-containing
ethosomes, they found an increased penetration of rhodamine from
ethosomes compared to the hydroethanolic solution. Moreover, as we
observed in the CLSM studies on the IPHSF model, they also observed a
strong fluorescence from rhodamine in the SC when incorporated in
ethosomes. Penetration of rhodamine from all nanocarriers through the
IPHSF model was found to be more similar to the ex vivo human skin
than through cellophane membrane and pig skin; the same trend as
observed for calcein.
Although the penetration profile observed for all nanocarriers in-
corporating either calcein or rhodamine through all the full thickness
skin barrier models was the same, the retention of the two markers on
the top of cellophane membrane and pig skin differed significantly
(p < 0.03) from the human skin and IPHSF model. The artificial
membranes have already shown their limited ability to reflect the
complex interactions between the human skin and the applied for-
mulations, often resulting in non-comparable findings [55]. Although
pig ear skin is more able to represent in vivo human skin than artificial
membranes [56], recent studies have shown that frozen/thawed pig
skin is more permeable than freshly excised skin. It has been postulated
that the high ceramide and low cholesterol levels in pig skin might
cause an easy disruption of the SC due to ice crystalline formation. This
leads to impaired SC barrier and thus higher permeability of drugs [57].
Moreover, especially for pig skin, the total recovery of both markers
was reported to be lower than the stated ideal value (100 ± 15%)
[58]. Although we only quantified the markers penetrated through the
full thickness skin barriers and non-penetrated markers and did not
extract any markers retained in the barriers, it might be hypothesised
that the impaired SC barrier of frozen/thawed pig skin favours the re-
tention of the markers, especially the lipophilic rhodamine, within the
skin. Therefore, the low recovery might be explained by the non-con-
sidered amount of markers retained in the skin. Moreover, the markers
penetrated through the full thickness skin barriers and non-penetrated
amounts of both markers were calculated from the content of the two
markers in the formulations determined fluorometrically prior to the
penetration study. Therefore, another possible explanation for the low
recovery might be an underestimation of the marker content, de-
termined prior to the experiment, from the theoretical amount.
The results indicate that it is crucial to test the nanocarriers on the
reliable skin models able to mimic in vivo studies as close as possible
and that the direct comparison of various nanocarriers can serve as an
important step in development of the optimal dermal formulation tar-
geting a specific dermal condition. It is necessary to note that the de-
scribed nanocarriers will require a suitable vehicle to assure their re-
tention on the skin.
Fig. 4. Penetration profiles of calcein (left column) and rhodamine (right column) from CLs, DLs and SLNs through the cellophane membrane (A, B) and full thickness pig skin (C, D) using
the Franz diffusion cells. As control, calcein in KHb and rhodamine in KHb/PG (0.5%, v/v) were used. The concentration of markers was equalised in all tested formulations to assure the
same concentration gradient. The skin penetration experiments were carried out for a period of 8 h and results are presented as the mean ± SD (n = 3). *p < 0.05.
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4. Conclusions
This study confirmed the different skin penetration potential of
three phospholipid-based nanocarriers using the IPHSF model, a model
closely resembling the human studies. The differences in their lipid
nanocarriers composition and surface charge determined their me-
chanism of action and a different skin penetration depth of the two
markers. DLs and SLNs exhibited higher penetration of the two markers
compared to CLs through the isolated perfused human skin flap model.
Moreover, DLs and SLNs delivered both markers deeper into the skin
layers compared to CLs. This comparative study could serve in the
optimization of phospholipid-based nanosystems for localized skin
therapy and assist in the right selection of the nanocarrier for targeted
drug delivery into the specific skin layers, depending on the targeted
skin condition/disease.
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Fig. S1. IR images of the representative human skin flaps taken during 6 h of skin penetration 
experiments. (A) IR images recorded before application of the formulations. (B), (C) and (D) IR 
images recorded at time 0, 3 and 6 h after the application of the formulations, respectively. A 
perfused skin area (skin temperature at ca. 32 ºC) was assured throughout the experiment. 
 
Fig. S2. Physiological parameters recorded throughout the skin penetration experiments (6 h). 
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Improving chronic wound therapy is becoming essential considering the increasing healthcare 
burden related to treatment of increasingly prevalent non-healed chronic wounds. The topical 
administration of exogenous human epidermal growth factor (hEGF) is an improved and a 
promising approach for chronic wound treatment. Deformable liposomes (DLs) are an 
attractive nanocarrier formulations since they can provide sustained drug release and 
prolonged drug retention within the skin layers, thus minimizing both systemic absorption and 
administration frequency. To develop therapeutically superior hEGF formulation, we prepared 
hEGF-containing neutral (NDLs), cationic (CDLs) and anionic (ADLs) DLs, respectively, 
since it is known that the liposomal surface charge can affect both the liposomal 
physicochemical properties and their skin penetration potential. All prepared liposomes were 
of similar size (300-350 nm) with high hEGF load (~80 % entrapment efficacy). Among the 
studied DLs, ADLs were found to be most promising for sustained release of hEGF, as 
assessed in vitro using the polyamide membrane. Ex vivo studies revealed that all DLs were 
excellent carriers for dermal delivery and no penetration of hEGF through the full thickness 
human skin was detected. ADLs provided a depot exhibiting the highest hEGF retention onto 
the human skin surface. ADLs also revealed enhanced mitogenic activities in human 
fibroblasts compared to both NDLs and CDLs after 48 hrs treatment. Moreover, hEGF-
containing ADLs significantly enhanced mitogenic activity in fibroblast as comparing to 
activity of hEGF solution (positive control). Similar trends were observed in human 
keratinocytes after 24 hrs of treatment. We proved that the liposomal surface charge affects 
the therapeutic potential of hEGF-containing liposomes. hEGF-containing ADLs are thus a 




Key words: hEGF (human epidermal growth factor); deformable liposomes; liposome 
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Abbreviations: ADLs, anionic deformable liposomes; CDLs, cationic deformable liposomes; 
DLs, deformable liposomes; ELISA, enzyme-linked immunosorbent assay; HaCaT, human 
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The high prevalence of chronic wounds, their impact on patients' quality of life and the high 
healthcare costs call for an urgent need for improved chronic wound therapies (Hamdan et al., 
2017). Moreover, the increasing proportion of high-risk population, such as diabetic, obese, 
and elderly people, further rises chronic wounds' incidence; it is estimated that up to 2 % of 
the today’s population will experience chronic wounds in their lifetime (Garcia-Orue, et al., 
2017b; Ashtikar and Wacker, 2018). To enhance wound healing, novel strategies comprising 
agents to prevent/reduce wound infection, moisturize the wound, stimulate the healing 
mechanism and accelerate wound closing as well as scarring control are proposed 
(Kalashnikova et al., 2015). In the normal wound healing process, growth factors play a 
central role since they are involved in different phases of wound healing by promoting 
angiogenesis, stimulating the formation of granulation tissue and remodelling the re-
epithelisation (Jahromi et al., 2018). Chronic wounds fail to achieve the anatomic and 
functional integrity of the wounded area due to persistent inflammation, impaired 
angiogenesis, poor and delayed cellular proliferation and re-epithelialisation (Xue et al., 
2018). The high levels of inflammatory cells are responsible for massive secretion of 
proteases in the wound bed. These enzymes degrade the growth factors, whose deficiency 
further delays the chronic wound healing (Saghazadeh et al., 2018). Human epidermal growth 
factor (hEGF) represents one of the main growth factors involved in the wound healing 
phases. Therefore, topical application of exogenous hEGF represents a promising approach 
for improving chronic wound therapy assuring faster and more effective wound healing 
(Garcia-Orue, et al., 2017b). However, there are several challenges related to the employment 
of hEGF in dermal therapy for treatment of chronic wounds. Major limitations related to local 
administration of hEGF are its low in vivo stability and rapid degradation by proteases present 
in the wound (Zeng and Harris, 2014). Those limitations would require frequent hEGF 
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administrations to assure sufficiently high local concentrations for exerting its therapeutic 
effect (Gainza et al., 2015b). Subsequently, a systemic absorption and undesired side effects 
can occur.  
Phospholipid-based nanocarriers have shown to be promising dermal drug delivery systems 
for improved chronic wound therapy. Liposomes were employed as superior alternative to 
traditional drug delivery systems due to their excellent biocompatibility and biodegradability 
(Boateng and Catanzano, 2015). Their peculiar structure of the phospholipid bilayer closely 
resembles human cell membranes thus allowing high tolerance for liposomes applied on the 
skin. Moreover, they can offer i) protection of the incorporated drug, ii) sustained and 
controlled drug release, and iii) drug accumulation onto/into the skin due to their structure 
resembling the skin composition (Sala et al., 2018). All these functions exerted by liposomes 
might synergistically assure reduction in the frequencies of administration, high drug 
concentration at the skin site and avoidance of rapid absorption into the systemic circulation 
(Xue et al., 2018). However, conventional liposomes commonly bear an unstable membrane, 
which negatively affects the entrapment efficiency and causes relatively uncontrolled drug 
release (Garcia-Orue, et al., 2017b). Deformable liposomes (DLs), on the other hand, are 
designed as superior system to conventional liposomes overcoming the limitations of the 
latter in assuring effective dermal delivery of drugs (Sala et al., 2018). The surface charge has 
shown to contribute to the efficacy of liposomes as dermal delivery systems. The liposomal 
surface charge assures the interactions between liposomes and membrane of keratinocytes, 
which can contribute to the successful delivery of the associated drug (Mota et al., 2017). It 
has been postulated that this interaction might be better promoted when liposomes are 
positively charged thus triggering electrostatic interactions with the negatively charged skin 
membrane (Jain et al., 2017). However, negatively charged liposomes have also proven their 
ability in promoting drug delivery through skin (Mota et al., 2017).  
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So far, different phospholipid-based nanocarriers have been employed for dermal delivery of 
hEGF, such as conventional liposomes, solid lipid nanoparticles, nanostructured lipid carriers 
and nanofibers (Alemdaroğlu et al., 2008; Gainza et al., 2014; Garcia-Orue et al., 2017a; Jeon 
et al., 2012; Kaminski et al., 2016). To the best of our knowledge, deformable liposomes 
containing hEGF have only been investigated as positively charged nanocarriers (Choi et al., 
2017).  
To further explore the effect of liposomal charge on the dermal delivery of hEGF, we 
prepared hEGF-containing neutral (NDLs), cationic (CDLs) and anionic (ADLs) deformable 
liposomes, respectively. All liposomes were characterised for in vitro hEGF release through 
polyamide membrane and ex vivo hEGF penetration through full thickness human skin. The 
toxicity of liposomes was evaluated in vitro by MTT assay. Finally, the mitogenic activity of 
hEGF-containing DLs was evaluated in vitro in human foreskin fibroblasts (HF) and human 
immortalised keratinocytes (HaCaT).  
 
2. Material and methods 
2.1 Material 
Soybean phosphatidylcholine (Lipoid S100, SPC) was a generous gift from Lipoid GmbH 
(Ludwigshafen, Germany). hEGF, methanol CHROMASOLV®, acetic acid, sodium 
phosphate dibasic dihydrate, potassium phosphate monobasic, sodium chloride, polysorbate 
20, stearylamine and sodium deoxycholate were obtained from Sigma-Aldrich Chemie 





2.2 Preparation of liposomes 
Stock solution of hEGF (1 mg/mL) was prepared by dissolving hEGF (500 µg) in 0.5 mL of 
10 mM acetic acid solution in MilliQ water, previously filtered through 0.20 µm syringe filter 
(Bulk Acrodisc® 25 mm Syringe Filter, Pall Life Sciences, East Hills, New York, USA). The 
stock solution was then diluted to the final concentration of 20 µg/mL with phosphate buffer 
saline (PBS) (pH 7.4, 2.98 g/L Na2HPO4 x 2H2O, 0.19 g/L KH2PO4 and 8 g/L NaCl). PBS 
was employed to assure optimal binding of hEGF to receptors (Nunez et al., 1993). 
NDLs were composed of SPC and polysorbate 20 in a ratio of 85:15 (w/w), respectively. 
CDLs were made of SPC and stearylamine (weight ratio of 9:1, respectively), and polysorbate 
20. The ratio between SPC and polysorbate 20 was the same as employed for NDLs (85:15, 
w/w). ADLs were composed of SPC and sodium deoxycholate (85:15, w/w). Table 1 provides 
an overview of different liposomal compositions. hEGF-containing deformable liposomes 
were prepared by the dry film method (Ternullo et al., 2017b). SPC and different surfactants, 
depending on the type of deformable liposomes (Table 1), were dissolved in methanol. The 
solvent was evaporated on a Büchi Rotavapor R-124 with Büchi Vacuum Pump V-700 (Büchi 
Labortechnik AG, Flawil, Switzerland) for 1 hr at 55 mbar and 45 °C. The obtained lipid film 
was then resuspended in 5 mL of hEGF solution (20 µg/mL) in PBS (pH 7.4), previously 
prepared as described above. Liposomal formulations were stored at 4 °C for 24 hrs prior 
further processing. 
For the cell toxicity and proliferation studies, empty DLs of different surface charges were 
prepared using the same lipid and surfactant compositions as for hEGF-containing DLs (Table 
1). 
 




2.3 Size reduction of DLs 
Extrusion through polycarbonate membrane (Nuclepore® Track-Etched Membranes, 
Whatman House, Maidstone, UK) was employed to reduce liposomal size (Ternullo et al., 
2017b). The pore size of the polycarbonate membrane and the number of extrusion cycles 
employed for each liposomal formulation were adjusted to obtain a vesicle ranging between 
300-350 nm in size. Therefore, NDLs were extruded 10 times through 800 nm pore size 
membrane and 15 times through 400 nm. CDLs were extruded 10 times through 800 nm pore 
size membrane. ADLs were extruded 5 times through 800 nm pore size membrane. All 
extruded liposomal formulations were stored at 4 °C for a minimum of 2 hrs before further 
usage. 
 
2.4 Liposomal characterization 
Size distribution and zeta potential analyses of hEGF-containing deformable liposomes were 
performed using a Malvern Zetasizer Nano – ZS (Malvern, Oxford, UK) (Ingebrigtsen et al., 
2017; Ternullo et al., 2017b). For size measurements, all liposomes were diluted 1:50 with 
filtered PBS (0.20 µm syringe filter) to achieve an attenuator of 6-7. The zeta potential of all 
liposomes was determined by diluting each liposomal formulation with filtered (0.20 µm 
syringe filter) water (1:20 volume ratio). Prior to the actual measurement, an attenuator of 6-7 
was assured for each formulation. Both the size and zeta potential measurements were 






2.5 hEGF entrapment 
Free (non-encapsulated) hEGF was removed from liposomal dispersions by dialysis (MW 
cutoff 12,000-14,000 Da, Medicell International Ltd, London, UK). Liposomal dispersion (2 
mL) was dialysed against 200 mL of PBS under the sink conditions. Dialysis was carried out 
for 6 hrs. Both the original and dialysed liposomes were diluted in methanol to dissolve 
liposomes and hEGF was subsequently quantified using the Enzyme-Linked Immunosorbent 
Assay (ELISA) as explained in Section 2.6. The entrapment efficiency (%) was determined by 
the following relationship (µg hEGFretenate/ µg hEGFtotal) x 100, which compares the amount 
of hEGF in dialysed liposomes and the total amount of hEGF in the original liposomes.  
 
2.6 Quantification of hEGF 
The quantification of hEGF was performed using ELISA kit for hEGF (Human EGF ELISA 
kit, Sigma-Aldrich, Saint Louis, USA), according to the manufacturer’s instructions. Aliquots 
of samples were diluted with ELISA Diluent Buffer B, the solutions added onto an antibody-
coated ELISA plate together with standards, and finally incubated for 2.5 hrs at room 
temperature (23 C). Diluted biotinylated antibody solution, horseradish peroxidase-
conjugated streptavidin solution and tetramethyl benzidine reagent were stepwise added and 
incubated according to the incubation times recommended in the kit instructions. The final 
colorimetric reaction was stopped by addition of Stop Solution and absorbance was read 
immediately at 450 nm with a SpectraMax 190 Microplate Reader (Molecular Devices, 
California, USA). A standard curve was obtained using standard hEGF provided in the ELISA 
kit within the concentration range of 1 and 200 pg/mL. Data was fitted with a four-parameter 




2.7 In vitro hEGF release 
The in vitro hEGF release from all deformable liposomes was conducted using polyamide 
membrane (Sartorius polyamide membrane, 0.2 µm pore size, Sartorius AG, Gröttingen, 
Germany) in the Franz diffusion cells (1.77 cm2 diffusion area, 12 mL acceptor volume; 
PermeGear, Bethlehem, USA) (Jøraholmen et al., 2017). The acceptor chamber was filled 
with PBS (pH 7.4) and kept at 32 °C during the whole experiment using a heating circulator. 
hEGF-NDLs, hEGF-CDLs and hEGF-ADLs were added in the donor chamber (600 µL) and 
hEGF release from liposomes was investigated for 6 hrs. Sampling (500 µL) of the acceptor 
medium was performed after 1, 4 and 6 hrs. Equal volume of fresh PBS was used to replace 
the withdrawn samples to maintain the sink conditions. hEGF in withdrawn samples was 
quantified by ELISA as described in Section 2.6. The experiments were performed in 
duplicates. 
 
2.8 Preparation of human skin tissue 
The human skin used in this study was obtained from the abdomen of female patients who 
underwent abdominoplasty and gave their written consent prior the surgery and patient 
identity was protected. The excess of skin panni from plastic surgery is generally disposed, 
thus no ethical approval by the Norwegian Ethical Committee was required. The experiments 
were conducted in accordance with the Declaration of Helsinki Principles. The skin panni 
obtained from plastic surgery was cleared from the subcutaneous fat and the remaining full 
thickness skin rinsed and moisten with PBS (pH 7.4) and stored at -20 °C. Prior use, skin 
slices were thawed in PBS at room temperature (23 C). The thickness of full thickness 




2.9 Ex vivo skin penetration studies 
The effect of the different surface charge of deformable liposomes on the skin penetration of 
hEGF was evaluated using the full thickness human skin, prepared as described above 
(Section 2.8) (Ternullo et al., 2017b). After thawing, the human skin was cut to slices to 
closely fit between the donor and acceptor chambers of the same Franz diffusion cells system 
used for the in vitro drug release experiments (Section 2.7). All liposomal formulations 
(hEGF-NDLs, hEGF-CDLs and hEGF-ADLs) and control (hEGF in PBS solution) (600 µL), 
respectively were added in the donor chamber and the experiments carried out for 6 hrs. 
Samples (500 µL) from the acceptor medium (PBS at 32 °C) were withdrawn after 1, 4 and 6 
hrs and replaced with equal volume of fresh PBS, assuring sink conditions. Penetrated (found 
in the acceptor medium) and non-penetrated (retained in the donor chamber) hEGF were 
quantified by ELISA following the protocol described in Section 2.6. The experiments were 
done in triplicates. 
 
2.10 In vitro cell toxicity and proliferation study 
2.10.1 Cell culture 
Human foreskin fibroblasts (HF) (CCD-1112Sk, ATCC® CRL-2429™, ATCC, Manassas, 
USA) were cultured in a 75 cm2 flask with Iscove's modified Dulbecco's medium (IMDM) 
(Sigma-Aldrich Chemie, Steinheim, Germany), supplemented with 10 % (v/v) fetal bovine 
serum and penicillin-streptomycin at 37 °C in 5 % CO2. 
Human immortalised keratinocytes (HaCaT) (ATCC, Manassas, USA) were cultured on 
RPMI-1640 medium (Sigma-Aldrich Chemie, Steinheim, Germany) supplemented with 10 % 




2.10.2 Cell toxicity and proliferation study  
All liposomal formulations containing hEGF were tested for their toxicity and capability to 
stimulate cell proliferation in HF and HaCaT cells, respectively. To perform the experiment, 
all liposomes (hEGF-NDLs, hEGF-CDLs and hEGF-ADLs) were prepared to be of a smaller 
size (ca. 150 nm) to avoid sedimentation of liposomal dispersions during the experiments. The 
amount of entrapped hEGF in the 150 nm-deformable liposomes was quantified as described 
in Sections 2.5 and 2.6. Moreover, the amount of lipid in all extruded liposomal formulations 
was determined to confirm that no loss of SPC during the extrusion and separation of 
unentrapped hEGF from liposomes occurred (data not shown). The cells, previously grown as 
described in Section 2.10.1, were seeded (100 µL) on a 96-wells plate with a density of 
25.000 cells/mL, using the same medium as for cell culture (IMDM and RPMI-1640 for HF 
and HaCaT, respectively) (Section 2.10.1). The plates were then incubated for 24 hrs at 37 °C 
in 5 % CO2 to allow the cells to stabilise and adhere. After 24 hrs, 10 µL of each formulation 
(hEGF-NDLs, hEGF-CDLs, hEGF-ADLs) were added to the cells and the cells subsequently 
incubated for 24 and 48 hrs, respectively. Three different lipid concentrations of each 
liposomal formulation were tested, namely 1, 10 and 50 µg/mL, which were prepared by 
diluting each liposomal formulation in the growth medium used for cell culturing. The 
corresponding concentrations of hEGF in the diluted liposomal dispersions were 0.08, 0.8 and 
4 µg/mL, respectively. Additionally, the following formulations were tested: 1) PBS, 2) 
empty NDLs, CDLs and ADLs, at the same lipid concentrations as for hEGF-containing 
liposomes, 3) free hEGF, in PBS in similar concentration as in liposomes. Untreated cells 
were used as a negative control. After the incubation times, the HF living cells were 
quantified using CCK-8 kit (Sigma-Aldrich Chemie, Steinheim, Germany). Briefly, 10 µL of 
CCK-8 were added to each well and incubated for 4 hrs. The absorbance was read at 450 nm 
using an Epoch Microplate Spectrophotometer (BioTek Instruments, Vermont, USA). HaCaT 
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living cells were quantified using Cell Proliferation Kit I (MTT) (Roche Diagnostics GmbH, 
Mannheim, Germany). MTT labeling reagent (10 µL, final concentration of 0.5 mg/mL) was 
added to each well and cells were incubated for 4 hrs under the same conditions. After the 
incubation period, the formed formazan crystals were dissolved with solubilization buffer 
(100 µL). Absorbance was then measured at 600 nm (Epoch Microplate Spectrophotometer, 
BioTek Instruments, Vermont, USA). All experiments were performed in triplicates. 
 
2.11 Statistical analysis 
All results are expressed as mean ± standard deviation. To determine statistical significance, 
Student's t-test or one-way ANOVA followed by Bonferroni’s multiple comparisons test were 
performed using GraphPad Prism version 7.00 for Windows (GraphPad Software, La Jolla 
CA, USA). A p value < 0.05 was considered significant. 
 
3. Results and discussion 
The chronic wounds are, in addition to a decreased quality of patient’s life, causing a serious 
financial burden on healthcare systems (Xue et al., 2018). This burden is destined to rise due 
to the increase of risk factors, such as age, obesity, diabetes, all responsible of delayed chronic 
wound healing (Gainza et al., 2015b). The urgent need for improved chronic wound therapies 
is essential to improve the life quality of patients and reduce healthcare costs (Frykberg and 
Banks, 2015). Nanopharmaceuticals offer potential to improve the healing of chronic wounds 
by acting on infection control, wound closure, quality of skin regeneration, both functionally 
and aesthetically (Ashtikar and Wacker, 2018). Since all chronic wounds are characterised by 
the impaired perfusion, oxygenation and limited angiogenesis, the growth factors have been 
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proposed as an emerging strategy to improve wound healing of chronic wounds by increasing 
the oxygenation in the wound tissue (Desmet et al., 2018). This led to the increased interest in 
developing effective topical formulations for exogenous growth factors such as hEGF. 
Although hEGF represents one of the main growth factor involved in the wound healing 
phases, its clinical application is restricted due to its low in vivo stability and rapid 
degradation by proteases (Zeng and Harris, 2014). Future chronic wound treatments that can 
assure a sustained release of the active ingredients might reduce the frequencies of 
administration, pain and stress to the patients, as well as increase the effectiveness of the 
incorporated drug (Boateng and Catanzano, 2015). Phospholipid-based nanocarriers have 
shown to be promising for improved chronic wound therapy. We focused on deformable 
liposomes, which have shown to possess better capability in enhancing drug penetration 
through the skin and delivering the incorporated drug deeper into the skin layers than 
conventional liposomes (Brewer, et al., 2013; Zhai et al., 2014). One of the factors 
responsible for the efficiency of liposomes as dermal delivery systems is their surface charge 
(González-Rodríguez and Rabasco, 2011). The incorporation of hEGF in deformable 
liposomes might lead to the development of an effective liposomal formulation destined for 
the treatment of chronic wounds.  
 
3.1 Characteristics of deformable liposomes 
In the optimisation process of effective liposomal formulations destined for dermal drug 
delivery, it is important to screen liposomal physicochemical properties, not only their vesicle 
size distribution but also their surface charge (Roberts et al., 2017). Moreover, it is also 
interesting to investigate how the type of surfactants used to obtain deformable liposomes 
influences their physicochemical properties.  
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The optimal size of liposomes destined for dermal therapies, in terms of offering the highest 
drug concentration in the reservoir provided by liposomes, has been shown to be around 300 
nm (du Plessis et al., 1994). Furthermore, our previous study on different types of 
phospholipid-based nanosystems has shown that the incorporation of a model hydrophilic 
compound, calcein, in 200 nm deformable liposomes was effective in terms of both high 
entrapment efficiency and successful dermal delivery of the hydrophilic compound even in 
the deeper human skin layers (Ternullo et al., 2017b). In contrast, smaller liposomes (30-40 
nm) have shown to be appropriate for transdermal drug delivery by passing through the SC 
and enabling the incorporated drug access to systemic absorption (Hood et al., 2014). We 
therefore aimed at obtaining deformable liposomes of 300-350 nm, considering also that 
hEGF is a rather large molecule (6 kDa) and that smaller liposome may provide limited 
aqueous space for its entrapment. We selected the extrusion as method for liposome size 
reduction since we reported earlier that the extrusion results in vesicles of homogenous size 
distributions (low polydispersity index, PI) (Ternullo et al., 2017b). All our hEGF-containing 
liposomes exhibited vesicle size within the targeted size range with a PI below 0.30 (Table 2). 
The hEGF-containing CDLs exhibited a slightly larger vesicle size (361.7 nm) and PI (0.30) 
than NDLs and ADLs (Table 2). The most homogenous vesicle population was observed for 
NDLs (PI = 0.22). Therefore, the incorporation of ionic surfactants in the lipid bilayer 
resulted in a slight increase in polydispersity as compared to neutral deformable liposomes. 
Similar findings were reported by Dragicevic-Curic and collaborators (Dragicevic-Curic et 
al., 2010). A possible explanation might rely on the number of the hydrophobic carbon chains 
in the surfactants incorporated in the deformable liposomes. It has been previously stated that 
surfactants with more than one hydrophobic chain are responsible for a more homogeneous 
size distribution due to their better capability to anchor within the lipid bilayer (Bnyan et al., 
2018). In our case, NDLs contained only polysorbate 20 that possesses more than one 
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hydrophobic chain, thus explaining the lower PI compared to CDLs and ADLs. CDLs and 
ADLs were prepared using stearylamine and sodium deoxycholate, respectively; two ionic 
surfactants with only one hydrophobic chain in the structure thus resulting in the increased 
polydispersity. 
The surface charge has been proven to contribute to the liposomes' capability as dermal 
delivery systems. Promising outcomes in terms of skin penetration enhancing effect mediated 
by deformable liposomes have been observed for both positively and negatively charged 
liposomes (Mota et al., 2017). To the best of our knowledge, only cationic hEGF-containing 
deformable liposomes have been previously studied (Choi et al., 2017). The cationic 
liposomes developed by Choi and co-workers showed to enhance skin penetration of hEGF 
and to improve its therapeutic effect in diabetic wounds. The effect of the negative surface 
charge in improving wound healing with hEGF-containing nanoformulations was only 
revealed with other types of nanocarriers, namely solid lipid nanoparticles and nanostructured 
lipid nanocarriers. As observed for cationic nanocarriers, the anionic nanoparticles exhibited 
good potentials for treatment of chronic wounds (Gainza et al., 2014). We therefore aimed to 
prepare neutral, cationic and anionic deformable liposomes to investigate the role of the 
surface charge in the optimization of an effective liposomal formulation for dermal delivery 
of hEGF and treatment of chronic wounds. The surfactants were selected to prepare liposomes 
with neutral, cationic and anionic surface charge (Table 2). NDLs exhibited a slightly 
negative zeta potential (-0.5 mV), which can be considered as neutral. CDLs and ADLs 
possessed highly positive and negative surface charges (45.8 mV and - 35.7 mV, respectively) 
due to the presence of stearylamine, known to provide positive zeta potential and sodium 
deoxycholate, which exerts negative surface charge (Al Shuwaili et al., 2016; Dragicevic-
Curic et al., 2010). The absolute values of the zeta potential of CDLs and ADLs were very 
similar, thus allowing comparison of the two charged deformable liposomal formulations.  
17 
 
One important factor to consider when developing effective nanosystems is drug entrapment 
efficiency since a high drug concentration on the site of action is a prerequisite to exert the 
targeted therapeutic effect. All our liposomes exhibited a high entrapment efficiency (Table 
2). Moreover, the entrapment efficiency appeared not to be affected by liposomal surface 
charge. A hydrophilic drug 5-aminolevulinic acid was successfully entrapped in deformable 
liposomes bearing different surface charges (Oh et al., 2011). We have used two surfactants 
with high hydrophilic-lipophilic balance (HLB) value (~ 16 for both polysorbate 20 and 
sodium deoxycholate), which are considered to provide better encapsulation of hydrophilic 
drugs (Bnyan et al., 2018). Al Shuwaili et al. (2016) reported similar results by loading a 
hydrophilic drug, pentoxifylline, in deformable liposomes both containing amphiphilic 
surfactant (sodium cholate) and non-ionic surfactant (polysorbate 20). The authors compared 
these surfactants with other type of surfactants, stating that the higher drug entrapment was 
obtained when sodium cholate and polysorbate 20 were used. The explanation might be 
related to their chemical structures; the presence of OH groups assures good hydrophilic 
binding sites for the incorporated hydrophilic drugs (Al Shuwaili et al., 2016). This further 
supports the hypothesis that by using surfactants with high HLB values, a high incorporation 
of hydrophilic drugs is promoted. Zhang and co-workers, who incorporated a protein, 
ovalbumin, in deformable liposomes made of sodium cholate and stearylamine also reported 
the same findings for ionic surfactants. Therefore, the interaction between the two ionic 
surfactants and lipids in the deformable liposomes can provide a high protein entrapment 
(Zhang et al., 2017). Moreover, the hEGF entrapment in all our liposomes was corresponding 
to the published data on other phospholipid-based nanocarriers, such as solid lipid 
nanoparticles and nanostructured lipid carriers. Gainza and collaborators (2014) prepared 
vesicles of similar size as our liposomes (300 nm) and reported a high hEGF entrapment in 
both solid lipid and nanostructured lipid carriers (Gainza et al., 2014). Although the difference 
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was not significant, our hEGF-ADLs exhibited slightly higher hEGF entrapment (84.1 %) 
compared to both NDLs and CDLs (80.5 and 80.8 %, respectively). The good entrapment 
efficiency exhibited by ADLs was already observed in our previous work, where anionic 
deformable liposomes with sodium deoxycholate revealed high entrapment of a hydrophilic 
marker, calcein (Ternullo et al., 2017b). Considering the higher hEGF entrapment observed 
for ADLs, ADLs might be the most suitable nanocarriers for dermal delivery of hEGF 
compared to NDLs and CDLs.   
 
Table 2. Characteristics of the deformable liposomes containing hEGF (n = 3 ± SD). 
 
3.2 In vitro hEGF release  
To explore the effect of liposomal charge on the dermal delivery of hEGF, we firstly 
performed a pilot study on hEGF release from DLs using polyamide membrane in the Franz 
diffusion cells (Fig.1). Polyamide membrane has earlier been employed for testing in vitro 
release of high molecular weight and hydrophilic drugs, such as interferon α-2β; the pore size 
of the membrane should be sufficiently large to allow the diffusion of the hEGF (Jøraholmen 
et al., 2017). We could also exclude the possible passage of liposomes through the polyamide 
membrane. No presence of lipids in the acceptor chamber in the Franz cell systems was 
detected when liposomes, smaller (200-300 nm) than our deformable liposomes (ca. 350 nm), 
were tested (Hurler et al., 2012). Therefore, the release of hEGF mediated by all deformable 
liposomes was mainly attributed to their intrinsic properties of nanocarriers. Considering the 
liposome surface charge, no significant differences in mediating the in vitro hEGF release 
from liposomes were observed. However, CDLs exhibited a slightly higher hEGF release 
after 6 hrs than both NDLs and ADLs. Therefore, it might be postulated that the positive 
surface charge of cationic liposomes exerts a positive effect on the hEGF release through the 
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artificial membrane. Choi and collaborators have recently found an enhancement in the 
release of EGF mediated by cationic elastic liposomes as compared to neutral elastic 
liposomes (Choi et al., 2017). On the other hand, liposomes coated with a negatively charged 
polymer (xanthan) exhibited a more sustained EGF release (Kaminski et al., 2016); results 
similar to ADLs. The in vitro release of hEGF from ADLs was also in agreement with 
findings reported by Gainza and collaborators. Although the authors investigated the in vitro 
hEGF release from different phospholipid-based nanocarriers, namely solid lipid 
nanoparticles and nanostructured lipid carriers, the amount of hEGF released in 6 hrs was 
similar (ca. 50 % in 5 hrs) in agreement to our findings for ADLs (Gainza et al., 2014).   
 
Fig. 1. In vitro hEGF release over 6 hrs from different liposomal formulations through 
polyamide membrane (n = 2 ± SD). 
 
3.3 Ex vivo hEGF penetration through human skin 
The development of effective topical formulations destined to exert local effect onto/into the 
skin requires testing the drug penetration into/through the skin under the conditions that 
closely mimic the in vivo conditions (Flaten et al., 2015). Therefore, in addition to the in vitro 
hEGF release from the liposomal formulations, we tested hEGF-containing deformable 
liposomes under ex vivo conditions using the full thickness human skin and the Franz 
diffusion cells system. No hEGF was found to penetrate the human skin. These results differ 
from the in vitro drug release findings, where hEGF was found to permeate through 
polyamide membrane from all liposomes and could be detected in the acceptor phase of the 
Franz cells system (Fig. 1). Similarly, for a lipophilic drug (tretinoin), the same difference 
between in vitro and ex vivo studies was observed when testing deformable liposomes 
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(Ascenso et al., 2014). Polyamide membrane, and other artificial membranes, do not possess 
the lipid composition and arrangement of the human skin, thus leading to discrepancy 
between in vitro and ex vivo results (Flaten et al., 2015; Ternullo et al., 2017a), indicating the 
limitations of in vitro release studies. Moreover, this finding shows that our liposomes are 
suitable for dermal delivery of hEGF by reducing any possible systemic absorption of the 
drug and consequently minimizing undesired side effects. However, one can argue that in the 
conditions of wounded skin with reduced barrier properties, the findings may differ. We, 
therefore, decided to quantify the amount of hEGF retained onto the human skin surface at the 
end of the ex vivo skin penetration studies to possibly detect any differences among the 
surface charged liposomes and their effect regarding skin penetration of hEGF. The charged 
deformable liposomes exhibited higher retention of hEGF onto the skin surface compared to 
both hEGF in solution (control) and NDLs (Fig. 2). NDLs showed minimal improvement in 
skin penetration enhancement of hEGF (0.55 % more compared to control). On the other 
hand, both CDLs and ADLs exhibited higher hEGF retention onto the skin surface, retaining 
3.72 and 7.94 % more hEGF onto the skin surface than control, respectively. This 
enhancement in the depot effect mediated by charged DLs was more evident in comparison to 
NDLs; the CDLs and ADLs retained 4.26 and 8.48 % more hEGF than NDLs, respectively. 
This indicates that the liposomal surface charge affects the dermal delivery of hEGF mediated 
by DLs. Deformable liposomes have been reported to provide protection of the drug against 
rapid clearance into the dermis blood circulation, assuring depot system of the drug on, in and 
below the skin barrier (Ascenso et al., 2014). Moreover, hEGF reservoir onto the skin, due to 
the drug incorporation in micro- and nanosystems, has been previously reported (Al Haushey 
et al., 2010; Gainza et al., 2015a; Jin et al., 2013). In our case, the comparison of DLs bearing 
different surface charge allowed us to hypothesise that a better retention of hEGF onto the 
skin surface is achieved when DLs are negatively charged. The ability of anionic nanocarriers 
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in allowing high retention of hEGF onto the skin surface was also observed for solid lipid 
nanoparticles and nanostructured lipid carriers (Gainza et al., 2015a). This further confirms 
the ability of anionic nanocarriers in assuring a sustained hEGF release over time, as observed 
in the in vitro study (Fig. 1). Regarding effective chronic wound therapy, the hEGF depot and 
its sustained release mediated by ADLs can reduce the frequency of administration thus 
improving patient compliance, as well as reducing the pain related to dressing change. 
Pleguezuelos-Villa and co-workers reported similar skin penetration profiles mediated by 
ADLs. They incorporated naringin, a high molecular weight compound with hydrophilic 
properties as hEGF, in deformable liposomes and tested the ex vivo penetration through pig 
skin. Similarly to what we observed for hEGF-ADLs, more than 90 % of detected compound 
was found in the donor compartment after the ex vivo penetration study (Pleguezuelos-Villa et 
al., 2018),  
CDLs were slightly superior to ADLs in terms of their ability to enhance hEGF penetration 
through the skin, which is in accordance with published data (Oh et al., 2011). Although the 
authors incorporated a different hydrophilic drug, anionic deformable liposomes retained 
higher amount of the drug onto the mouse skin surface, while cationic deformable liposomes 
exhibited better ability in enhancing drug penetration through the skin (Oh et al., 2011). The 
same behaviour was also observed for lipophilic compounds, such as imperatorin. When the 
compound was incorporated in different surface charged deformable liposomes, cationic 
deformable liposomes exhibited the best penetration enhancing effect through rat skin (Lin et 
al., 2018). The possible explanation might rely on the electrostatic interaction between the 
positive surface charge of CDLs and the negative charge of the skin surface thus resulting in 




Fig. 2. Retention of hEGF onto the full thickness human skin surface from different 
liposomal formulations after ex vivo skin penetration studies over 6 hrs (n = 3 ± SD). 
 
3.4 Mitogenic effect of hEGF-containing deformable liposomes 
hEGF is one of the growth factors involved in the cell growth, differentiation and proliferation 
processes. These properties of hEGF are responsible for its positive contribution in many 
phases of wound healing (Desmet et al., 2018). Due to its low concentrations within chronic 
wounds, the external administration of hEGF is a promising approach for successful treatment 
of chronic wounds. However, hEGF bears several drawbacks that make its topical 
administration challenging. hEGF possesses a short half-life and is undergoing to rapid 
enzymatic degradation in the wound bed (Zeng and Harris, 2014). The incorporation of hEGF 
in nanosystems has already shown to assure its protection against degradation, a sustained 
drug release in the administration site and an increase in its therapeutic effect. We therefore 
tested our hEGF-containing deformable liposomes for mitogenic activity in human cells. We 
chose two dermal cell lines, namely human fibroblasts (HF) and human keratinocytes 
(HaCaT), whose proliferation in the wound bed would contribute to wound healing (Stunova 
and Vistejnova, 2018; Werner et al., 2007).  
To perform the in vitro cell proliferation assay, we firstly reduced the liposome size to ca. 150 
nm to avoid possible liposome precipitation during the experiment. Therefore, we performed 
more cycles of extrusion through polycarbonate membrane to obtain the desired liposome size 
(172.80±2.80, 191.53±7.44 and 168.23±2.73 nm for NDLs, CDLs and ADLs, respectively). 
We also determined the entrapment efficiency, which was found to be of 82.03, 79.33 and 
82.52 % for NDLs, CDLs and ADLs, respectively. The additional size reduction did not affect 
the entrapment efficiency in all liposomes compared to liposomes having a size of 350 nm 
(Table 2). The amount of SPC in all liposomes was also determined in order to assure any 
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SPC loss during the extrusion and separation of unentrapped hEGF by dialysis. A SPC loss 
below 3.5 % was found for all liposomal formulations (data not shown).  
Regarding hEGF-NDLs, a mitogenic effect in HF was observed only at the highest lipid 
concentration (50 µg/mL) (Fig. 3a). This effect was already evident after 24 hrs treatment, 
when a significant increase (p < 0.03) was observed compared to the untreated HF cells 
(control) and became even more evident after 48 hrs treatment (p < 0.0001). The mitogenic 
activity of hEGF-NDLs was, at the highest lipid concentration, stronger than activity of free 
hEGF (hEGF in PBS; p < 0.03) (Fig. 3a, d) after 48 hrs treatment. 
hEGF-CDLs at both 1 and 10 µg/mL lipid concentrations showed no significant improvement 
on HF proliferation after 24 hrs treatment compared to control (Fig. 3b). However, the highest 
concentration of hEGF-CDLs exhibited a lower cell proliferation rate compared to the other 
tested formulations (Fig. 3b, d). This dose-dependent cytotoxic effect might be related to the 
presence of stearylamine, which can interact with the cell membrane thus damaging 
membranes’ integrity and function (Tahara et al., 2018). However, empty CDLs at the same 
(highest) lipid concentration were not toxic to HF, therefore, the low cell proliferation 
observed for the highest concentration of hEGF-CDLs might be contributed to the high dose 
of hEGF (4 µg/mL), rather than the lipid. Interestingly, after 48 hrs treatment, hEGF-CDLs at 
lipid concentration of 10 µg/mL increased the HF proliferation by 40 % as compared to 
control (p < 0.0001) (Fig. 3b). This indicates that up to 10 µg/mL lipid concentration and 0.8 
µg/mL hEGF concentration, hEGF-CDLs are not toxic to cells and can be employed for 
wound healing treatment. This positive effect was not detectable after 24 hrs treatment 
indicating that the cell response is dependent on the incubation time, as previously reported 
(Bertoncelj et al., 2014). The highest tested concentration of hEGF-CDLs showed lower 




hEGF-ADLs did not exhibit any significant enhancement in terms of HF proliferation after 24 
hrs treatment compared to control and the other tested formulations (Fig. 3c, d). However, 
after 48 hrs, hEGF-ADLs at both lipid concentrations (10 and 50 µg/mL) exhibited a greater 
mitogenic effect than untreated cells (p < 0.002), allowing 48 and 77 % HF more proliferation 
than control, respectively. Moreover, the highest lipid and hEGF concentrations in hEGF-
ADLs enhanced HF proliferation to a greater extent than both empty ADLs and free hEGF, by 
33 and 45 % respectively (Fig. 3c, d). This further confirms the findings for hEGF-NDLs and 
hEGF-CDLs, indicating that the keratinocytes response depends both on the incubation time 
and hEGF/lipid concentrations. This is in accordance with previously published data on the 
keratinocytes response when exposed to growth factors-containing nanosystems (Bertoncelj et 
al., 2014). Comparing the three hEGF-containing liposomal formulations, the hEGF-ADLs 
assured the greatest mitogenic effect when tested at the highest lipid and hEGF concentrations 
(Fig. 3). Ex vivo skin penetration studies revealed the depot effect of hEGF-ADLs (Fig. 2), 
thus enabling its sustained release into human skin. This can assure a continuous binding of 
hEGF to its receptor, thus constantly activating the signalling pathway and prolonging the 
proliferation effect in cells. The similar trend was observed for hEGF incorporated in other 
nanosystems, such as nanofibers, solid lipid nanoparticles and nanostructured lipid carriers 
(Gainza et al., 2014; Garcia-Orue et al., 2017a; Jin et al., 2013).  
The mitogenic effect of the hEGF liposomal formulations on HaCaT cells is shown in Fig. 4. 
The 24 hrs treatment showed that only the highest tested hEGF concentration (4 µg/mL), in 
both NDLs and ADLs was more effective in enhancing cell proliferation compared to both 
untreated cells and free hEGF (Fig.4a, c, d). hEGF-NDLs assured 26 and 32 % more cell 
proliferation more than control and free hEGF, respectively. On the other hand, hEGF-ADLs 
increased the percentage of living cells by respectively 36 and 41 % more compared to control 
and free hEGF. Therefore, between the two liposomal formulations, anionic deformable 
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liposomes (hEGF-ADLs) exhibited stronger mitogenic activity compared to hEGF-NDLs. 
This confirms the findings from the cell proliferation studies in HF, which, taken together, 
highlights the superiority of ADLs in improving the mitogenic effect of hEGF as compared to 
NDLs and CDLs. Regarding CDLs, 24 hrs treatment revealed the same trend as observed for 
the HF cell line (Fig. 3b). Up to a lipid concentration of 10 µg/mL, hEGF-containing CDLs 
showed to be not toxic also in HaCaT cell line, while a lower cell proliferation rate was 
observed for hEGF-CDLs at the highest lipid concentration (Fig. 4b). HaCaT cells treated for 
48 hrs with all liposomal formulations proliferated to a lower extent compared to control (Fig. 
4a, b, c). These findings differ from the results obtained with the HF cell line (Fig. 3a, b, c), 
showing that the growth rate is also dependent on the cell line employed for the in vitro cell 
proliferation assay in agreement with Gainza et al. (2014). In the case of hEGF-CDLs at the 
highest lipid and hEGF concentrations, lower mitogenic effect was also observed for both 
empty CDLs and free hEGF (Fig. 4b, d). Considering NDLs and CDLs, the lower 
proliferation activity might be related to the presence of polysorbate 20. Contri and co-
workers observed the same decrease in cellular viability when nanocapsules containing 
similar surfactant, polysorbate 80, were tested on keratinocytes (Contri et al., 2016). The 
stronger cytotoxic effect observed for hEGF-CDLs compared to hEGF-NDLs might be due to 
a synergistic effect between polysorbate 20 and stearylamine. The stronger toxicity observed 
for hEGF-CDLs compared to empty CDLs highlights the dose-dependency response of 
HaCaT to hEGF, as found for HF cell line (Fig. 3b).  
In addition to the influence of the surfactants, the reduced mitogenic effect observed at the 
highest concentration of hEGF-CDLs in both cell lines might be explained by the results from 
in vitro drug release and ex vivo skin penetration studies (Fig. 1, 2). CDLs were able to 
enhance both in vitro hEGF release and its skin penetration through the SC, resulting in a 
faster hEGF release from the cationic vesicles compared to neutral and anionic ones. This 
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might cause a faster uptake of hEGF followed by a rapid clearance from the site of action, 
thus reducing its therapeutic effect. ADLs enabled a more sustained hEGF release and depot 
onto the skin surface, which could explain the prolonged and stronger mitogenic activity of 
hEGF when incorporated in ADLs. This might be considered a further advantage in terms of 
reduction of administration frequency (Gainza et al., 2015a). Moreover, the enhanced long-
term mitogenic effect of hEGF when incorporated in ADLs compared to the free hEGF 
suggests that ADLs offer protection of the drug, assuring longer stability and thus 
contributing to an enhanced therapeutic effect. 
 
Fig. 3. Mitogenic effect of hEGF-containing deformable liposomes on human skin 
fibroblasts (HF) (n = 3 ± SD). 
 
Fig. 4. Mitogenic effect of hEGF-containing deformable liposomes on human 
immortalized keratinocytes (HaCaT) (n = 3 ± SD). 
 
We confirmed the potential of anionic deformable liposomes in in vitro conditions; however, 
their real clinical potential will have to be confirmed in animal and clinical studies. 
 
4. Conclusions  
Neutral, cationic and anionic deformable liposomes containing hEGF were prepared to 
improve dermal delivery of growth factors. The formulations were evaluated in terms of their 
physicochemical characteristics, in vitro drug release, ex vivo drug penetration through human 
skin, as well as the in vitro mitogenic activity in human fibroblasts and keratinocytes. All 
27 
 
deformable liposomes exhibited high hEGF entrapment, with a slightly higher entrapment 
efficiency for anionic deformable liposomes. hEGF-containing anionic deformable liposomes 
exhibited the most sustained in vitro release of hEGF and assured a depot system on the ex 
vivo human skin compared to neutral and cationic deformable liposomes. In addition, anionic 
deformable liposomes revealed to be the most effective in enhancing the mitogenic effect of 
hEGF in HF and HaCaT cell lines compared to the neutral and cationic deformable liposomes 
as well as hEGF in solution. Anionic deformable liposomes have shown to be a promising 
system for improved chronic wound therapy. Their clinical potential will have to be further 
explored. 
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Fig. 1. In vitro hEGF release over 6 hrs from different liposomal formulations through 












Fig. 2. Retention of hEGF onto the full thickness human skin surface from different 
liposomal formulations after ex vivo skin penetration studies over 6 hrs (n = 3 ± SD). 
As a control, hEGF in PBS at similar concentration as hEGF in liposomes was used. 











Fig. 3. Mitogenic effect of hEGF-containing deformable liposomes on human skin 
fibroblasts (HF) (n = 3 ± SD). 
The mitogenic effect of hEGF-NDLs (a), hEGF-CDLs (b) and hEGF-ADLs (c) on HF cells 
was investigated for 24 and 48 hours, respectively. NDLs, CDLs and ADLs represent empty 
neutral, cationic and anionic deformable liposomes, respectively. Untreated cells are referred 
as control. The d represents the mitogenic effect of hEGF in PBS (free hEGF) at same tested 
concentrations as for hEGF entrapped in liposomes. 








Fig. 4. Mitogenic effect of hEGF-containing deformable liposomes on human 
immortalized keratinocytes (HaCaT) (n = 3 ± SD). 
The mitogenic effect of hEGF-NDLs (a), hEGF-CDLs (b) and hEGF-ADLs (c) on HaCaT 
cells was investigated for 24 and 48 hours, respectively. NDLs, CDLs and ADLs represent 
empty neutral, cationic and anionic deformable liposomes, respectively. Untreated cells are 
referred as control. The d represents the mitogenic effect of drug in PBS (free hEGF) at same 
tested concentrations as for hEGF entrapped in liposomes. 
























hEGF-NDLs 100 170 30 - - 
hEGF-CDLs 100 153 30 17 - 
hEGF-ADLs 100 170 - - 30 
aAll liposomal formulations were prepared to a final volume of 5 mL. 
bEmpty NDLs, CDLs and ADLs (without hEGF) were prepared using the same composition 























hEGF-NDLs 350.0 ± 8.2 0.22 ± 0.01 -0.5 ± 0.6 80.5 ± 1.5 
hEGF-CDLs 361.7 ± 32.5 0.30 ± 0.02 45.8 ± 1.8 80.8 ± 0.7 
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Curcumin, a multi-targeting pharmacologically active compound, is a promising molecule for 
the treatment of skin inflammation and infections. However, its hydrophobic nature is a 
challenge for the development of its pharmaceutical products, including 
dermatopharmaceuticals. Here we propose deformable liposomes (DLs) as a mean to overcome 
the curcumin limitations related to skin treatment. We explored the properties and biological 
effects of curcumin containing DLs with varying surface charge by preparing the neutral 
(NDLs), cationic (CDLs) and anionic (ADLs) nanocarriers. With a vesicle size range of 200-
300 nm, DLs exhibited entrapment efficiencies mirroring the type of employed surfactant. 
Curcumin-CDLs provided the most sustained ex vivo penetration of curcumin through the full 
thickness human skin. When tested against Staphylococcus aureus and Streptococcus pyogenes, 
all DLs inhibited in vitro bacterial growth significantly. CDLs showed the most potent anti-
bacterial activity. All curcumin-DLs showed better in vitro anti-inflammatory activity 
compared to curcumin in solution (control); curcumin-CDLs were found to be the most potent. 
Curcumin-DLs did not show toxic effects in vitro on human skin fibroblasts. The incorporation 
of curcumin in DLs enabled both its sustained skin penetration and enhancement of its 
therapeutic properties. Cationic nanocarriers enhanced the activities of curcumin to a greatest 
extent. 
 
Keywords: curcumin; deformable liposomes; liposome surface charge; skin penetration; anti-
bacterial; anti-inflammatory.  
 
Abbreviations: ADLs, anionic deformable liposomes; CCK-8, Cell Counting Kit-8; CDLs, 
cationic deformable liposomes; DLs, deformable liposomes; DOTAP, 1,2-dioleoyl-3-
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trimethylammonium propane; HFF, human foreskin fibroblasts; HLB, hydrophilic/lipophilic 
balance; IMDM, Iscove's modified Dulbecco's medium; LPS, lipopolysaccharide; NDLs, 
neutral deformable liposomes; NO, nitric oxide; NFĸB, nuclear transcription factor kappa B; 
PBS, phosphate buffer saline; PCS, photon correlation spectroscopy; PI, polydispersity index; 
P20, polysorbate 20; PG, propylene glycol; SDC, sodium deoxycholate; SPC, soybean 



















Curcumin is a polyphenol found in the rhizome of the turmeric plant Curcuma longa L. This 
natural compound is nowadays considered a “gold” molecule due to its anti-oxidant, anti-
bacterial and anti-inflammatory properties, among other therapeutic activities [1]. Research 
over the past 30 years confirmed its therapeutic potential against several inflammatory-related 
diseases, such as the cancer, autoimmune diseases, neurological diseases, lung and liver 
diseases [2]. The anti-inflammatory properties of curcumin are the result of its interaction with 
several molecules involved in inflammation pathways. Curcumin is able to decrease the 
expression of various pro-inflammatory cytokines by downregulating the nuclear transcription 
factor kappa B (NFĸB) pathway thus contributing to reduced inflammation [3]. Additionally, 
the suppression of cyclooxygenases, lipoxygenase and inducible nitric oxide (NO) synthase 
enzymes mediated by curcumin has shown to be beneficial to decrease the inflammation degree 
in several inflammatory diseases [4,5,6]. In spite of the evidently high potential of this 
pleiotropic active compound in the treatment of inflammatory diseases, its limitations such as 
low solubility and poor bioavailability limit its oral administration. Research has therefore 
moved towards topical administration of curcumin, which has shown to be equally promising; 
for example, in vaginal administration for treatment of chronic vaginal inflammation [4]. 
Topical administration onto skin appears equally encouraging and curcumin has shown to be a 
good candidate for the treatment of hyper-inflammatory wounds, such as chronic wounds and 
burns [7]. Moreover, curcumin is highly promising in controlling the scar formation and 
treatment of hypertrophic post burn scarring [8]. In addition to the well-established anti-
inflammatory property of curcumin, its anti-bacterial activity become equally important as 
alternative antimicrobial considering the ongoing evolvement of bacterial resistance to 
antibiotics [9]. Moreover, curcumin as a topical anti-bacterial agent might be a promising 
alternative to the overuse of antibiotics, both locally and systemically. The wounded/impaired 
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skin is highly prone to bacterial colonization due to the nutrient-rich environment provided by 
high levels of wound exudate [10]. Curcumin might therefore synergistically act in the 
treatment of chronic wounds and burns. Similarly to its anti-inflammatory activity, the anti-
bacterial potential of curcumin is related to its action at molecular level, including suppression 
of one of the essential protein, FtsZ, which initiates bacterial cell division [11].  
However, the hydrophobic nature of curcumin limits its formulation in pharmaceutical products 
for localized skin therapy, such as hydrophilic wound dressings such as hydrogels. Moreover, 
it is chemically unstable, especially at the physiological pH, if not protected by a carrier. Its 
direct applications locally onto the skin, in a vehicle without a carrier, might cause erythema, 
peeling and hot phenomenon, due to its photosensitivity [12]. Therefore, the main focus is on 
finding novel approaches to enable curcumin solubilization and increase its stability to achieve 
optimal therapeutic outcome while minimizing the side effects. Nanotechnology-based delivery 
systems are one of the novel strategies employed to overcome limited pharmaceutical and 
therapeutic potential of curcumin for topical administration. Up to now, several phospholipid-
based nanocarriers have been employed to overcome its limitations in dermal delivery [1,7]. 
Deformable liposomes (DLs) were proposed a superior carrier for dermal delivery of molecules, 
including poorly soluble ones. DLs can incorporate lipophilic drugs in their phospholipid 
bilayer thus improving their solubility and assuring protection from chemical instability 
[13,14]. Moreover, DLs can prolong drug retention time onto/in the skin and assure 
sustained/controlled drug release [15]. An additional advantage of DLs is the possibility to 
modify their composition to obtain tailored physicochemical properties, directly affecting their 
fate as dermal nanocarriers. The liposomal surface charge plays an important role in the 
interaction between liposomes and stratum corneum (SC) corneocytes, thus influencing the skin 
penetration of incorporated drug mediated by the liposomes [16]. Curcumin, as described 
earlier, is active at cellular level exerting both anti-bacterial and anti-inflammatory activities 
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[17]. Therefore, it is expected that DLs enable a targeted delivery of curcumin to the cellular 
level, thus enhancing its cellular uptake and improving its therapeutic effect. This mechanism 
has shown to be related to the liposomal surface charge [18]. As for the nanocarrier/corneocytes 
interaction, electrostatic interactions might occur between charged DLs and cell membranes. 
Positively charged DLs are expected to exhibit higher affinity for the negatively charged 
domains of the cell membranes thus enhancing a cellular uptake of curcumin [19].  
The aim of the present study was to develop an efficient liposomal formulation for dermal 
delivery of curcumin focusing on its potential for treatment of skin infection and inflammation. 
Therefore, neutral, cationic and anionic deformable liposomes (NDLs, CDLs and ADLs, 
respectively) containing curcumin were prepared. The role of the liposomal surface charge was 
evaluated in ex vivo skin penetration studies using the full thickness human skin. The in vitro 
anti-bacterial and anti-inflammatory activities of curcumin-DLs were evaluated. In vitro cell 
viability study using human foreskin fibroblasts (HFF) was performed to assess the safety of 
the liposomal formulations in healthy human skin cells. 
 
2. Materials and methods 
2.1. Materials 
Curcumin (≥ 94 % curcuminoid content; ≥ 80 % curcumin) was purchased from Sigma-Aldrich 
(St. Louis, USA). Lipoid S 100 (> 94 % soybean phosphatidylcholine, SPC) was a generous 
gift from Lipoid GmbH (Ludwigshafen, Germany). Polysorbate 20 (P20), stearylamine (SA), 
sodium deoxycholate (SDC), propylene glycol (PG), methanol, disodium hydrogen phosphate 
dihydrate, monobasic potassium phosphate, sodium chloride, ammonium molybdate, Fiske-
Subbarow reducer agent, phosphorus standard solution, RPMI 1640 medium, 
lipopolysaccharide (LPS) and Iscove's modified Dulbecco's medium (IMDM) were obtained 
8 
 
from Sigma-Aldrich (St. Louis, USA). Hydrogen peroxide 30 % was purchased from Merck 
KGaA (Darmstadt, Germany), sulphuric acid from May & Baker LTD (Dagenham, UK), 
sulfanilamide, naphthylethylenediamine dihydrochloride and phosphoric acid from Sigma Life 
Science (Sigma-Aldrich Norway AS, Oslo) and Albunorm® (human serum albumin, 200 
mg/mL) from Octapharma AG (Lachen, Switzerland). HFF (CCD-1112Sk, ATCC® CRL-
2429™) and murine macrophage RAW 264.7 cell lines were purchased from ATCC (Manassas, 
USA). 
 
2.2. Preparation of deformable liposomes  
NDLs were made of SPC and P20 (total 200 mg) in a weight ratio of 85:15, respectively. CDLs 
were prepared by addition of SA in the same lipid mixture as used for NDLs. The ratio of SA 
to SPC was 1:9 (w/w). ADLs were made of SPC and SDC, maintaining the same weight ratio 
between lipid and surfactant (85:15, respectively) as for NDLs and CDLs. A complete overview 
of the liposomal composition is given in Table 1.  
All DLs were prepared by the conventional film method [20]. Briefly, curcumin (20 mg) and 
lipid (200 mg: SPC and, when applicable, P20, SA and SDC), were dissolved in methanol. A 
thin lipid film was obtained after evaporation of the solvent in a rotary vacuum evaporator 
(Büchi Rotavapor R-124 with Büchi Vacuum Pump V-700, Büchi Labortechnik AG, Flawil, 
Switzerland). The lipid film was kept under vacuum (55 mbar) for 1 hr at 55 ºC and 
subsequently resuspended in 10 mL of phosphate buffer saline (PBS) (pH 7.4; 2.98 g/L 
Na2HPO4 2H2O, 0.19 g/L KH2PO4, 8 g/L NaCl). The liposomal formulations were stored at 4 
°C overnight. For assessment of liposomes’ elasticity, anti-bacterial and anti-inflammatory 
activities of curcumin-DLs and in vitro cell viability study, empty (curcumin-free) NDLs, CDLs 




The size of all DLs was reduced by hand extrusion through the polycarbonate membrane 
(Nuclepore® Track-Etched Membranes, Whatman House, Maidstone, UK). The pore size of the 
membranes and the number of extrusion cycles were optimized for each liposomal formulation 
to obtain liposomes between 200 and 300 nm in size (Table 1). Five cycles of extrusion through 
800 nm pore size membrane were performed for all DLs. Subsequently, NDLs were extruded 
four times through 400 nm pore size membrane, while CDLs and ADLs were extruded through 
the same pore size membrane two and seven times, respectively. Prior to extrusion, CDLs 
(empty and curcumin containing) were thermostated for 10 min at 55 C. 
 














NDLs 20 170 30 - - 
5 x 800 nm 
4 x 400 nm 
CDLs 20 153 30 17 - 
5 x 800 nm 
2 x 400 nm 
ADLs 20 170 - - 30 
5 x 800 nm 
7 x 400 nm 
aEach liposomal formulation was prepared in triplicates. The final volume was 10 mL. For 
empty liposomes (without curcumin), the same lipid/surfactant composition was used. 
bThe extrusion is described as the number of extrusion cycles through the corresponding pore 
size membrane (nm). 
 
2.3. Liposomal size and zeta potential measurements   
The vesicle size of all DLs was determined by photon correlation spectroscopy (PCS) using a 
NICOMP Submicron Particle Sizer Model 370 (NICOMP Particle Sizing system, Santa 
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Barbara, California, USA) [20]. The liposomes were diluted with PBS to obtain a suitable 
particle intensity (250-350 kHz). All measurements were run in triplicates (run time of 10 min 
for each measurement) at room temperature (23-24 °C) and using the intensity-weighted 
distribution mode.   
Zeta potential determination was performed using Malvern Zetasizer Nano – ZS (Malvern, 
Oxford, UK) [20]. Samples were diluted 1:20 (v/v) with filtered water (0.2 µm syringe filter, 
Bulk Acrodisc® 25 mm Syringe Filter, Pall Life Sciences, East Hills, New York, USA) or 
filtered water containing SDC for ADLs. An attenuator of 6-7 was used for all measurement 
runs (equilibration time of 180 s, 25 °C). The measurements were performed in triplicates. 
 
2.4. Entrapment efficiency of curcumin in DLs  
DLs were centrifuged (Biofuge stratos centrifuge with a swinging bucket rotor 4 x 180 mL; 
Heraeus instruments GmbH, Hanau, Germany) at 3,000 g for 10 min (10 °C) to remove the free 
(unentrapped) curcumin. After dissolving the lipids with methanol, the entrapped curcumin in 
all DLs (supernatant) was quantified by UV–VIS spectrophotometry at 425 nm (SpectraMax 
190 Microplate Reader, Molecular Devices, California, USA). Prior to the absorbance 
measurement, all samples were further diluted 1:1 (v/v) with PBS to avoid evaporation of 
methanol. A standard curve of curcumin in methanol/PBS (1:1, v/v) was used in the 
concentration range of 1-20 µg/mL (R2 = 0.9996).  
 
2.5. Phospholipid content measurement 
To express the entrapment efficiency as the curcumin/lipid ratio and follow to possible loss of 
lipids during the extrusion, the amount of SPC in all liposomal dispersions was quantified by 
phosphorous assay [21]. Aliquots of liposomes (50 µL) were diluted to a final volume of 10 
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mL with distilled water and then incubated at 160 °C for 3 hrs after the addition of sulfuric acid 
(5 M). Hydrogen peroxide 30 % was added and the samples incubated at 160 °C for additional 
1.5 hrs. After the heating, ammonium molybdate (0.22 %, w/v) and Fiske-Subbarow reducer 
were added and the solution incubated at 100 °C for 7 min. The samples were then analyzed 
spectrophotometrically on a SpectraMax 190 Microplate Reader (Molecular Devices, 
California, USA) at 830 nm using a standard curve of phosphorous standard solution. 
 
2.6. Liposome elasticity measurements 
The bilayer elasticity of all DLs was determined as reported earlier [22]. The liposomal 
dispersions were extruded through the polycarbonate membrane with a pore size of 100 nm at 
a constant external pressure of 2.5 bar. The amount of liposomal dispersion after 5 min of 
extrusion was determined (J). The vesicle mean diameter and polydispersity index were 
monitored by PCS measurements before and after the extrusion, respectively. The degree of 
membrane elasticity (E) of all curcumin-DLs was calculated using the following equation: 
E J	 ∙ 	 r r⁄ , 
where J is the amount of liposomal dispersion (g) extruded in 5 min, rv is the mean diameter 
(nm) of liposomes after the extrusion and rp is the pore size membrane (nm). 
Empty NDLs, CDLs and ADLs (without curcumin) were used as control, respectively.  
Empty and curcumin containing CDLs were thermostated at 55C prior to measurements.  
 
2.7. Ex vivo skin penetration studies 
Curcumin penetration through the full thickness human skin was investigated in the Franz 
diffusion cells of 1.77 cm2 diffusion area (PermeGear, Bethlehem, USA) [20]. Human skin, 
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derived from the excess of skin panni, was obtained from the abdomen of female patients after 
plastic surgery. The patients were informed on the use of the skin residue for this study and 
signed a written consent prior the surgery. The excess of skin panni is normally discarded after 
surgery, therefore no ethical approval by the Norwegian Ethical Committee was required. The 
experiments were carried out in accordance with the Declaration of Helsinki Principles. The 
full thickness human skin was separated from the subcutaneous fat and rinsed with PBS (pH 
7.4). The human skin samples were stored at -20 °C and thawed prior the use. The human skin, 
with a thickness of 1.10-1.30 mm, was mounted with SC facing the donor chamber. The 
receptor chamber (volume of 12 mL) was filled with Albunorm® (5 %, v/v) in PBS (pH 7.4) 
solution and the receptor medium was maintained at 32 °C during the experiment. All 
curcumin-DLs were tested. To explore the effect of the liposomal surface charge on the skin 
penetration of curcumin, deformable liposomes with neutral surface (NDLs) were used as a 
control. Each formulation (600 µL) was pipetted in the donor chamber; the experiments were 
performed for 24 hrs and samples (500 µL) withdrawn from receptor medium at certain time 
intervals (1, 2, 3, 4, 5, 6, 7, 8 and 24 hrs, respectively). After each sampling, the receptor 
chamber was refilled with equal volume of fresh receptor medium to assure the sink conditions. 
At the end of the experiment, curcumin in the receptor medium (penetrated) was quantified as 
described in Section 2.4. The quantification of penetrated curcumin was performed using a 
standard curve in Albunorm® (5 %, v/v) in PBS (pH 7.4). The experiments were run in 
triplicates. 
 
2.8. Anti-bacterial susceptibility testing 
All curcumin-DLs were assessed in terms for their in vitro anti-bacterial activity against two 
clinical strains of Gram-positive bacteria, namely Staphylococcus aureus subsp. aureus 
Rosenbach MSSA476 (ATCC- BAA-1721, LGC standard AB, Sweden) and Streptococcus 
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pyogenes (ATCC 19615), using the modified broth dilution method [23]. To perform the 
experiment, a bacterial suspension with a turbidity of 0.5 McFarland was prepared in sterile 
saline solution (0.85 %, w/v), corresponding to 1-2·108 CFU/mL. The bacterial suspension 
containing S. aureus and S. pyogenes was further diluted in Mueller Hinton broth or Mueller 
Hinton broth with 5 % horse blood, respectively, to obtain the concentration of approx. 106 
CFU/mL. Subsequently, two-fold serial dilutions of the test formulations were prepared in 
growth medium using a 96-well plate. All tested DLs were reduced in size to approx. 100 nm 
average diameter to avoid possible liposome precipitation during the experiment. Curcumin and 
lipid contents in the liposomal formulations were determined as described in Sections 2.4 and 
2.5, respectively. Two lipid concentrations of curcumin-DLs were tested, namely 2 and 4 
mg/mL, corresponding to the curcumin concentrations of 100 and 200 µg/mL, respectively. 
Moreover, as the controls, the following samples (in growth medium) were tested: i) PG (20 %, 
w/v) solution in PBS, ii) empty NDLs, CDLs, ADLs, at similar lipid concentration as in 
curcumin-DLs, iii) curcumin in PG solution (20 %, w/v) in similar concentrations as curcumin 
in DLs. As a negative control, one row of the 96-well plate was filled only with the growth 
medium. The bacterial suspension, previously prepared as described above, was then added to 
each well to a final concentration of 5x105 CFU/mL and incubated at 37 °C for 4 hrs. The 
bacterial survival after treatment with the tested formulations was evaluated by serial dilution 
of the bacterial suspension from each well with subsequent plating on blood agar plates 
following overnight incubation at 37 °C. The percentage of bacterial survival was determined 
by comparing surviving bacteria to the negative control (100%). 
 
2.9. Inhibition of NO production measurements  
The in vitro anti-inflammatory activity of curcumin-DLs was assessed in terms of their effect 
on the inhibition of NO production in LPS-induced murine macrophage RAW 264.7 cells [4]. 
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The cells (1×105 cells/mL) were cultured in a 24-wells plate with RPMI 1640 medium 
supplemented containing 10 % fetal bovine serum and glutamine. The cells were then incubated 
for 24 hrs at 37 °C/5 % CO2. RPMI medium was replaced with LPS solution (1 µg/mL) in 
RPMI to induce NO production. Additionally, the test formulations (curcumin-DLs) were 
added (10 µL) at various lipid concentrations, namely 1, 10 and 50 µg/mL, corresponding to 
curcumin concentrations of 0.05, 0.5 and 2.5 µg/mL. The controls for curcumin and curcumin 
liposomes were the same as the ones used for anti-bacterial susceptibility testing (Section 2.8). 
As a negative control, the cells treated with LPS were used. After 24 hrs incubation, the NO 
production was measured in terms of nitrite formation in the media by the addition of Griess 
reagent (1 % sulfanilamide, 0.1 % naphthylethylenediamine dihydrochloride, 2.5 % phosphoric 
acid) (1:1 as volume ratio with RPMI). The absorbance was read at 540 nm using an Epoch 
Microplate Spectrophotometer (BioTek Instruments, Vermont, USA). The effect of the 
curcumin in liposomal formulations on the inhibition of NO production was expressed as 
percentage of produced NO, in comparison to 100 % NO detected in the control (cells treated 
with 1 µg/mL LPS). 
 
2.10. In vitro cell viability testing 
The cell viability of HFF cells exposed to curcumin-DLs was tested to evaluate possible 
cytotoxic effect of curcumin-DLs on healthy skin cells. The HFF cells (50,000 cells/mL) were 
cultured in a 96-wells plate with IMDM together with 10 % (v/v) fetal bovine serum at 37 °C 
in 5 % CO2. After 24 hrs, 10 µL of test formulations were added and incubated for 12 and 24 
hrs, respectively. All test formulations were the same as the ones tested in NO production 
measurements (Section 2.9). Living cells were quantified using the Cell Counting Kit-8 (CCK-
8) (Sigma-Aldrich Chemie, Steinheim, Germany) after 12 and 24 hrs exposure, respectively. 
CCK-8 (10 µL) was added to the cells and the absorbance was read at 450 nm using an Epoch 
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Microplate Spectrophotometer (BioTek Instruments, Vermont, USA) after 4 hrs incubation 
following the instruction provided by the kit supplier. 
 
2.11. Statistical analysis 
Statistical analyses were performed using one-way ANOVA test followed by Bonferroni’s 
multiple comparisons test performed on GraphPad Prism version 7.00 for Windows (GraphPad 
Software, La Jolla CA, USA). Results were expressed as mean ± SD. A p value < 0.05 was 
considered significant. 
 
3. Results and discussion 
Curcumin is one of the “hot” molecules with potential in treatment of various diseases, 
especially chronic, ranging from cancer to skin diseases [24]. However, its poor solubility, low 
chemical stability and short half-life following systemic absorption make curcumin a 
pharmaceutical challenge [1,5]. Numerous delivery systems have been proposed as means to 
tailor its biological properties [25,26]. We were particularly interested in a potential of 
curcumin as active ingredient in wound dressings. Various topical formulations have been 
evaluated for their potential to enhance curcumin’s therapeutic activities relevant for wound 
healing [6]. The conventional liposomes can incorporate lipophilic compounds, such as 
curcumin, in their phospholipid bilayer thus enhancing their solubilization and providing their 
stability and protection [5]. Their phospholipid structure resembles the skin lipid composition 
thus enabling accumulation of the incorporated drug into the skin [14]. However, conventional 
liposomes act by forming a depot on the skin surface and our aim was to act on the bacterial 
infections in wound bed, which are often not reachable and require drug/carrier penetration to 
achieve total eradication [27]. Deformable liposomes have been shown superior to conventional 
16 
 
liposomes in improving dermal drug delivery, assuring prolonged retention time of the drug 
within the skin and sustained/controlled drug release [15]. Incorporation of curcumin in DLs 
should provide solubilization of curcumin, increase its stability and assure sustained release 
over the desired time. This can subsequently provide a high curcumin concentration within the 
skin, including wound bed, minimizing systemic absorption and undesired side effects. 
Moreover, the liposomal surface charge contributes to the liposomes' behavior as dermal 
nanocarriers [16]. Considering that curcumin acts at cellular level, the liposomal surface charge 
might facilitate the interaction between curcumin carrier and targeted cell membrane [18]. 
Consequently, the targeted delivery of curcumin at the cellular level mediated by DLs is 
expected to improve its therapeutic effects.  
 
3.1. Liposomal characteristics 
The characterization of liposomes in terms of their physicochemical properties is fundamental 
to develop effective liposomal formulations destined for dermal therapy. The vesicle size has 
shown to play an important role in the dermal delivery mediated by nanocarriers. The liposome 
size will determine the depth in skin layers where the entrapped drug is delivered [28]. 
Considering that our aim was to assure local effects of curcumin, we chose to develop 
curcumin-DLs within a size range of 200-300 nm; the size range has shown to provide the 
highest reservoir in the deeper skin layers [29]. Based on our previous findings [20], the hand 
extrusion through polycarbonate membrane was found to be optimal for manufacturing the DLs 
of desired size. Table 2 shows the vesicle size of all curcumin-DLs. A bimodal size distribution 
(Nicomp distribution) was observed for both NDLs and CDLs, presenting a minor particle size 
peak out of the targeted size range. However, the main peaks in size distribution were in the 
range of 200-300 nm, as targeted. The polydispersity index (PI) below 0.25 confirmed a 
satisfactory size distribution for all curcumin-DLs regardless of the liposomal surface charge. 
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The surface charge of all DLs mirrored the type of surfactants/lipids used in the liposome 
preparation (Table 2). The slightly negative zeta potential observed for NDLs was still 
considered to be neutral, due to the presence of a neutral lipid (SPC) and a non-ionic surfactant 
(P20). CDLs bear a strong positive surface charge, whereas ADLs a strong negative charge; 
both can be attributed to the incorporation of a positively surface charged lipid (SA) and 
negatively surface charged ionic surfactant (SDC), respectively. 
In the development of effective nanocarriers for dermal drug delivery, it is important to obtain 
high drug loading capacity to assure a high drug concentration in/within the skin. It is known 
that for DLs, the incorporation of surfactants in the phospholipid bilayer can affect the 
entrapment efficiency [16]. This mainly affects incorporation of lipophilic/amphiphilic drugs 
in DLs. Their lipophilic nature permits their accommodation in the phospholipid bilayer of 
liposomes. Therefore, a competition might occur between the lipophilic drug and surfactant 
thus affecting the amount of incorporated drug in the DLs. This also applies to curcumin, a 
lipophilic compound with high log P (3.29) [30]. Therefore, curcumin is expected to 
accommodate itself in the phospholipid bilayer of the liposomes, similarly as other 
polyphenolic compounds, such as resveratrol [31]. As reported in Table 2, the amount of 
incorporated curcumin varied among the DLs. ADLs exhibited the highest entrapment of 
curcumin, whereas the lowest was found for CDLs. The presence of SA in CDLs has previously 
been shown to cause low entrapment efficiency for celecoxib, drug with similar lipophilicity as 
curcumin [32]. SA might be responsible for causing the repulsions within the lipid bilayers, 
thus triggering alterations in bilayers packing [33]. Therefore, curcumin might encounter 
impediments when accommodating itself in the lipid bilayer of CDLs. Moreover, CDLs were 
made of P20 and SA, both confined in the lipid bilayer together with curcumin. In ADLs, 
curcumin has only to compete with SDC, thus allowing incorporation of higher amount of 
curcumin. Although NDLs include only P20 as a surfactant in the lipid bilayers, the entrapment 
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of curcumin in NDLs was still lower than in ADLs. The reason behind could be the different 
carbon chain length of the two surfactants, which determines their lipophilicity. The longer the 
carbon chain length, in our case SDC, the higher lipophilicity is expected, thus increasing the 
entrapment efficiency of lipophilic compounds [34,35]. 
The SPC recovery after the extrusion was found to be more than 80 % for all liposomal 
formulations (Table 2). This confirmed that the incorporated curcumin was associated with the 
phospholipid bilayer. This was in accordance with previously published data on conventional 
liposomes [4]. 
 


























0.20±0.03 -54.3±4.3 0.11±0.01 89.1±0.9 
aThe diameter is indicated as peaks in size distributions (nm). The weight intensity of each peak 
(%) is indicated in parentheses. 
bPolydispersity index. 




The membrane elasticity is the distinctive characteristic of DLs enabling them to squeeze 
through the skin pores much smaller than their size and consequently enhance the transport of 
incorporated drug into the deeper skin layers [16]. The DLs elasticity is determined by the 
presence of surfactant in the lipid bilayer. Surfactants possess high radius curvature thus 
destabilizing the lipid bilayer and improving liposome membrane elasticity by influencing the 
interfacial tension of DLs. The membrane elasticity can therefore be affected by the type of 
employed surfactant [33]. In this study, we employed different surfactants to prepare DLs 
bearing different surface charges. We incorporated P20 in both NDLs and CDLs, whereas SDC 
was employed to prepare ADLs. CDLs additionally contained SA to confer the positive surface 
charge to the vesicles. To determine the DLs elasticity and liposomal deformability, the 
liposomal dispersions were passed through the polycarbonate membrane (100 nm as pore size) 
using a constant external pressure of 2.5 bar. The DLs elasticity was determined considering 
both the vesicle size (rv) after the extrusion and the amount of liposomal dispersions (J) extruded 
in 5 min. Table 3 shows the degree of membrane elasticity (E) of all DLs, together with the 
determined parameters after the extrusion used to calculate the E. Regarding empty DLs 
(without curcumin), E was mostly dependent on the J. The highest E was obtained with empty 
ADLs, whereas empty CDLs exhibited the lowest E value. CDLs were composed of both P20 
and SA. Although P20 showed to provide elasticity to NDLs, the same effect was not observed 
when incorporated in CDLs. As discussed above, the presence of SA in CDLs might cause 
repulsions when accommodating itself in the lipid bilayers consequently causing alterations in 
the lipid packing. This might reduce the CDLs elasticity. The presence of curcumin in all DLs 
influenced their degree of membrane elasticity (Table 3). The incorporation of curcumin in both 
NDLs and ADLs reduced their E values by more than five- and three-fold, respectively, as 
compared to empty vesicles. Interestingly, the entrapment of curcumin in CDLs enabled an 
increase in membrane elasticity by more than 30-fold in comparison to empty CDLs. A possible 
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explanation might be that the presence of curcumin in CDLs can change the surfactant 
arrangement in the lipid bilayer and limit the lipid packing alterations caused by SA. The degree 
of membrane elasticity of all curcumin-DLs was in agreement with E values typical for elastic 
vesicles reported in literature [22]. Moreover, all curcumin-DLs exhibited similar E values. In 
this study, our focus was on the role of liposome surface charge in the dermal delivery of 
curcumin. Therefore, the similar membrane elasticity observed for all curcumin-DLs allowed 
us to compare the different DLs only exploring the effect of their surface charge and excluding 
any possible effects related to their membrane elasticity.    
 
Table 3. The membrane elasticity of curcumin-DLs.  
Liposomes Surface charge rv/rp  J (g) E 
Empty DLs  
Neutral 1.76 ± 0.04 4.73 ± 0.11 14.59 ± 0.30 
Cationic 1.75 ± 0.02 0.05 ± 0.00 0.16 ± 0.01 
Anionica 1.44  12.70 26.41 
Curcumin-DLs 
Neutrala 1.71 1.61 4.72 
Cationic 1.64 ± 0.07 2.36 ± 0.14 6.38 ± 0.90 
Anionica 1.39 2.83 5.46 
The degree of membrane elasticity (E) was calculated considering both the rv/rp and J. rv is the 
vesicle diameter (nm) after extrusion, rp is the pore size membrane (nm) and J is the amount (g) 
of liposomal dispersion extruded in 5 min (constant pressure of 2.5 bar). Empty DLs bearing 
different surface charge were used as control.  




3.2. Ex vivo human skin penetration of curcumin mediated by DLs 
The skin penetration potential of liposomally-associated substance/drug is fundamental to 
assure targeted drug delivery and, consequently, effectiveness of the nanoformulation. The use 
of human skin in the Franz diffusion cells is one of the most appropriate skin model to obtain 
diffusion kinetics closer to the in vivo conditions [36]. Although diseased skin often exhibits 
compromised SC barrier and the drug/substance penetration might be therefore enhanced, the 
assessment of the skin penetration potential of nanocarriers using the full thickness human skin 
can serve as a pilot study assisting in the selection of the appropriate nanocarrier. This is mainly 
applicable during the screening of nanocarriers with different properties, as, in our case, with 
different liposomal surface charge. Curcumin, a lipophilic compound, is not expected to 
partition from the skin into the aqueous receptor fluid. We therefore incorporated 5 % (v/v) of 
Albunorm® in receptor medium, corresponding to 10 mg/L of albumin, to overcome the scarce 
solubility of curcumin in an aqueous media and avoid negligible diffusion kinetics. Moreover, 
it is known that the in vitro testing tends to underestimate in vivo skin penetration of lipophilic 
compounds. It was therefore suggested that the addition of solubilizing agents in the receptor 
medium could overcome the poor in vitro/in vivo correlation [37]. Commonly used are 
solubilizing agents such as alcohol derivatives [37,38], however their presence does not mimic 
the physiological composition of receptor media. We therefore used Albunorm® as a source of 
albumin, which is physiologically present in the receptor fluid; thus mimicking the in vivo 
conditions to a higher extent while avoiding impairment of the membrane barrier function [39]. 
The cumulative amount of penetrated curcumin from the different DLs through the full 
thickness human skin is presented in Fig. 1.  
After 24 hrs, the amount of penetrated curcumin through the full thickness human skin was low 
for all DLs. These results are in accordance with previous reports on human skin penetration 
profiles of curcumin when incorporated in lipid-core nanocapsules [40]. Although the 
22 
 
penetration of curcumin through the full thickness human skin mediated by our DLs was 
limited, these findings confirm the ability of DLs to deliver the incorporated active compound 
in the deeper skin layers reaching the dermis layer [41]. We have proven that our curcumin-
DLs possess elastic membrane contributing to the curcumin delivery into the deeper skin layers 
mediated by DLs [22,42]. However, the low amount of curcumin that reached the receptor 
medium indicates also a retention of curcumin within the skin thus showing good suitability of 
these nanocarriers for dermal therapy of curcumin. The comparison of the different DLs 
indicates different behavior of nanocarriers as dermal delivery systems. CDLs enabled the most 
sustained skin penetration of curcumin, whereas ADLs exhibited the highest skin penetration 
enhancement of curcumin (Fig.1). The similar degree of membrane elasticity observed for all 
curcumin-DLs (Table 3) indicates that the differences in the skin penetration profiles of 
curcumin were mainly determined by the liposomal surface charge, which has shown to 
influence skin penetration of drugs mediated by liposomes [43]. Considering the negative 
charge of the corneocytes membrane, electrostatic interactions between liposome and SC cells 
might be favorable when the liposomal surface charge is positive [16]. This stronger interaction 
might cause a long-term retention of curcumin on the skin thus sustaining its penetration 
through/into the skin layers. Cationic deformable liposomes containing curcumin have been 
recently studied by Jose and co-workers [44]. The authors prepared cationic deformable 
liposomes made of 1,2-dioleoyl-3-trimethylammonium propane (DOTAP) and sodium cholate 
with a vesicle size of 100 nm, whereas our curcumin-CDLs differed in lipid/surfactant 
composition and were bigger in vesicle size (231 nm). Although dissimilarities in liposomes’ 
composition and size, the sustained skin penetration of curcumin observed for our CDLs in 
human skin was in accordance with their findings using pig skin [44]. The skin penetration 
enhancement effect of negatively charged DLs for incorporated lipophilic compounds has been 
previously observed using pig skin [45,46]. Paolino and collaborators [41] found an 
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enhancement in human skin penetration of lipophilic compounds for DLs comprising SDC, in 
accordance with our findings. More recently, we have also shown the capability of ADLs to 
deliver lipophilic compounds into the deeper skin layers through ex vivo human skin in Franz 
diffusion cells [20].  
 
 
Fig. 1. Curcumin penetration from different deformable liposomes through the full 
thickness human skin over 24 hrs. Results are expressed as mean ± SD (n = 3). 







3.3. Anti-bacterial activity of curcumin-DLs  
Skin, especially skin with compromised barrier and chronic wounds, are prone to colonization 
by bacteria. Bacterial infections contribute to delayed healing thereof increasing the incidence 
of morbidity and mortality in patients [47]. Gram-positive bacteria, specifically S. aureus and 
S. pyogenes are responsible for skin infections in general [10,48,49]. Therefore, curcumin 
liposomal formulations that prevent/treat microbial contamination can contribute to improved 
skin therapy and prevention of bacterial biofilms in chronic wounds [50]. Additionally, dermal 
(localized) therapy for chronic wound treatment might limit the high incidence of bacterial 
resistance related to the overuse of antibiotics orally and systemically [51]. Curcumin can 
therefore be a promising alternative to common antibiotics with evolved resistance against 
broad spectrum of bacteria, including S. aureus [9]. All liposomal formulations with curcumin 
were tested against two clinical strains, S. aureus and S. pyogenes. Curcumin as antimicrobial 
is not fully utilized and the potential of nanocarriers in modulating its antimicrobial effects are 
currently, although very promising, not fully explored [11]. Therefore, broader use of curcumin 
as antimicrobials can contribute to limiting the use of antibiotics. We aimed firstly to evaluate 
the anti-bacterial effect of curcumin when incorporated in DLs and secondly, to explore the 
effect of the liposomal surface charge on curcumin-DLs anti-bacterial activity. Since we 
developed a system which would serve as an alternative to antibiotics, and as a mean to recue 
antibiotic use, we did not include antibiotics as positive control in the anti-bacterial activity 
testing.  
All curcumin-DLs inhibited both S. aureus and S. pyogenes growth compared to control 
(untreated bacteria) (Fig. 2a, c). No differences in anti-bacterial activity were observed between 
the two tested concentrations of curcumin (100 and 200 µg/mL, respectively), indicating that 
lower curcumin concentration was already sufficient to exert the anti-bacterial effect. This 
might also be beneficial considering the possibility of side effects related to high curcumin 
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concentration at the site of administration [12]. Curcumin-NDLs exhibited the weakest 
inhibition of S. aureus growth compared to both CDLs and ADLs (Fig. 2a). The same trend 
was observed with S. pyogenes (Fig. 2c). These findings suggest that the liposomal surface 
charge influences the liposomal interaction with the bacterial cell membrane. The neutral 
liposomal membrane of NDLs might limit this interaction thus reducing curcumin availability 
at the targeted bacterial membrane resulting in a weak anti-bacterial activity. The strongest 
activity was observed for curcumin-CDLs against both S. aureus and S. pyogenes. Moreover, 
CDLs inhibited bacterial growth to a higher extent than free curcumin (curcumin in PG 
solution) (Fig. 2b, d). Therefore, the positive surface charge of CDLs may facilitates their 
interactions with the negatively charged bacterial cell membrane thus increasing the anti-
bacterial activity of the incorporated curcumin. The effect could have been even more 
pronounced if the incubation time was prolonged. However, we were very encouraged by the 
promising findings achieved after 4 hrs incubation time allowing detection of differences 
between the DLs bearing different surface charges. Moreover, all curcumin-DLs inhibited 
bacteria growth by more than 50 %, therefore longer incubation time may result in stronger 
effect making the differences among the DLs less evident. Free curcumin would require more 






Fig. 2. Effect of different curcumin-DLs on S. aureus (upper part) and S. pyogenes (lower 
part) growth after 4 hrs incubation.  
(a) and (c) show the effect of curcumin-DLs on S. aureus and S. pyogenes, respectively. Control 
refers to untreated bacteria. Empty DLs are curcumin-free NDLs, CDLs and ADLs, 
respectively, with similar lipid concentrations as curcumin-DLs. (b) and (d) represent the effect 
of free curcumin (CUR-PG), meaning curcumin in PG solution (20 % w/v) with same 
concentrations as in deformable liposomes. PG sol is PG (20 % w/v) solution in PBS.  
Bar graphs showing mean ± SD (n = 2). a: p < 0.03, a’: p < 0.002, a’’: p < 0.0002, a’’’: p < 0.0001. 
 
Additionally, we also tested all liposomal formulations against a clinical strain of Gram-
negative bacteria, namely Pseudomonas aeruginosa (ATCC 27853), using the agar diffusion 
method to determine eventual zones of inhibition, as described earlier [52]. However, none of 
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the curcumin-DLs exhibited stronger inhibition of P. aeruginosa growth than the free curcumin 
(curcumin in PG solution) (data not shown). Krausz and collaborators [50] also observed that 
Gram-negative bacteria, particularly P. aeruginosa, were less susceptible than Gram-positive 
bacteria to curcumin-containing nanoparticles. The properties of Gram-negative bacteria cell 
membrane, both in terms of the surface charge and composition, compared to Gram-positive 
bacteria might result in a limited nanoparticle interaction with the Gram-negative cells [50]. 
 
3.4. Effect of curcumin-DLs on NO production in LPS-induced macrophages   
Skin inflammatory diseases, especially chronic wounds and burns, are often delayed in the 
healing process due to persistent inflammation. NO is known to play a central role in the 
inflammation pathways thus worsening healing of chronic wounds [6]. During the 
inflammation process, NO is secreted in large quantities by LPS-induced macrophages. NO 
production can help as cytotoxic mediator thus preventing microorganism invasion. However, 
an excessive NO production can interact with oxygen radicals forming an extremely reactive 
radical (peroxinitrite), which induces inflammatory cellular cytokines thus causing cell death 
and impaired healing [53]. Moreover, in chronic wounds, an excessive production of NO also 
causes an impairment of collagen synthesis [54], further delaying the wound healing process. 
Therefore, a local therapy based on a formulation that inhibits NO production will possibly 
reduce the persistent inflammation distinctive in chronic wounds and burns. Fig. 3 shows the 
effect of curcumin-DLs on NO production in LPS-induced macrophages. Regardless of the 
liposomal surface charge, a concentration-dependent inhibition of NO production was observed 
for all curcumin-DLs (Fig. 3a-c). At the lowest lipid concentration (1 µg/mL), no inhibitory 
effect on NO production was observed for all DLs. In contrast, they exhibited an inhibitory 
effect at 10 µg/mL, which was stronger than the effect of free curcumin (curcumin in PG 
solution) (Fig. 3d). This effect was more evident at the highest tested lipid concentration (50 
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µg/mL). Free curcumin (curcumin in solution) has widely confirmed to possess anti-
inflammatory activity, exhibiting even stronger effect compared to other well-known anti-
inflammatory compounds, such as vitamin C, lipoid acid and L-nitro-arginine methyl ester [4]. 
In this study we could observe that DLs enhanced curcumin’s anti-inflammatory activity, as 
previously shown for conventional neutral liposomes [4]. The increased inhibitory effect of NO 
production when curcumin is incorporated in DLs might be a consequence of i) increased 
curcumin stability due to the liposomes' ability to protect it from UV- and pH-induced 
degradation, ii) enhanced curcumin uptake in macrophages, and iii) improvement of curcumin 
aqueous solubility thus maximizing its bioavailability and tissue distribution [1]. Recent studies 
on liposomes containing glucocorticoid by Gauthier and collaborators [55] have showed the 
ability of phosphatidylserine-modified liposomes to enable faster uptake in macrophages, thus 
promoting targeted delivery of the incorporated drug and enhancing its anti-inflammatory 
effect.  
Comparing the liposomal surface charge, the strongest inhibitory effect was obtained with 
CDLs (Fig. 3b). At the highest lipid concentration, CDLs inhibited NO production by almost 
10 % more than both NDLs and ADLs (Fig. 3a, c). The stronger effect of CDLs might be 
explained by the higher affinity of positively charged DLs towards the negative cell membrane, 
facilitating their interactions. Moreover, the more sustained skin penetration of curcumin 
observed with CDLs (Fig. 1) might prolong the retention time of curcumin at the targeted site 
of action. This would facilitate and prolong CDLs interaction with macrophages, thus allowing 
continuous curcumin cellular uptake and enhancing its effect at cellular level, as observed for 
the anti-bacterial effect (Fig. 2a, c). Studies regarding possible curcumin uptake by 
macrophages would be necessary to confirm our hypothesis, however this correlation between 
sustained release and enhanced anti-inflammatory activity has been previously observed with 





Fig. 3. Effect of different curcumin-DLs on NO production in LPS-induced macrophages.  
LPS-induced macrophages were treated with: (a) curcumin neutral deformable liposomes 
(CUR-NDLs), (b) curcumin cationic deformable liposomes (CUR-CDLs) and (c) curcumin 
anionic deformable liposomes (CUR-ADLs), incubated for 24 hrs. Untreated LPS-induced 
macrophages were used as a control. NDLs, CDLs and ADLs are empty deformable liposomes, 
tested at the same lipid concentrations as curcumin-DLs. (d) curcumin in PG solution (CUR-
PG) at the same curcumin concentration as in deformable liposomes. PG sol is PG (20 % w/v) 
solution in PBS. 





3.5. Effect of curcumin-DLs on healthy human skin cells   
The incorporation of cationic lipid and surfactants, especially ionic, in DLs destined for dermal 
therapy might rise toxicity concerns [19]. Moreover, curcumin as polyphenolic compound 
might exhibit side effects on skin cells when administered at high concentrations [6]. To explore 
possible cytotoxic effect of curcumin-DLs to skin fibroblasts, different surface charged DLs 
were incubated with HFF cells for 12 and 24 hrs, respectively. As shown in Fig. 4, all DLs were 
found to be safe for HFF cells, in agreement with previous findings on other type of nanocarriers 
containing curcumin [40]. Moreover, a proliferation effect of curcumin-DLs was observed (Fig. 
4a, b, c). Similar findings have been reported by Gopinath and co-workers [56], who observed 
fibroblast proliferation mediated by curcumin in collagen films. More recently, Manca and co-
workers [57] studied the effect of curcumin-in-hyalurosomes on human keratinocytes and found 
an increase in cell viability, as observed for our liposomal formulations. Curcumin-NDLs (Fig. 
4a) and curcumin-ADLs (Fig. 4c) showed a concentration dependent cell proliferation 
enhancement. After 12 hrs exposure, both curcumin-NDLs and curcumin-ADLs exhibited 
greater proliferation effect than the control (untreated HFF cells) at lipid concentrations of 10 
and 50 µg/mL. NDLs, at 10 and 50 µg/mL, enhanced the number of living cells by 24 and 32 
% compared to control, respectively. ADLs exhibited weaker cell proliferation ability compared 
to NDLs, however they still enabled 12 and 14 % more proliferation than control at 10 and 50 
µg/mL, respectively. The same trend was observed when comparing curcumin-DLs with free 
curcumin (curcumin in PG solution) (Fig. 4d). At the highest lipid concentration (50 µg/mL), 
NDLs enhanced cell proliferation by 32 %, whereas ADLs enhanced by 14 %. This cell 
proliferation activity was more evident after 24 hrs exposure. For both NDLs and ADLs, an 
enhancement in cell proliferation by 50 % compared to free curcumin was observed (Fig. 4a, c, 
d). Our results are in agreement with published data on other type of nanocarriers, showing that 
curcumin incorporation in phospholipid-based nanosystems is beneficial to diminish its toxicity 
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concerns [26]. Regarding CDLs (Fig. 4b), the tested lipid concentrations of 1 and 10 µg/mL 
exhibited similar proliferation effect as observed for NDLs and ADLs. The enhanced in vitro 
proliferation effect in HFF observed for curcumin-DLs may be additionally beneficial in 
treatment of chronic wounds and burns, but also in atopic dermatitis, ichthyosis vulgaris, all 
characterized by a conspicuous human skin cells death. In these conditions, a cell proliferation 
effect helps and accelerate the normal reconstitution of the skin layers. Interestingly, the CDLs 
at the highest lipid concentration (50 µg/mL) showed lower proliferation effect than at 
concentration of 10 µg/mL. By increasing the surfactant concentration, the interaction between 
the amphiphilic ionic surfactant and the cellular lipid bilayer is more likely to occur, resulting 
in disruption of the plasma membrane [58]. This lower proliferation effect of CDLs at higher 
concentrations (50 µg/mL) was not observed for NDLs and ADLs, indicating that the liposomal 
surface charge influences the extent of the interaction between nanocarrier and cell membrane. 
Due to the negative charge of the cellular membrane, electrostatic interactions are more likely 
to occur with positively charged liposomes thus facilitating the possible cytotoxic effect exerted 
by CDLs. However, CDLs at the highest lipid concentration assured equal or higher cell 
viability than control after both 12 and 24 hrs exposure. This excludes any cytotoxic effect of 
CDLs. To the best of our knowledge, the cytotoxicity of stearylamine liposomes, as our CDLs, 
has only been tested in human lung epithelial cells by Tahara and collaborators, who found no 
negative effect of stearylamine liposomes on cell viability after 4 hrs exposure [59].  
Regarding the anti-inflammatory activity of curcumin-CDLs (Fig. 3b), it can be postulated that 
the strong inhibitory effect on NO production observed for CDLs is due to their potential cell 
toxicity and that the reduction of NO production is only a consequence of apoptosis/necrosis of 
macrophages caused by CDLs. However, the findings from the cell viability study showed a 
clear lack of cytotoxicity of CDLs (Fig. 4b) and even more, demonstrated a proliferative effect, 





Fig. 4. Effect of different curcumin-DLs on viability of human foreskin fibroblast (HFF) 
cells after 12 and 24 hrs exposure.  
HFF cells were exposed to: (a) curcumin neutral deformable liposomes (CUR-NDLs), (b) 
curcumin cationic deformable liposomes (CUR-CDLs) and (c) curcumin anionic deformable 
liposomes (CUR-ADLs), respectively. Untreated HFF cells were used as control. NDLs, CDLs 
and ADLs represent empty deformable liposomes, tested at the same lipid concentrations as 
curcumin-DLs. (d) represents the percentage of living cells after exposure to PG (20 % w/v) 
solution (PG sol) in PBS and curcumin in PG solution (CUR-PG) at the same curcumin 
concentration as in deformable liposomes. 




Considering that DLs suspensions are liquid in nature, their topical administration onto the skin 
surface can be improved by their incorporation into a vehicle, such as hydrogel, to develop final 
skin formulations. The selection of the best final formulation, according to the liposomal 
surface charge, would be a consequent step for further studies on the effectiveness of curcumin-
DLs in hydrogel systems destined for localized skin therapy. Using the same approach as 
applied in this study, the future investigations would possibly be performed avoiding in vivo 
animal testing due to the rising ethical restrictions that limit their use further leading to find 
other alternatives.  
 
4. Conclusion 
We achieved a successful employment of nanotechnology by optimizing deformable vesicles 
to improve dermal delivery of curcumin. All prepared deformable liposomes enabled relatively 
high curcumin entrapment, thus assuring high curcumin concentration at the skin site and 
limiting the systemic absorption, as observed in the ex vivo skin penetration studies. Moreover, 
we were able to discriminate between the different skin penetration potentials of the 
nanocarriers. Cationic deformable liposomes exhibited the most sustained curcumin penetration 
through the full thickness human skin, assuring high retention of curcumin within the skin. All 
liposomal formulations exerted concentration-dependent anti-bacterial and anti-inflammatory 
activities, superior to activities of non-liposomal curcumin. Additionally, all liposomal 
formulations were found non-toxic in the tested human skin fibroblast cells and even more, 
exhibited a cell proliferation effect. We propose that successful incorporation of curcumin in 
cationic deformable liposomes enhances its multi-targeting properties. Moreover, the 
curcumin-containing novel liposomes can be utilized in treatment of various skin diseases 
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Fig. 1. Curcumin penetration from different deformable liposomes through the full 
thickness human skin over 24 hrs. Results are expressed as mean ± SD (n = 3). 
a: p < 0.05, a’: p < 0.005 vs. CDL. 
 
Fig. 2. Effect of different curcumin-DLs on S. aureus (upper part) and S. pyogenes (lower 
part) growth after 4 hrs incubation.  
(a) and (c) show the effect of curcumin-DLs on S. aureus and S. pyogenes, respectively. Control 
refers to untreated bacteria. Empty DLs are curcumin-free NDLs, CDLs and ADLs, 
respectively, with similar lipid concentrations as curcumin-DLs. (b) and (d) represent the effect 
of free curcumin (CUR-PG), meaning curcumin in PG solution (20 % w/v) with same 
concentrations as in deformable liposomes. PG sol is PG (20 % w/v) solution in PBS.  
Bar graphs showing mean ± SD (n = 2). a: p < 0.03, a’: p < 0.002, a’’: p < 0.0002, a’’’: p < 0.0001. 
 
Fig. 3. Effect of different curcumin-DLs on NO production in LPS-induced macrophages.  
LPS-induced macrophages were treated with neutral deformable liposomes (CUR-NDLs) (a), 
cationic deformable liposomes (CUR-CDLs) (b) and anionic deformable liposomes (CUR-
ADLs) (c) containing curcumin and incubated for 24 hrs. Untreated LPS-induced macrophages 
were used as a control. NDLs, CDLs and ADLs are empty deformable liposomes, tested at the 
same lipid concentrations as curcumin-DLs. (d) is curcumin in PG solution (CUR-PG) at the 
same curcumin concentration as in deformable liposomes. PG sol is PG (20 % w/v) solution in 
PBS. 





Fig. 4. Effect of different curcumin-DLs on viability of human foreskin fibroblast (HFF) 
cells after 12 and 24 hrs exposure.  
HFF cells were exposed to neutral deformable liposomes (CUR-NDLs) (a), cationic deformable 
liposomes (CUR-CDLs) (b) and anionic deformable liposomes (CUR-ADLs) (c) containing 
curcumin, respectively. Untreated HFF cells were used as control. NDLs, CDLs and ADLs 
represent empty deformable liposomes, tested at the same lipid concentrations as curcumin-
DLs. The (d) represents the percentage of living cells after exposure to PG (20 % w/v) solution 
(PG sol) in PBS and curcumin in PG solution (CUR-PG) at the same curcumin concentration 
as in deformable liposomes. 















Table 1. Composition of curcumin-DLs. 
aEach liposomal formulation was prepared in triplicates. The final volume was 10 mL. For 
empty liposomes (without curcumin), the same lipid/surfactant composition was used. 
bThe extrusion is described as the number of extrusion cycles through the corresponding pore 
size membrane (nm). 
 
Table 2. Characteristics of curcumin-DLs. 
aThe diameter is indicated as peaks in size distributions (nm). The weight intensity of each peak 
(%) is indicated in parentheses. 
bPolydispersity index. 
Results are expressed as mean ± SD (n = 3). 
 
Table 3. The membrane elasticity of curcumin-DLs. 
The degree of membrane elasticity (E) was calculated considering both the rv/rp and J. rv is the 
vesicle diameter after extrusion, rp is the pore size membrane and J is the amount of liposomal 
dispersion extruded in 5 min. Empty DLs bearing different surface charge were used as control.  








































Liposomes‐in‐hydrogel  systems  as  advanced wound  dressings  are  promising  for  improved 
chronic  wound  therapy,  including  dermal  delivery  of  curcumin.  The  combined  delivery 
systems, comprising the nanocarriers able to enhance solubility of poorly soluble drugs/active 
substance  and  hydrogels  with  superior  dressing  properties,  can  assure  controlled  and 
sustained skin penetration of  the  incorporated drug/active substance,  increase drug/active 
substance retention at the skin site, improving the therapy outcome. With the aim to optimize 
the properties of the two advanced delivery systems, we incorporated curcumin‐containing 
deformable  liposomes  (DLs)  in  chitosan hydrogel  and explored  the effect of  the  liposomal 





the  hydrogel´s  cohesiveness  and  adhesiveness.  Interestingly,  the  incorporation  of  DLs, 
regardless of  their  charge,  in  chitosan hydrogel, did not decrease  system´s bioadhesion  to 
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human  skin.  Moreover,  NDLs‐in‐hydrogel  exhibited  the  strongest  bioadhesion.  Stability 
testing  showed  that  the  incorporation  of  CDLs  in  hydrogel  preserved  hydrogel´s 
bioadhesiveness  to  a  higher  degree  as  compared  to  both  NDLs  and  ADLs.  Ex  vivo  skin 
penetration studies revealed that CDLs‐in‐hydrogel system enabled the most sustained skin 
penetration of curcumin. Cationic deformable liposomes and chitosan hydrogel as a vehicle 









dressings  that,  in contrast  to  traditional dressings,  can guarantee controlled and sustained 
release  of  the  incorporated  drug  thus  resulting  in  enhanced  therapeutic  outcome  and 
reduction of pain accompanied with wound dressing changes (Boateng and Catanzano, 2015). 




the  incorporated  drug/active  substance  at  the wounded  skin  site.  This,  together with  the 
sustained  drug  release  via  hydrogel,  can  result  in  higher  drug/active  substances 
concentrations at the skin site while reducing possible systemic absorption and consequent 
adverse effects  (Pitorre et  al.,  2017). Chitosan  represents one of  the most  studied natural 
polymer for development of effective hydrogel‐based wound dressings due to its numerous 
intrinsic  biological  properties  (Billard  et  al.,  2015).  Chitosan  biocompatibility  and 
bioadhesiveness together with its intrinsic bacteriostatic effect make this biopolymer effective 
in promoting wound healing while also preventing biofilm formation (Ng et al., 2014; Pérez‐
Díaz  et  al.,  2016).  In  spite  of  the  numerous  advantages  of  chitosan  hydrogels  as  dermal 
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2016,  Hurler  et  al.,  2013a).  The  liposomal  phospholipid  bilayers  allow  incorporation  of 
lipophilic substances improving their solubilisation and enabling their incorporation into the 
hydrophilic  chitosan  hydrogel.  Moreover,  the  ability  of  liposomes  to  assure  controlled 
drug/substance  release might  improve  targeted  drug  delivery  to  the  specific  skin  layer(s) 
(Banerjee, 2013). The sustained drug release from both advanced delivery systems might be 
increased and the retention time at skin site improved, resulting in an enhanced efficacy of 











liposomal  composition,  size  and  surface  charge.  In  addition,  the  lipophilicity  of  the 
incorporated drug needs  to be considered.  Lipophilic drugs will have  to partition  from the 
liposomal membrane into the hydrophilic hydrogel matrix and their release will be therefore 
mainly affected by the lipid concentration of liposomes embedded in the hydrogel (Mourtas 
et  al.,  2007; Hurler  et  al.,  2013b).  To  the best  of  our  knowledge,  relatively  little has been 
published  on  incorporation  of  deformable  liposomes  (DLs)  in  chitosan  hydrogel.  DLs  have 















inflammatory  and  anti‐bacterial,  making  this  pleiotropic  molecule  highly  promising  for 
treatment of chronic wounds and management of scars (Mehanny et al., 2016; Amini‐Nik et 







from  Lipoid  GmbH  (Ludwigshafen,  Germany).  High  molecular  weight  (MW)  chitosan 
(Brookfield  viscosity  800.000  cps  and  degree  of  deacetylation  of  77%),  polysorbate  20, 

















PBS  (pH  7.4)  was  previously  prepared  with  the  following  salts  composition:  2.98  g/L 
Na2HPO4.2H2O, 0.19 g/L KH2PO4, 8 g/L NaCl. The liposomal dispersions were kept at 4 °C for 
24 hrs prior to size reduction. 
All  DLs were  reduced  to  a  vesicle  size  of  200‐300  nm  by  the  hand  extrusion  through  the 
polycarbonate  membrane  (Nuclepore®  Track‐Etched  Membranes,  Whatman  House, 
Maidstone,  UK).  In  brief,  all  DLs  were  extruded  five  times  through  800  nm  pore  size 
membrane. NDLs were  further extruded  four  times  through 400 nm pore  size membrane, 
whereas CDLs and ADLs were extruded through the same pore size membrane two and seven 
times, respectively. All  liposomal dispersions were characterized  in terms of vesicle size by 
photon  correlation  spectroscopy  using  a  NICOMP  Submicron  Particle  Sizer  Model  370 
(NICOMP  Particle  Sizing  system,  Santa  Barbara,  California,  USA)  and  zeta  potential  using 
Malvern Zetasizer Nano – ZS (Malvern, Oxford, UK) (Ternullo et al., 2017).  
The entrapment efficiency of curcumin in all DLs was determined after the centrifugation of 

















individually  incorporated  in  the  freshly  prepared  chitosan  hydrogel  (Section  2.3)  by  hand‐
stirring (Hurler et al., 2012). The final concentration of curcumin in the liposomal hydrogel was 
135  µg/g.  As  a  control,  free  curcumin  was  incorporated  in  the  hydrogel  in  the  same 
concentration. For that purpose, curcumin was dissolved in PG in the same concentration as 
in  DLs  and  then  incorporated  in  chitosan  hydrogel  by  hand‐stirring.  The  DLs‐in‐hydrogel 










was  expressed  as  the work  necessary  to  push  down  the  disc  into  the  hydrogel, while  the 































Ex  vivo  curcumin  penetration  from  the  different  DLs‐in‐chitosan  hydrogels  was  evaluated 
using  the  full  thickness  human  skin  in  Franz  diffusion  cells  (diffusion  area  of  1.77  cm2, 
PermeGear, Bethlehem, USA) (Ternullo et al., 2017). The human skin derived from the excised 


































DLs bearing different  surface charge  (Table 1) were obtained by  including  the appropriate 
surfactant in the liposomal phospholipid bilayers. NDLs contained polysorbate 20 as a non‐
ionic surfactant, which conferred neutral surface to DLs  together with the presence of  the 






The  entrapment  efficiency  of  curcumin  in  the  different  DLs  varied  according  to  their 
composition (Table 1). The presence of surfactant might contribute to a  lower entrapment 
efficiency of lipophilic compounds, such as curcumin, both competing for accommodation in 












in  terms  of  hydrogel  texture  properties.  Hydrogel’s  hardness  can  determine  the  ease  of 






properties  (Hurler  et  al.,  2013b).  Possible  interactions  between  charged  DLs  and  positive 
chitosan  chains  might  change/affect  the  chitosan  network  thus  modifying  its  texture 









positive  effect  on  the  viscoelastic  properties  of  hydrogels  by  triggering  hydrogen  bonding 
between chitosan, water and the solvent (Islam et al., 2004). This might explain the positive 
effect of free curcumin on the hydrogel properties compared to DLs. Vanić and co‐workers 
(2014)  observed  reduced  hydrogel  texture  properties  when  deformable  propylene  glycol 





have  been observed  by Hurler  and  collaborators  (2013b),  in  agreement with  our  findings. 
Considering the liposomal surface charge, the charged DLs enhanced the hydrogel hardness 
while  weakening  both  cohesiveness  and  adhesiveness,  as  compared  to  NDLs.  Possible 
electrostatic  interactions between charged DLs and chitosan might destabilize the chitosan 
network to a higher extent compared to the neutral DLs. NDLs are not expected to interact 




Bioadhesiveness  represents  an  important  feature  responsible  for  the  effectiveness  of 
hydrogel‐based wound dressings. Good hydrogel bioadhesion to human skin can prolong the 
retention  time of  the  incorporated drug/active  substance at  the  skin  site  thus  resulting  in 
enhanced  therapeutic  effect.  Considering  the  presence  of  the  exudate  in  chronic 
wounds/burns,  the contact  time of  the hydrogel  to  the skin might be reduced by a  loss of 
hydrogel texture characteristics due to the presence of high water content in the wounded 
area (Boateng and Catanzano, 2015). Satisfactory hydrogel bioadhesion to human skin might 
overcome  this  limitation. We  therefore  evaluated  any possible  effect  of  liposomal  surface 
charge on the chitosan hydrogel’s bioadhesiveness. Based on the method developed earlier 
in our laboratory (Hurler and Škalko‐Basnet, 2012), we determined the hydrogel bioadhesion 





The  bioadhesiveness  expressed  as  the  detachment  force  was  not  affected  by  the 
incorporation of curcumin‐containing DLs, regardless of the  liposomal surface charge. Both 







systems.  Moreover,  the  high  amount  of  hydrogel  retained  onto  the  skin  (approx.  70%) 











texture  properties  (Table  2)  and  bioadhesiveness  (Figure  1),  possibly  related  to  triggered 
interactions between charged DLs and chitosan. We therefore further explored the effect of 










seems  to alter  the original hydrogel  texture properties  to a  lower extent compared  to  the 











between  positive  CDLs  and  chitosan  chains might  stabilize  the  liposomes  in  the  hydrogel 
matrix to a greater extent thus preserving chitosan bioadhesion to human skin.  
The bioadhesiveness is one of the main factors determining the prolonged retention time of 
curcumin  at  the  skin  administration  time.  Despite  the  rather  negative  effect  of  charged 
liposomes on the texture properties of DLs‐in‐hydrogel, the incorporation of CDLs in hydrogel 





















lipophilicity  of  curcumin  will  influence  this  process,  especially  its  partitioning  into  the 
hydrogel,  whereas  its  aqueous  solubility  will  determine  the  diffusion  rate  through  the 















to  curcumin‐in‐hydrogel  (control)  (Figure  4).  As  discussed  earlier,  NDLs  with  their  neutral 
surface are not expected  to  interact with  the chitosan chains. This might  result  in a minor 
impact  on  the  curcumin  release  and  further  penetration  into  the  skin  thus  explaining  the 
highest skin penetration of curcumin via NDLs‐in‐hydrogel. The minimal interaction between 
NDLs  and  chitosan  chains  might  also  marginally  interfere  with  NDLs’  mobility  within  the 
polymer  matrix  allowing  faster  curcumin  delivery  into/through  the  skin  via  NDLs.  The 
enhancement  of  skin  penetration  of  curcumin  from  nanosystems‐in‐chitosan  hydrogel 
compared to free curcumin‐in‐hydrogel has been also observed by Thomas and collaborators 
(2017). They incorporated curcumin in nanoemulsions further loaded in chitosan hydrogel and 
observed  a  higher  rat  skin  penetration  of  curcumin  when  compared  to  free  curcumin‐in‐
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hydrogel.  Sun and  co‐workers  (2017) observed higher penetration of  curcumin  from PLGA 
nanoparticles‐loaded in Carbopol gel compared to free curcumin‐in‐gel, although they tested 
the formulations in mouse skin.  
The  charged  DLs‐in‐hydrogel  exhibited  the  most  sustained  skin  penetration  of  curcumin 
compared to NDLs‐in‐hydrogel and control (curcumin‐in‐hydrogel). Considering the possible 
electrostatic  interactions  that  can  be  triggered when  charged DLs  are  embedded  into  the 
chitosan network, the liposomal membrane might be more preserved thus limiting curcumin 
partitioning  into  the  hydrogel.  The  electrostatic  interactions  between  negative  DLs  and 
positive  chitosan chains  can cause  immobilization of ADLs within  the hydrogel matrix  thus 
limiting curcumin diffusion initially and then into the hydrogel in order to reach the skin. Low 
mobility of  liposomes bearing opposite  charge  compared  to  the hydrogel  chains has been 
recently reported by El Kechai and collaborators (2017), who observed that positive liposomes 
were highly  immobilized  in  the negative hyaluronic  acid hydrogel. On  the other hand,  the 
higher repulsion occurring between CDLs and chitosan, both positively charged, might leave 
the CDLs membrane more intact and limit curcumin partitioning into the chitosan hydrogel, 
thus  explaining  the  most  sustained  skin  penetration  of  curcumin  via  CDLs.  Hurler  and 
collaborators  (2013b)  observed  the  same  findings  when  testing  the  in  vitro  release  of  a 
lipophilic compound from positively charged liposomes embedded in chitosan hydrogel. This 
can  result  in  a  more  prolonged  retention  time  of  curcumin  at  the  skin  site  to  exert  its 





wound  dressing.  Both  texture  properties  and  bioadhesiveness  of  DLs‐in‐chitosan  hydrogel 
were found to be affected by the liposomal surface charge. Although the texture properties 
were  weakened  to  a  certain  degree,  the  incorporation  of  deformable  liposomes  in  the 
chitosan  hydrogel  did  not  negatively  affect  its  bioadhesiveness.  Neutral  deformable 
liposomes‐in‐hydrogel exhibited the strongest bioadhesiveness, however their neutral surface 
did not preserve the hydrogels´s bioadhesion to human skin over longer periods of time. The 
positively  charged  deformable  liposomes  exhibited  the  best  ability  in  stabilizing  chitosan 
15 
 
bioadhesiveness  and  additionally  assured  the  most  sustained  penetration  of  curcumin 
through the ex vivo full human skin. By exploring the effect of  liposomal surface charge on 
both the chitosan properties and skin penetration of curcumin, cationic deformable liposomes 
in  chitosan hydrogel  showed  to  be  the most  appropriate  combination of  the  two delivery 
systems assuring good and stable hydrogel´s bioadhesiveness and sustained skin penetration 
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Figure 2. The effect of  liposomal  surface charge on hydrogel  texture properties:  stability 















































NDLs  288.73 ± 2.46  0.17 ± 0.02  ‐3.03 ± 0.24  51.54a ± 0.99 
CDLs  252.24 ± 51.63  0.17 ± 0.01  34.01 ± 0.56  71.94 ± 2.32 
































Plain hydrogel  164.8 ± 11.1  359.6 ± 10.6  346.8 ± 8.0 
CUR‐in‐hydrogel  148.7 ± 20.1  262.2 ± 17.0  248.5 ± 20.1 
CUR‐NDL‐in‐hydrogel  107.0a ± 4.2  226.5a, b ± 1.7  216.5a ± 2.8 
CUR‐CDL‐in‐hydrogel  116.8a ± 6.7  212.3a, b ± 5.5  200.9a, b ± 9.4 
CUR‐ADL‐in‐hydrogel  124.6 ± 21.0  204.0a, b ± 13.5  190.7a, b ± 8.6 
Results  are  presented  as mean  (n  =  3)  ±  SD.  CUR:  curcumin.  aSignificantly  lower  vs.  plain 
hydrogel (p < 0.05), bsignificantly lower vs. CUR‐in‐hydrogel (p < 0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
